id	sid	tid	token	lemma	pos
cord-254580-nhpjvgt4	1	1	key	key	JJ
cord-254580-nhpjvgt4	1	2	:	:	:
cord-254580-nhpjvgt4	1	3	cord-254580-nhpjvgt4	cord-254580-nhpjvgt4	NN
cord-254580-nhpjvgt4	1	4	authors	author	NNS
cord-254580-nhpjvgt4	1	5	:	:	:
cord-254580-nhpjvgt4	1	6	Ricardo	Ricardo	NNP
cord-254580-nhpjvgt4	1	7	,	,	,
cord-254580-nhpjvgt4	1	8	Jose	Jose	NNP
cord-254580-nhpjvgt4	1	9	W.	W.	NNP
cord-254580-nhpjvgt4	1	10	;	;	:
cord-254580-nhpjvgt4	1	11	Lipner	Lipner	NNP
cord-254580-nhpjvgt4	1	12	,	,	,
cord-254580-nhpjvgt4	1	13	Shari	Shari	NNP
cord-254580-nhpjvgt4	1	14	R.	R.	NNP
cord-254580-nhpjvgt4	1	15	title	title	NN
cord-254580-nhpjvgt4	1	16	:	:	:
cord-254580-nhpjvgt4	1	17	Considerations	consideration	NNS
cord-254580-nhpjvgt4	1	18	for	for	IN
cord-254580-nhpjvgt4	1	19	Safety	safety	NN
cord-254580-nhpjvgt4	1	20	in	in	IN
cord-254580-nhpjvgt4	1	21	the	the	DT
cord-254580-nhpjvgt4	1	22	Use	Use	NNP
cord-254580-nhpjvgt4	1	23	of	of	IN
cord-254580-nhpjvgt4	1	24	Systemic	systemic	JJ
cord-254580-nhpjvgt4	1	25	Medications	medication	NNS
cord-254580-nhpjvgt4	1	26	for	for	IN
cord-254580-nhpjvgt4	1	27	Psoriasis	Psoriasis	NNP
cord-254580-nhpjvgt4	1	28	and	and	CC
cord-254580-nhpjvgt4	1	29	Atopic	Atopic	NNP
cord-254580-nhpjvgt4	1	30	Dermatitis	Dermatitis	NNP
cord-254580-nhpjvgt4	1	31	during	during	IN
cord-254580-nhpjvgt4	1	32	the	the	DT
cord-254580-nhpjvgt4	1	33	COVID‐19	COVID‐19	NNP
cord-254580-nhpjvgt4	1	34	pandemic	pandemic	NN
cord-254580-nhpjvgt4	1	35	date	date	NN
cord-254580-nhpjvgt4	1	36	:	:	:
cord-254580-nhpjvgt4	1	37	2020	2020	CD
cord-254580-nhpjvgt4	1	38	-	-	HYPH
cord-254580-nhpjvgt4	1	39	05	05	CD
cord-254580-nhpjvgt4	1	40	-	-	HYPH
cord-254580-nhpjvgt4	1	41	27	27	CD
cord-254580-nhpjvgt4	1	42	journal	journal	NN
cord-254580-nhpjvgt4	1	43	:	:	:
cord-254580-nhpjvgt4	2	1	Dermatol	Dermatol	NNP
cord-254580-nhpjvgt4	3	1	Ther	ther	JJ
cord-254580-nhpjvgt4	3	2	DOI	DOI	NNP
cord-254580-nhpjvgt4	3	3	:	:	:
cord-254580-nhpjvgt4	4	1	10.1111	10.1111	CD
cord-254580-nhpjvgt4	4	2	/	/	SYM
cord-254580-nhpjvgt4	4	3	dth.13687	dth.13687	NN
cord-254580-nhpjvgt4	4	4	sha	sha	NNP
cord-254580-nhpjvgt4	4	5	:	:	:
cord-254580-nhpjvgt4	5	1	da516a5f665fcb8a6f3a1fd350bcfa34820d951a	da516a5f665fcb8a6f3a1fd350bcfa34820d951a	NNP
cord-254580-nhpjvgt4	5	2	doc_id	doc_id	CD
cord-254580-nhpjvgt4	5	3	:	:	:
cord-254580-nhpjvgt4	5	4	254580	254580	CD
cord-254580-nhpjvgt4	6	1	cord_uid	cord_uid	NN
cord-254580-nhpjvgt4	6	2	:	:	:
cord-254580-nhpjvgt4	7	1	nhpjvgt4	nhpjvgt4	NN
cord-254580-nhpjvgt4	7	2	Coronavirus	Coronavirus	NNP
cord-254580-nhpjvgt4	7	3	disease	disease	NN
cord-254580-nhpjvgt4	7	4	2019	2019	CD
cord-254580-nhpjvgt4	8	1	(	(	-LRB-
cord-254580-nhpjvgt4	8	2	COVID‐19	COVID‐19	NNP
cord-254580-nhpjvgt4	8	3	)	)	-RRB-
cord-254580-nhpjvgt4	8	4	,	,	,
cord-254580-nhpjvgt4	8	5	is	be	VBZ
cord-254580-nhpjvgt4	8	6	responsible	responsible	JJ
cord-254580-nhpjvgt4	8	7	for	for	IN
cord-254580-nhpjvgt4	8	8	at	at	RB
cord-254580-nhpjvgt4	8	9	least	least	JJS
cord-254580-nhpjvgt4	8	10	2,546,527	2,546,527	CD
cord-254580-nhpjvgt4	8	11	cases	case	NNS
cord-254580-nhpjvgt4	8	12	and	and	CC
cord-254580-nhpjvgt4	8	13	175,812	175,812	CD
cord-254580-nhpjvgt4	8	14	deaths	death	NNS
cord-254580-nhpjvgt4	8	15	as	as	IN
cord-254580-nhpjvgt4	8	16	of	of	IN
cord-254580-nhpjvgt4	8	17	April	April	NNP
cord-254580-nhpjvgt4	8	18	21	21	CD
cord-254580-nhpjvgt4	8	19	,	,	,
cord-254580-nhpjvgt4	8	20	2020	2020	CD
cord-254580-nhpjvgt4	8	21	.	.	.
cord-254580-nhpjvgt4	9	1	Psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	9	2	and	and	CC
cord-254580-nhpjvgt4	9	3	atopic	atopic	JJ
cord-254580-nhpjvgt4	9	4	dermatitis	dermatitis	NN
cord-254580-nhpjvgt4	9	5	are	be	VBP
cord-254580-nhpjvgt4	9	6	common	common	JJ
cord-254580-nhpjvgt4	9	7	,	,	,
cord-254580-nhpjvgt4	9	8	chronic	chronic	JJ
cord-254580-nhpjvgt4	9	9	,	,	,
cord-254580-nhpjvgt4	9	10	inflammatory	inflammatory	JJ
cord-254580-nhpjvgt4	9	11	skin	skin	NN
cord-254580-nhpjvgt4	9	12	conditions	condition	NNS
cord-254580-nhpjvgt4	9	13	,	,	,
cord-254580-nhpjvgt4	9	14	with	with	IN
cord-254580-nhpjvgt4	9	15	immune	immune	JJ
cord-254580-nhpjvgt4	9	16	dysregulation	dysregulation	NN
cord-254580-nhpjvgt4	9	17	as	as	IN
cord-254580-nhpjvgt4	9	18	a	a	DT
cord-254580-nhpjvgt4	9	19	shared	share	VBN
cord-254580-nhpjvgt4	9	20	mechanism	mechanism	NN
cord-254580-nhpjvgt4	9	21	;	;	:
cord-254580-nhpjvgt4	9	22	therefore	therefore	RB
cord-254580-nhpjvgt4	9	23	,	,	,
cord-254580-nhpjvgt4	9	24	mainstays	mainstay	NNS
cord-254580-nhpjvgt4	9	25	of	of	IN
cord-254580-nhpjvgt4	9	26	treatment	treatment	NN
cord-254580-nhpjvgt4	9	27	include	include	VBP
cord-254580-nhpjvgt4	9	28	systemic	systemic	JJ
cord-254580-nhpjvgt4	9	29	immunomodulating	immunomodulating	JJ
cord-254580-nhpjvgt4	9	30	therapies	therapy	NNS
cord-254580-nhpjvgt4	9	31	.	.	.
cord-254580-nhpjvgt4	10	1	It	-PRON-	PRP
cord-254580-nhpjvgt4	10	2	is	be	VBZ
cord-254580-nhpjvgt4	10	3	unknown	unknown	JJ
cord-254580-nhpjvgt4	10	4	whether	whether	IN
cord-254580-nhpjvgt4	10	5	these	these	DT
cord-254580-nhpjvgt4	10	6	therapies	therapy	NNS
cord-254580-nhpjvgt4	10	7	are	be	VBP
cord-254580-nhpjvgt4	10	8	associated	associate	VBN
cord-254580-nhpjvgt4	10	9	with	with	IN
cord-254580-nhpjvgt4	10	10	increased	increase	VBN
cord-254580-nhpjvgt4	10	11	to	to	IN
cord-254580-nhpjvgt4	10	12	COVID‐19	covid‐19	NN
cord-254580-nhpjvgt4	10	13	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	10	14	or	or	CC
cord-254580-nhpjvgt4	10	15	worse	bad	JJR
cord-254580-nhpjvgt4	10	16	outcomes	outcome	NNS
cord-254580-nhpjvgt4	10	17	in	in	IN
cord-254580-nhpjvgt4	10	18	infected	infected	JJ
cord-254580-nhpjvgt4	10	19	patients	patient	NNS
cord-254580-nhpjvgt4	10	20	.	.	.
cord-254580-nhpjvgt4	11	1	In	in	IN
cord-254580-nhpjvgt4	11	2	this	this	DT
cord-254580-nhpjvgt4	11	3	review	review	NN
cord-254580-nhpjvgt4	11	4	,	,	,
cord-254580-nhpjvgt4	11	5	we	-PRON-	PRP
cord-254580-nhpjvgt4	11	6	discuss	discuss	VBP
cord-254580-nhpjvgt4	11	7	overall	overall	JJ
cord-254580-nhpjvgt4	11	8	infection	infection	NN
cord-254580-nhpjvgt4	11	9	risks	risk	NNS
cord-254580-nhpjvgt4	11	10	of	of	IN
cord-254580-nhpjvgt4	11	11	non‐biologic	non‐biologic	JJ
cord-254580-nhpjvgt4	11	12	and	and	CC
cord-254580-nhpjvgt4	11	13	biologic	biologic	JJ
cord-254580-nhpjvgt4	11	14	systemic	systemic	JJ
cord-254580-nhpjvgt4	11	15	medications	medication	NNS
cord-254580-nhpjvgt4	11	16	for	for	IN
cord-254580-nhpjvgt4	11	17	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	11	18	and	and	CC
cord-254580-nhpjvgt4	11	19	atopic	atopic	JJ
cord-254580-nhpjvgt4	11	20	dermatitis	dermatitis	NN
cord-254580-nhpjvgt4	11	21	,	,	,
cord-254580-nhpjvgt4	11	22	and	and	CC
cord-254580-nhpjvgt4	11	23	provide	provide	VB
cord-254580-nhpjvgt4	11	24	therapeutic	therapeutic	JJ
cord-254580-nhpjvgt4	11	25	recommendations	recommendation	NNS
cord-254580-nhpjvgt4	11	26	.	.	.
cord-254580-nhpjvgt4	12	1	In	in	IN
cord-254580-nhpjvgt4	12	2	summary	summary	NN
cord-254580-nhpjvgt4	12	3	,	,	,
cord-254580-nhpjvgt4	12	4	in	in	IN
cord-254580-nhpjvgt4	12	5	patients	patient	NNS
cord-254580-nhpjvgt4	12	6	with	with	IN
cord-254580-nhpjvgt4	12	7	active	active	JJ
cord-254580-nhpjvgt4	12	8	infection	infection	NN
cord-254580-nhpjvgt4	12	9	,	,	,
cord-254580-nhpjvgt4	12	10	systemic	systemic	JJ
cord-254580-nhpjvgt4	12	11	conventional	conventional	JJ
cord-254580-nhpjvgt4	12	12	medications	medication	NNS
cord-254580-nhpjvgt4	12	13	,	,	,
cord-254580-nhpjvgt4	12	14	the	the	DT
cord-254580-nhpjvgt4	12	15	JAK	JAK	NNP
cord-254580-nhpjvgt4	12	16	inhibitor	inhibitor	NN
cord-254580-nhpjvgt4	12	17	tofacitinib	tofacitinib	NNP
cord-254580-nhpjvgt4	12	18	,	,	,
cord-254580-nhpjvgt4	12	19	and	and	CC
cord-254580-nhpjvgt4	12	20	biologics	biologic	NNS
cord-254580-nhpjvgt4	12	21	for	for	IN
cord-254580-nhpjvgt4	12	22	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	12	23	should	should	MD
cord-254580-nhpjvgt4	12	24	be	be	VB
cord-254580-nhpjvgt4	12	25	temporarily	temporarily	RB
cord-254580-nhpjvgt4	12	26	held	hold	VBN
cord-254580-nhpjvgt4	12	27	until	until	IN
cord-254580-nhpjvgt4	12	28	there	there	EX
cord-254580-nhpjvgt4	12	29	is	be	VBZ
cord-254580-nhpjvgt4	12	30	more	more	JJR
cord-254580-nhpjvgt4	12	31	data	datum	NNS
cord-254580-nhpjvgt4	12	32	;	;	:
cord-254580-nhpjvgt4	12	33	in	in	IN
cord-254580-nhpjvgt4	12	34	uninfected	uninfected	JJ
cord-254580-nhpjvgt4	12	35	patients	patient	NNS
cord-254580-nhpjvgt4	12	36	switching	switch	VBG
cord-254580-nhpjvgt4	12	37	to	to	IN
cord-254580-nhpjvgt4	12	38	safer	safe	JJR
cord-254580-nhpjvgt4	12	39	alternatives	alternative	NNS
cord-254580-nhpjvgt4	12	40	should	should	MD
cord-254580-nhpjvgt4	12	41	be	be	VB
cord-254580-nhpjvgt4	12	42	considered	consider	VBN
cord-254580-nhpjvgt4	12	43	.	.	.
cord-254580-nhpjvgt4	13	1	Interleukin	Interleukin	NNP
cord-254580-nhpjvgt4	13	2	(	(	-LRB-
cord-254580-nhpjvgt4	13	3	IL)‐17	IL)‐17	NNP
cord-254580-nhpjvgt4	13	4	,	,	,
cord-254580-nhpjvgt4	13	5	IL‐12/23	il‐12/23	JJ
cord-254580-nhpjvgt4	13	6	and	and	CC
cord-254580-nhpjvgt4	13	7	IL‐23	il‐23	CD
cord-254580-nhpjvgt4	14	1	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	14	2	are	be	VBP
cord-254580-nhpjvgt4	14	3	associated	associate	VBN
cord-254580-nhpjvgt4	14	4	with	with	IN
cord-254580-nhpjvgt4	14	5	low	low	JJ
cord-254580-nhpjvgt4	14	6	infection	infection	NN
cord-254580-nhpjvgt4	14	7	risk	risk	NN
cord-254580-nhpjvgt4	14	8	,	,	,
cord-254580-nhpjvgt4	14	9	with	with	IN
cord-254580-nhpjvgt4	14	10	IL‐17	IL‐17	NNP
cord-254580-nhpjvgt4	14	11	and	and	CC
cord-254580-nhpjvgt4	14	12	IL‐23	IL‐23	NNP
cord-254580-nhpjvgt4	14	13	favored	favor	VBD
cord-254580-nhpjvgt4	14	14	over	over	IN
cord-254580-nhpjvgt4	14	15	IL‐12/23	il‐12/23	JJ
cord-254580-nhpjvgt4	14	16	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	14	17	.	.	.
cord-254580-nhpjvgt4	15	1	Pivotal	pivotal	JJ
cord-254580-nhpjvgt4	15	2	trials	trial	NNS
cord-254580-nhpjvgt4	15	3	and	and	CC
cord-254580-nhpjvgt4	15	4	postmarketing	postmarkete	VBG
cord-254580-nhpjvgt4	15	5	data	datum	NNS
cord-254580-nhpjvgt4	15	6	also	also	RB
cord-254580-nhpjvgt4	15	7	suggest	suggest	VBP
cord-254580-nhpjvgt4	15	8	that	that	IN
cord-254580-nhpjvgt4	15	9	IL‐17	IL‐17	NNP
cord-254580-nhpjvgt4	15	10	and	and	CC
cord-254580-nhpjvgt4	15	11	IL‐23	il‐23	NN
cord-254580-nhpjvgt4	15	12	blockers	blocker	NNS
cord-254580-nhpjvgt4	15	13	are	be	VBP
cord-254580-nhpjvgt4	15	14	safer	safe	JJR
cord-254580-nhpjvgt4	15	15	than	than	IN
cord-254580-nhpjvgt4	15	16	TNF‐blockers	tnf‐blocker	NNS
cord-254580-nhpjvgt4	15	17	.	.	.
cord-254580-nhpjvgt4	16	1	Apremilast	Apremilast	NNP
cord-254580-nhpjvgt4	16	2	,	,	,
cord-254580-nhpjvgt4	16	3	acitretin	acitretin	NNP
cord-254580-nhpjvgt4	16	4	and	and	CC
cord-254580-nhpjvgt4	16	5	dupilumab	dupilumab	NNP
cord-254580-nhpjvgt4	16	6	,	,	,
cord-254580-nhpjvgt4	16	7	have	have	VBP
cord-254580-nhpjvgt4	16	8	favorable	favorable	JJ
cord-254580-nhpjvgt4	16	9	safety	safety	NN
cord-254580-nhpjvgt4	16	10	data	datum	NNS
cord-254580-nhpjvgt4	16	11	,	,	,
cord-254580-nhpjvgt4	16	12	and	and	CC
cord-254580-nhpjvgt4	16	13	may	may	MD
cord-254580-nhpjvgt4	16	14	be	be	VB
cord-254580-nhpjvgt4	16	15	safely	safely	RB
cord-254580-nhpjvgt4	16	16	initiated	initiate	VBN
cord-254580-nhpjvgt4	16	17	and	and	CC
cord-254580-nhpjvgt4	16	18	continued	continue	VBN
cord-254580-nhpjvgt4	16	19	in	in	IN
cord-254580-nhpjvgt4	16	20	uninfected	uninfected	JJ
cord-254580-nhpjvgt4	16	21	patients	patient	NNS
cord-254580-nhpjvgt4	16	22	.	.	.
cord-254580-nhpjvgt4	17	1	Without	without	IN
cord-254580-nhpjvgt4	17	2	definitive	definitive	JJ
cord-254580-nhpjvgt4	17	3	COVID‐19	COVID‐19	NNP
cord-254580-nhpjvgt4	17	4	data	datum	NNS
cord-254580-nhpjvgt4	17	5	,	,	,
cord-254580-nhpjvgt4	17	6	these	these	DT
cord-254580-nhpjvgt4	17	7	recommendations	recommendation	NNS
cord-254580-nhpjvgt4	17	8	may	may	MD
cord-254580-nhpjvgt4	17	9	be	be	VB
cord-254580-nhpjvgt4	17	10	useful	useful	JJ
cord-254580-nhpjvgt4	17	11	in	in	IN
cord-254580-nhpjvgt4	17	12	guiding	guide	VBG
cord-254580-nhpjvgt4	17	13	treatment	treatment	NN
cord-254580-nhpjvgt4	17	14	of	of	IN
cord-254580-nhpjvgt4	17	15	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	17	16	and	and	CC
cord-254580-nhpjvgt4	17	17	atopic	atopic	JJ
cord-254580-nhpjvgt4	17	18	dermatitis	dermatitis	NN
cord-254580-nhpjvgt4	17	19	patients	patient	NNS
cord-254580-nhpjvgt4	17	20	during	during	IN
cord-254580-nhpjvgt4	17	21	the	the	DT
cord-254580-nhpjvgt4	17	22	COVID‐19	COVID‐19	NNP
cord-254580-nhpjvgt4	17	23	pandemic	pandemic	NN
cord-254580-nhpjvgt4	17	24	.	.	.
cord-254580-nhpjvgt4	18	1	This	this	DT
cord-254580-nhpjvgt4	18	2	article	article	NN
cord-254580-nhpjvgt4	18	3	is	be	VBZ
cord-254580-nhpjvgt4	18	4	protected	protect	VBN
cord-254580-nhpjvgt4	18	5	by	by	IN
cord-254580-nhpjvgt4	18	6	copyright	copyright	NN
cord-254580-nhpjvgt4	18	7	.	.	.
cord-254580-nhpjvgt4	19	1	All	all	DT
cord-254580-nhpjvgt4	19	2	rights	right	NNS
cord-254580-nhpjvgt4	19	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	19	4	.	.	.
cord-254580-nhpjvgt4	20	1	Severe	severe	JJ
cord-254580-nhpjvgt4	20	2	acute	acute	JJ
cord-254580-nhpjvgt4	20	3	respiratory	respiratory	JJ
cord-254580-nhpjvgt4	20	4	syndrome	syndrome	NN
cord-254580-nhpjvgt4	20	5	coronavirus	coronavirus	NN
cord-254580-nhpjvgt4	20	6	2	2	CD
cord-254580-nhpjvgt4	21	1	(	(	-LRB-
cord-254580-nhpjvgt4	21	2	SARS	SARS	NNP
cord-254580-nhpjvgt4	21	3	-	-	HYPH
cord-254580-nhpjvgt4	21	4	CoV-2	CoV-2	NNP
cord-254580-nhpjvgt4	21	5	)	)	-RRB-
cord-254580-nhpjvgt4	21	6	is	be	VBZ
cord-254580-nhpjvgt4	21	7	a	a	DT
cord-254580-nhpjvgt4	21	8	novel	novel	JJ
cord-254580-nhpjvgt4	21	9	human	human	JJ
cord-254580-nhpjvgt4	21	10	coronavirus	coronavirus	NN
cord-254580-nhpjvgt4	21	11	,	,	,
cord-254580-nhpjvgt4	21	12	with	with	IN
cord-254580-nhpjvgt4	21	13	2,546,527	2,546,527	CD
cord-254580-nhpjvgt4	21	14	confirmed	confirm	VBN
cord-254580-nhpjvgt4	21	15	cases	case	NNS
cord-254580-nhpjvgt4	21	16	of	of	IN
cord-254580-nhpjvgt4	21	17	coronavirus	coronavirus	NN
cord-254580-nhpjvgt4	21	18	disease	disease	NN
cord-254580-nhpjvgt4	21	19	2019	2019	CD
cord-254580-nhpjvgt4	21	20	(	(	-LRB-
cord-254580-nhpjvgt4	21	21	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	21	22	)	)	-RRB-
cord-254580-nhpjvgt4	21	23	and	and	CC
cord-254580-nhpjvgt4	21	24	175,812	175,812	CD
cord-254580-nhpjvgt4	21	25	deaths	death	NNS
cord-254580-nhpjvgt4	21	26	worldwide	worldwide	RB
cord-254580-nhpjvgt4	21	27	(	(	-LRB-
cord-254580-nhpjvgt4	21	28	April	April	NNP
cord-254580-nhpjvgt4	21	29	21	21	CD
cord-254580-nhpjvgt4	21	30	,	,	,
cord-254580-nhpjvgt4	21	31	2020	2020	CD
cord-254580-nhpjvgt4	21	32	)	)	-RRB-
cord-254580-nhpjvgt4	21	33	.	.	.
cord-254580-nhpjvgt4	22	1	1	1	LS
cord-254580-nhpjvgt4	23	1	It	-PRON-	PRP
cord-254580-nhpjvgt4	23	2	was	be	VBD
cord-254580-nhpjvgt4	23	3	declared	declare	VBN
cord-254580-nhpjvgt4	23	4	a	a	DT
cord-254580-nhpjvgt4	23	5	pandemic	pandemic	NN
cord-254580-nhpjvgt4	23	6	by	by	IN
cord-254580-nhpjvgt4	23	7	the	the	DT
cord-254580-nhpjvgt4	23	8	World	World	NNP
cord-254580-nhpjvgt4	23	9	Health	Health	NNP
cord-254580-nhpjvgt4	23	10	Organization	Organization	NNP
cord-254580-nhpjvgt4	23	11	.	.	.
cord-254580-nhpjvgt4	24	1	An	an	DT
cord-254580-nhpjvgt4	24	2	overall	overall	JJ
cord-254580-nhpjvgt4	24	3	case	case	NN
cord-254580-nhpjvgt4	24	4	fatality	fatality	NN
cord-254580-nhpjvgt4	24	5	rate	rate	NN
cord-254580-nhpjvgt4	24	6	of	of	IN
cord-254580-nhpjvgt4	24	7	3.61	3.61	CD
cord-254580-nhpjvgt4	24	8	%	%	NN
cord-254580-nhpjvgt4	24	9	has	have	VBZ
cord-254580-nhpjvgt4	24	10	been	be	VBN
cord-254580-nhpjvgt4	24	11	reported	report	VBN
cord-254580-nhpjvgt4	24	12	,	,	,
cord-254580-nhpjvgt4	24	13	2	2	CD
cord-254580-nhpjvgt4	24	14	however	however	RB
cord-254580-nhpjvgt4	24	15	,	,	,
cord-254580-nhpjvgt4	24	16	inaccuracies	inaccuracy	NNS
cord-254580-nhpjvgt4	24	17	may	may	MD
cord-254580-nhpjvgt4	24	18	exist	exist	VB
cord-254580-nhpjvgt4	24	19	because	because	IN
cord-254580-nhpjvgt4	24	20	those	those	DT
cord-254580-nhpjvgt4	24	21	who	who	WP
cord-254580-nhpjvgt4	24	22	are	be	VBP
cord-254580-nhpjvgt4	24	23	asymptomatic	asymptomatic	JJ
cord-254580-nhpjvgt4	24	24	or	or	CC
cord-254580-nhpjvgt4	24	25	suffer	suffer	VBP
cord-254580-nhpjvgt4	24	26	from	from	IN
cord-254580-nhpjvgt4	24	27	mild	mild	JJ
cord-254580-nhpjvgt4	24	28	disease	disease	NN
cord-254580-nhpjvgt4	24	29	may	may	MD
cord-254580-nhpjvgt4	24	30	never	never	RB
cord-254580-nhpjvgt4	24	31	receive	receive	VB
cord-254580-nhpjvgt4	24	32	confirmation	confirmation	NN
cord-254580-nhpjvgt4	24	33	.	.	.
cord-254580-nhpjvgt4	25	1	Psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	25	2	and	and	CC
cord-254580-nhpjvgt4	25	3	atopic	atopic	JJ
cord-254580-nhpjvgt4	25	4	dermatitis	dermatitis	NN
cord-254580-nhpjvgt4	25	5	(	(	-LRB-
cord-254580-nhpjvgt4	25	6	AD	ad	NN
cord-254580-nhpjvgt4	25	7	)	)	-RRB-
cord-254580-nhpjvgt4	25	8	are	be	VBP
cord-254580-nhpjvgt4	25	9	common	common	JJ
cord-254580-nhpjvgt4	25	10	,	,	,
cord-254580-nhpjvgt4	25	11	chronic	chronic	JJ
cord-254580-nhpjvgt4	25	12	,	,	,
cord-254580-nhpjvgt4	25	13	inflammatory	inflammatory	JJ
cord-254580-nhpjvgt4	25	14	skin	skin	NN
cord-254580-nhpjvgt4	25	15	diseases	disease	NNS
cord-254580-nhpjvgt4	25	16	,	,	,
cord-254580-nhpjvgt4	25	17	affecting	affect	VBG
cord-254580-nhpjvgt4	25	18	2	2	CD
cord-254580-nhpjvgt4	25	19	-	-	SYM
cord-254580-nhpjvgt4	25	20	3	3	CD
cord-254580-nhpjvgt4	25	21	%	%	NN
cord-254580-nhpjvgt4	25	22	of	of	IN
cord-254580-nhpjvgt4	25	23	the	the	DT
cord-254580-nhpjvgt4	25	24	general	general	JJ
cord-254580-nhpjvgt4	25	25	population	population	NN
cord-254580-nhpjvgt4	25	26	and	and	CC
cord-254580-nhpjvgt4	25	27	7	7	CD
cord-254580-nhpjvgt4	25	28	%	%	NN
cord-254580-nhpjvgt4	25	29	of	of	IN
cord-254580-nhpjvgt4	25	30	adults	adult	NNS
cord-254580-nhpjvgt4	25	31	in	in	IN
cord-254580-nhpjvgt4	25	32	the	the	DT
cord-254580-nhpjvgt4	25	33	United	United	NNP
cord-254580-nhpjvgt4	25	34	States	States	NNP
cord-254580-nhpjvgt4	25	35	(	(	-LRB-
cord-254580-nhpjvgt4	25	36	US	US	NNP
cord-254580-nhpjvgt4	25	37	)	)	-RRB-
cord-254580-nhpjvgt4	25	38	,	,	,
cord-254580-nhpjvgt4	25	39	respectively	respectively	RB
cord-254580-nhpjvgt4	25	40	.	.	.
cord-254580-nhpjvgt4	26	1	3	3	LS
cord-254580-nhpjvgt4	26	2	,	,	,
cord-254580-nhpjvgt4	26	3	4	4	CD
cord-254580-nhpjvgt4	26	4	Disease	Disease	NNP
cord-254580-nhpjvgt4	26	5	mechanisms	mechanism	NNS
cord-254580-nhpjvgt4	26	6	are	be	VBP
cord-254580-nhpjvgt4	26	7	multifactorial	multifactorial	JJ
cord-254580-nhpjvgt4	26	8	,	,	,
cord-254580-nhpjvgt4	26	9	with	with	IN
cord-254580-nhpjvgt4	26	10	immune	immune	JJ
cord-254580-nhpjvgt4	26	11	dysregulation	dysregulation	NN
cord-254580-nhpjvgt4	26	12	important	important	JJ
cord-254580-nhpjvgt4	26	13	for	for	IN
cord-254580-nhpjvgt4	26	14	both	both	DT
cord-254580-nhpjvgt4	26	15	conditions	condition	NNS
cord-254580-nhpjvgt4	26	16	,	,	,
cord-254580-nhpjvgt4	26	17	and	and	CC
cord-254580-nhpjvgt4	26	18	mainstays	mainstay	NNS
cord-254580-nhpjvgt4	26	19	of	of	IN
cord-254580-nhpjvgt4	26	20	treatment	treatment	NN
cord-254580-nhpjvgt4	26	21	immune	immune	JJ
cord-254580-nhpjvgt4	26	22	-	-	HYPH
cord-254580-nhpjvgt4	26	23	modulation	modulation	NN
cord-254580-nhpjvgt4	26	24	.	.	.
cord-254580-nhpjvgt4	27	1	5	5	CD
cord-254580-nhpjvgt4	27	2	Systemic	systemic	JJ
cord-254580-nhpjvgt4	27	3	therapy	therapy	NN
cord-254580-nhpjvgt4	27	4	is	be	VBZ
cord-254580-nhpjvgt4	27	5	preferred	prefer	VBN
cord-254580-nhpjvgt4	27	6	for	for	IN
cord-254580-nhpjvgt4	27	7	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	27	8	treatment	treatment	NN
cord-254580-nhpjvgt4	27	9	in	in	IN
cord-254580-nhpjvgt4	27	10	patients	patient	NNS
cord-254580-nhpjvgt4	27	11	with	with	IN
cord-254580-nhpjvgt4	27	12	Body	Body	NNP
cord-254580-nhpjvgt4	27	13	Surface	Surface	NNP
cord-254580-nhpjvgt4	27	14	Area>10	Area>10	NNP
cord-254580-nhpjvgt4	27	15	%	%	NN
cord-254580-nhpjvgt4	27	16	,	,	,
cord-254580-nhpjvgt4	27	17	involvement	involvement	NN
cord-254580-nhpjvgt4	27	18	of	of	IN
cord-254580-nhpjvgt4	27	19	sensitive	sensitive	JJ
cord-254580-nhpjvgt4	27	20	areas	area	NNS
cord-254580-nhpjvgt4	27	21	or	or	CC
cord-254580-nhpjvgt4	27	22	topical	topical	JJ
cord-254580-nhpjvgt4	27	23	therapy	therapy	NN
cord-254580-nhpjvgt4	27	24	failure	failure	NN
cord-254580-nhpjvgt4	27	25	.	.	.
cord-254580-nhpjvgt4	28	1	6	6	CD
cord-254580-nhpjvgt4	28	2	Systemic	systemic	JJ
cord-254580-nhpjvgt4	28	3	treatment	treatment	NN
cord-254580-nhpjvgt4	28	4	is	be	VBZ
cord-254580-nhpjvgt4	28	5	recommended	recommend	VBN
cord-254580-nhpjvgt4	28	6	for	for	IN
cord-254580-nhpjvgt4	28	7	AD	ad	NN
cord-254580-nhpjvgt4	28	8	patients	patient	NNS
cord-254580-nhpjvgt4	28	9	with	with	IN
cord-254580-nhpjvgt4	28	10	severe	severe	JJ
cord-254580-nhpjvgt4	28	11	disease	disease	NN
cord-254580-nhpjvgt4	28	12	or	or	CC
cord-254580-nhpjvgt4	28	13	recalcitrant	recalcitrant	JJ
cord-254580-nhpjvgt4	28	14	to	to	IN
cord-254580-nhpjvgt4	28	15	topical	topical	JJ
cord-254580-nhpjvgt4	28	16	therapy	therapy	NN
cord-254580-nhpjvgt4	28	17	.	.	.
cord-254580-nhpjvgt4	29	1	7	7	CD
cord-254580-nhpjvgt4	30	1	Immunocompromised	immunocompromise	VBN
cord-254580-nhpjvgt4	30	2	patients	patient	NNS
cord-254580-nhpjvgt4	30	3	are	be	VBP
cord-254580-nhpjvgt4	30	4	highly	highly	RB
cord-254580-nhpjvgt4	30	5	vulnerable	vulnerable	JJ
cord-254580-nhpjvgt4	30	6	to	to	IN
cord-254580-nhpjvgt4	30	7	infections	infection	NNS
cord-254580-nhpjvgt4	30	8	,	,	,
cord-254580-nhpjvgt4	30	9	which	which	WDT
cord-254580-nhpjvgt4	30	10	is	be	VBZ
cord-254580-nhpjvgt4	30	11	particularly	particularly	RB
cord-254580-nhpjvgt4	30	12	concerning	concern	VBG
cord-254580-nhpjvgt4	30	13	in	in	IN
cord-254580-nhpjvgt4	30	14	the	the	DT
cord-254580-nhpjvgt4	30	15	context	context	NN
cord-254580-nhpjvgt4	30	16	of	of	IN
cord-254580-nhpjvgt4	30	17	the	the	DT
cord-254580-nhpjvgt4	30	18	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	30	19	pandemic	pandemic	NN
cord-254580-nhpjvgt4	30	20	.	.	.
cord-254580-nhpjvgt4	31	1	In	in	IN
cord-254580-nhpjvgt4	31	2	this	this	DT
cord-254580-nhpjvgt4	31	3	review	review	NN
cord-254580-nhpjvgt4	31	4	,	,	,
cord-254580-nhpjvgt4	31	5	we	-PRON-	PRP
cord-254580-nhpjvgt4	31	6	summarize	summarize	VBP
cord-254580-nhpjvgt4	31	7	the	the	DT
cord-254580-nhpjvgt4	31	8	current	current	JJ
cord-254580-nhpjvgt4	31	9	literature	literature	NN
cord-254580-nhpjvgt4	31	10	regarding	regard	VBG
cord-254580-nhpjvgt4	31	11	overall	overall	JJ
cord-254580-nhpjvgt4	31	12	infection	infection	NN
cord-254580-nhpjvgt4	31	13	risks	risk	NNS
cord-254580-nhpjvgt4	31	14	with	with	IN
cord-254580-nhpjvgt4	31	15	systemic	systemic	JJ
cord-254580-nhpjvgt4	31	16	immunomodulating	immunomodulating	JJ
cord-254580-nhpjvgt4	31	17	agents	agent	NNS
cord-254580-nhpjvgt4	31	18	for	for	IN
cord-254580-nhpjvgt4	31	19	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	31	20	and	and	CC
cord-254580-nhpjvgt4	31	21	AD	ad	NN
cord-254580-nhpjvgt4	31	22	,	,	,
cord-254580-nhpjvgt4	31	23	and	and	CC
cord-254580-nhpjvgt4	31	24	provide	provide	VB
cord-254580-nhpjvgt4	31	25	evidence	evidence	NN
cord-254580-nhpjvgt4	31	26	-	-	HYPH
cord-254580-nhpjvgt4	31	27	based	base	VBN
cord-254580-nhpjvgt4	31	28	treatment	treatment	NN
cord-254580-nhpjvgt4	31	29	recommendations	recommendation	NNS
cord-254580-nhpjvgt4	31	30	during	during	IN
cord-254580-nhpjvgt4	31	31	the	the	DT
cord-254580-nhpjvgt4	31	32	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	31	33	pandemic	pandemic	NN
cord-254580-nhpjvgt4	31	34	.	.	.
cord-254580-nhpjvgt4	32	1	Systemic	systemic	JJ
cord-254580-nhpjvgt4	32	2	corticosteroids	corticosteroid	NNS
cord-254580-nhpjvgt4	32	3	are	be	VBP
cord-254580-nhpjvgt4	32	4	immunosuppressive	immunosuppressive	JJ
cord-254580-nhpjvgt4	32	5	medications	medication	NNS
cord-254580-nhpjvgt4	32	6	used	use	VBN
cord-254580-nhpjvgt4	32	7	to	to	TO
cord-254580-nhpjvgt4	32	8	treat	treat	VB
cord-254580-nhpjvgt4	32	9	AD	ad	NN
cord-254580-nhpjvgt4	32	10	flares	flare	NNS
cord-254580-nhpjvgt4	32	11	,	,	,
cord-254580-nhpjvgt4	32	12	but	but	CC
cord-254580-nhpjvgt4	32	13	very	very	RB
cord-254580-nhpjvgt4	32	14	rarely	rarely	RB
cord-254580-nhpjvgt4	32	15	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	32	16	.	.	.
cord-254580-nhpjvgt4	33	1	They	-PRON-	PRP
cord-254580-nhpjvgt4	33	2	have	have	VBP
cord-254580-nhpjvgt4	33	3	been	be	VBN
cord-254580-nhpjvgt4	33	4	shown	show	VBN
cord-254580-nhpjvgt4	33	5	to	to	TO
cord-254580-nhpjvgt4	33	6	increase	increase	VB
cord-254580-nhpjvgt4	33	7	infection	infection	NN
cord-254580-nhpjvgt4	33	8	risk	risk	NN
cord-254580-nhpjvgt4	33	9	.	.	.
cord-254580-nhpjvgt4	34	1	In	in	IN
cord-254580-nhpjvgt4	34	2	a	a	DT
cord-254580-nhpjvgt4	34	3	systematic	systematic	JJ
cord-254580-nhpjvgt4	34	4	review	review	NN
cord-254580-nhpjvgt4	34	5	of	of	IN
cord-254580-nhpjvgt4	34	6	101	101	CD
cord-254580-nhpjvgt4	34	7	studies	study	NNS
cord-254580-nhpjvgt4	34	8	on	on	IN
cord-254580-nhpjvgt4	34	9	AD	ad	NN
cord-254580-nhpjvgt4	34	10	children	child	NNS
cord-254580-nhpjvgt4	34	11	(	(	-LRB-
cord-254580-nhpjvgt4	34	12	n=6,817	n=6,817	NNP
cord-254580-nhpjvgt4	34	13	)	)	-RRB-
cord-254580-nhpjvgt4	34	14	treated	treat	VBN
cord-254580-nhpjvgt4	34	15	with	with	IN
cord-254580-nhpjvgt4	34	16	systemic	systemic	JJ
cord-254580-nhpjvgt4	34	17	corticosteroids	corticosteroid	NNS
cord-254580-nhpjvgt4	34	18	≥15	≥15	NNP
cord-254580-nhpjvgt4	34	19	days	day	NNS
cord-254580-nhpjvgt4	34	20	,	,	,
cord-254580-nhpjvgt4	34	21	infection	infection	NN
cord-254580-nhpjvgt4	34	22	rate	rate	NN
cord-254580-nhpjvgt4	34	23	was	be	VBD
cord-254580-nhpjvgt4	34	24	8.7	8.7	CD
cord-254580-nhpjvgt4	34	25	%	%	NN
cord-254580-nhpjvgt4	34	26	,	,	,
cord-254580-nhpjvgt4	34	27	with	with	IN
cord-254580-nhpjvgt4	34	28	21	21	CD
cord-254580-nhpjvgt4	34	29	associated	associate	VBN
cord-254580-nhpjvgt4	34	30	deaths	death	NNS
cord-254580-nhpjvgt4	34	31	.	.	.
cord-254580-nhpjvgt4	35	1	8	8	CD
cord-254580-nhpjvgt4	36	1	In	in	IN
cord-254580-nhpjvgt4	36	2	a	a	DT
cord-254580-nhpjvgt4	36	3	meta	meta	JJ
cord-254580-nhpjvgt4	36	4	-	-	HYPH
cord-254580-nhpjvgt4	36	5	analysis	analysis	NN
cord-254580-nhpjvgt4	36	6	of	of	IN
cord-254580-nhpjvgt4	36	7	corticosteroid	corticosteroid	NN
cord-254580-nhpjvgt4	36	8	use	use	NN
cord-254580-nhpjvgt4	36	9	in	in	IN
cord-254580-nhpjvgt4	36	10	patients	patient	NNS
cord-254580-nhpjvgt4	36	11	with	with	IN
cord-254580-nhpjvgt4	36	12	influenza	influenza	NN
cord-254580-nhpjvgt4	36	13	pneumonia	pneumonia	NN
cord-254580-nhpjvgt4	36	14	(	(	-LRB-
cord-254580-nhpjvgt4	36	15	10	10	CD
cord-254580-nhpjvgt4	36	16	studies	study	NNS
cord-254580-nhpjvgt4	36	17	,	,	,
cord-254580-nhpjvgt4	36	18	n=6548	n=6548	CD
cord-254580-nhpjvgt4	36	19	)	)	-RRB-
cord-254580-nhpjvgt4	36	20	,	,	,
cord-254580-nhpjvgt4	36	21	compared	compare	VBN
cord-254580-nhpjvgt4	36	22	with	with	IN
cord-254580-nhpjvgt4	36	23	placebo	placebo	NN
cord-254580-nhpjvgt4	36	24	,	,	,
cord-254580-nhpjvgt4	36	25	corticosteroids	corticosteroid	NNS
cord-254580-nhpjvgt4	36	26	were	be	VBD
cord-254580-nhpjvgt4	36	27	associated	associate	VBN
cord-254580-nhpjvgt4	36	28	with	with	IN
cord-254580-nhpjvgt4	36	29	higher	high	JJR
cord-254580-nhpjvgt4	36	30	mortality	mortality	NN
cord-254580-nhpjvgt4	36	31	,	,	,
cord-254580-nhpjvgt4	36	32	longer	long	RBR
cord-254580-nhpjvgt4	36	33	intensive	intensive	JJ
cord-254580-nhpjvgt4	36	34	care	care	NN
cord-254580-nhpjvgt4	36	35	unit	unit	NN
cord-254580-nhpjvgt4	36	36	length	length	NN
cord-254580-nhpjvgt4	36	37	of	of	IN
cord-254580-nhpjvgt4	36	38	stay	stay	NN
cord-254580-nhpjvgt4	36	39	and	and	CC
cord-254580-nhpjvgt4	36	40	a	a	DT
cord-254580-nhpjvgt4	36	41	higher	high	JJR
cord-254580-nhpjvgt4	36	42	rate	rate	NN
cord-254580-nhpjvgt4	36	43	of	of	IN
cord-254580-nhpjvgt4	36	44	secondary	secondary	JJ
cord-254580-nhpjvgt4	36	45	infection	infection	NN
cord-254580-nhpjvgt4	36	46	.	.	.
cord-254580-nhpjvgt4	37	1	9	9	CD
cord-254580-nhpjvgt4	38	1	Therefore	therefore	RB
cord-254580-nhpjvgt4	38	2	,	,	,
cord-254580-nhpjvgt4	38	3	oral	oral	JJ
cord-254580-nhpjvgt4	38	4	corticosteroids	corticosteroid	NNS
cord-254580-nhpjvgt4	38	5	should	should	MD
cord-254580-nhpjvgt4	38	6	be	be	VB
cord-254580-nhpjvgt4	38	7	avoided	avoid	VBN
cord-254580-nhpjvgt4	38	8	,	,	,
cord-254580-nhpjvgt4	38	9	weighing	weigh	VBG
cord-254580-nhpjvgt4	38	10	the	the	DT
cord-254580-nhpjvgt4	38	11	risks	risk	NNS
cord-254580-nhpjvgt4	38	12	of	of	IN
cord-254580-nhpjvgt4	38	13	disease	disease	NN
cord-254580-nhpjvgt4	38	14	flare	flare	NN
cord-254580-nhpjvgt4	38	15	vs.	vs.	FW
cord-254580-nhpjvgt4	38	16	SARS	SARS	NNP
cord-254580-nhpjvgt4	38	17	-	-	HYPH
cord-254580-nhpjvgt4	38	18	CoV-2	CoV-2	NNP
cord-254580-nhpjvgt4	38	19	infection	infection	NN
cord-254580-nhpjvgt4	38	20	,	,	,
cord-254580-nhpjvgt4	38	21	to	to	TO
cord-254580-nhpjvgt4	38	22	prevent	prevent	VB
cord-254580-nhpjvgt4	38	23	COVID-19	covid-19	JJ
cord-254580-nhpjvgt4	38	24	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	38	25	.	.	.
cord-254580-nhpjvgt4	39	1	Before	before	IN
cord-254580-nhpjvgt4	39	2	discontinuation	discontinuation	NN
cord-254580-nhpjvgt4	39	3	,	,	,
cord-254580-nhpjvgt4	39	4	dose	dose	NN
cord-254580-nhpjvgt4	39	5	tapering	tapering	NN
cord-254580-nhpjvgt4	39	6	may	may	MD
cord-254580-nhpjvgt4	39	7	be	be	VB
cord-254580-nhpjvgt4	39	8	considered	consider	VBN
cord-254580-nhpjvgt4	39	9	to	to	TO
cord-254580-nhpjvgt4	39	10	avoid	avoid	VB
cord-254580-nhpjvgt4	39	11	a	a	DT
cord-254580-nhpjvgt4	39	12	negative	negative	JJ
cord-254580-nhpjvgt4	39	13	effect	effect	NN
cord-254580-nhpjvgt4	39	14	on	on	IN
cord-254580-nhpjvgt4	39	15	respiratory	respiratory	JJ
cord-254580-nhpjvgt4	39	16	symptoms	symptom	NNS
cord-254580-nhpjvgt4	39	17	.	.	.
cord-254580-nhpjvgt4	40	1	Methotrexate	Methotrexate	NNP
cord-254580-nhpjvgt4	40	2	and	and	CC
cord-254580-nhpjvgt4	40	3	cyclosporine	cyclosporine	NN
cord-254580-nhpjvgt4	40	4	are	be	VBP
cord-254580-nhpjvgt4	40	5	amongst	amongst	IN
cord-254580-nhpjvgt4	40	6	the	the	DT
cord-254580-nhpjvgt4	40	7	most	most	RBS
cord-254580-nhpjvgt4	40	8	frequently	frequently	RB
cord-254580-nhpjvgt4	40	9	used	use	VBN
cord-254580-nhpjvgt4	40	10	systemic	systemic	JJ
cord-254580-nhpjvgt4	40	11	medications	medication	NNS
cord-254580-nhpjvgt4	40	12	for	for	IN
cord-254580-nhpjvgt4	40	13	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	40	14	and	and	CC
cord-254580-nhpjvgt4	40	15	AD	ad	NN
cord-254580-nhpjvgt4	40	16	,	,	,
cord-254580-nhpjvgt4	40	17	with	with	IN
cord-254580-nhpjvgt4	40	18	both	both	DT
cord-254580-nhpjvgt4	40	19	associated	associate	VBN
cord-254580-nhpjvgt4	40	20	with	with	IN
cord-254580-nhpjvgt4	40	21	increased	increase	VBN
cord-254580-nhpjvgt4	40	22	infection	infection	NN
cord-254580-nhpjvgt4	40	23	rates	rate	NNS
cord-254580-nhpjvgt4	40	24	.	.	.
cord-254580-nhpjvgt4	41	1	There	there	EX
cord-254580-nhpjvgt4	41	2	was	be	VBD
cord-254580-nhpjvgt4	41	3	a	a	DT
cord-254580-nhpjvgt4	41	4	58	58	CD
cord-254580-nhpjvgt4	41	5	%	%	NN
cord-254580-nhpjvgt4	41	6	higher	high	JJR
cord-254580-nhpjvgt4	41	7	overall	overall	JJ
cord-254580-nhpjvgt4	41	8	infection	infection	NN
cord-254580-nhpjvgt4	41	9	risk	risk	NN
cord-254580-nhpjvgt4	41	10	with	with	IN
cord-254580-nhpjvgt4	41	11	cyclosporine	cyclosporine	NN
cord-254580-nhpjvgt4	41	12	vs.	vs.	FW
cord-254580-nhpjvgt4	41	13	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	41	14	in	in	IN
cord-254580-nhpjvgt4	41	15	the	the	DT
cord-254580-nhpjvgt4	41	16	BIOBADADERM	BIOBADADERM	NNP
cord-254580-nhpjvgt4	41	17	registry	registry	NN
cord-254580-nhpjvgt4	41	18	(	(	-LRB-
cord-254580-nhpjvgt4	41	19	Spanish	Spanish	NNP
cord-254580-nhpjvgt4	41	20	Registry	Registry	NNP
cord-254580-nhpjvgt4	41	21	of	of	IN
cord-254580-nhpjvgt4	41	22	Adverse	adverse	JJ
cord-254580-nhpjvgt4	41	23	Events	event	NNS
cord-254580-nhpjvgt4	41	24	for	for	IN
cord-254580-nhpjvgt4	41	25	Biological	Biological	NNP
cord-254580-nhpjvgt4	41	26	Therapy	Therapy	NNP
cord-254580-nhpjvgt4	41	27	in	in	IN
cord-254580-nhpjvgt4	41	28	Dermatological	Dermatological	NNP
cord-254580-nhpjvgt4	41	29	Disease	Disease	NNP
cord-254580-nhpjvgt4	41	30	)	)	-RRB-
cord-254580-nhpjvgt4	41	31	including	include	VBG
cord-254580-nhpjvgt4	41	32	2153	2153	CD
cord-254580-nhpjvgt4	41	33	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	41	34	patients	patient	NNS
cord-254580-nhpjvgt4	41	35	.	.	.
cord-254580-nhpjvgt4	42	1	10	10	CD
cord-254580-nhpjvgt4	43	1	In	in	IN
cord-254580-nhpjvgt4	43	2	a	a	DT
cord-254580-nhpjvgt4	43	3	head	head	NN
cord-254580-nhpjvgt4	43	4	-	-	HYPH
cord-254580-nhpjvgt4	43	5	to	to	IN
cord-254580-nhpjvgt4	43	6	-	-	HYPH
cord-254580-nhpjvgt4	43	7	head	head	NN
cord-254580-nhpjvgt4	43	8	comparison	comparison	NN
cord-254580-nhpjvgt4	43	9	of	of	IN
cord-254580-nhpjvgt4	43	10	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	43	11	(	(	-LRB-
cord-254580-nhpjvgt4	43	12	n=50	n=50	NNP
cord-254580-nhpjvgt4	43	13	)	)	-RRB-
cord-254580-nhpjvgt4	43	14	versus	versus	IN
cord-254580-nhpjvgt4	43	15	cyclosporine	cyclosporine	NN
cord-254580-nhpjvgt4	43	16	(	(	-LRB-
cord-254580-nhpjvgt4	43	17	n=47	n=47	NN
cord-254580-nhpjvgt4	43	18	)	)	-RRB-
cord-254580-nhpjvgt4	43	19	in	in	IN
cord-254580-nhpjvgt4	43	20	moderate	moderate	JJ
cord-254580-nhpjvgt4	43	21	to	to	IN
cord-254580-nhpjvgt4	43	22	severe	severe	JJ
cord-254580-nhpjvgt4	43	23	AD	ad	NN
cord-254580-nhpjvgt4	43	24	adults	adult	NNS
cord-254580-nhpjvgt4	43	25	,	,	,
cord-254580-nhpjvgt4	43	26	infections	infection	NNS
cord-254580-nhpjvgt4	43	27	rates	rate	NNS
cord-254580-nhpjvgt4	43	28	were	be	VBD
cord-254580-nhpjvgt4	43	29	32	32	CD
cord-254580-nhpjvgt4	43	30	%	%	NN
cord-254580-nhpjvgt4	43	31	and	and	CC
cord-254580-nhpjvgt4	43	32	24	24	CD
cord-254580-nhpjvgt4	43	33	%	%	NN
cord-254580-nhpjvgt4	43	34	,	,	,
cord-254580-nhpjvgt4	43	35	respectively	respectively	RB
cord-254580-nhpjvgt4	43	36	.	.	.
cord-254580-nhpjvgt4	44	1	11	11	CD
cord-254580-nhpjvgt4	45	1	While	while	IN
cord-254580-nhpjvgt4	45	2	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	45	3	and	and	CC
cord-254580-nhpjvgt4	45	4	cyclosporine	cyclosporine	NN
cord-254580-nhpjvgt4	45	5	are	be	VBP
cord-254580-nhpjvgt4	45	6	associated	associate	VBN
cord-254580-nhpjvgt4	45	7	with	with	IN
cord-254580-nhpjvgt4	45	8	decreased	decrease	VBN
cord-254580-nhpjvgt4	45	9	infection	infection	NN
cord-254580-nhpjvgt4	45	10	rates	rate	NNS
cord-254580-nhpjvgt4	45	11	and	and	CC
cord-254580-nhpjvgt4	45	12	favored	favor	VBN
cord-254580-nhpjvgt4	45	13	over	over	IN
cord-254580-nhpjvgt4	45	14	treatment	treatment	NN
cord-254580-nhpjvgt4	45	15	with	with	IN
cord-254580-nhpjvgt4	45	16	systemic	systemic	JJ
cord-254580-nhpjvgt4	45	17	corticosteroids	corticosteroid	NNS
cord-254580-nhpjvgt4	45	18	,	,	,
cord-254580-nhpjvgt4	45	19	12	12	CD
cord-254580-nhpjvgt4	45	20	their	-PRON-	PRP$
cord-254580-nhpjvgt4	45	21	impact	impact	NN
cord-254580-nhpjvgt4	45	22	on	on	IN
cord-254580-nhpjvgt4	45	23	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	45	24	to	to	IN
cord-254580-nhpjvgt4	45	25	/	/	SYM
cord-254580-nhpjvgt4	45	26	severity	severity	NN
cord-254580-nhpjvgt4	45	27	of	of	IN
cord-254580-nhpjvgt4	45	28	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	45	29	is	be	VBZ
cord-254580-nhpjvgt4	45	30	unknown	unknown	JJ
cord-254580-nhpjvgt4	45	31	and	and	CC
cord-254580-nhpjvgt4	45	32	,	,	,
cord-254580-nhpjvgt4	45	33	if	if	IN
cord-254580-nhpjvgt4	45	34	essential	essential	JJ
cord-254580-nhpjvgt4	45	35	,	,	,
cord-254580-nhpjvgt4	45	36	precautions	precaution	NNS
cord-254580-nhpjvgt4	45	37	should	should	MD
cord-254580-nhpjvgt4	45	38	be	be	VB
cord-254580-nhpjvgt4	45	39	taken	take	VBN
cord-254580-nhpjvgt4	45	40	to	to	TO
cord-254580-nhpjvgt4	45	41	avoid	avoid	VB
cord-254580-nhpjvgt4	45	42	infection	infection	NN
cord-254580-nhpjvgt4	45	43	.	.	.
cord-254580-nhpjvgt4	46	1	Of	of	IN
cord-254580-nhpjvgt4	46	2	interest	interest	NN
cord-254580-nhpjvgt4	46	3	,	,	,
cord-254580-nhpjvgt4	46	4	cyclosporine	cyclosporine	NN
cord-254580-nhpjvgt4	46	5	has	have	VBZ
cord-254580-nhpjvgt4	46	6	anti	anti	JJ
cord-254580-nhpjvgt4	46	7	-	-	JJ
cord-254580-nhpjvgt4	46	8	coronavirus	coronavirus	JJ
cord-254580-nhpjvgt4	46	9	activity	activity	NN
cord-254580-nhpjvgt4	46	10	in	in	IN
cord-254580-nhpjvgt4	46	11	vitro	vitro	FW
cord-254580-nhpjvgt4	46	12	,	,	,
cord-254580-nhpjvgt4	46	13	but	but	CC
cord-254580-nhpjvgt4	46	14	the	the	DT
cord-254580-nhpjvgt4	46	15	effect	effect	NN
cord-254580-nhpjvgt4	46	16	in	in	IN
cord-254580-nhpjvgt4	46	17	humans	human	NNS
cord-254580-nhpjvgt4	46	18	is	be	VBZ
cord-254580-nhpjvgt4	46	19	unknown	unknown	JJ
cord-254580-nhpjvgt4	46	20	.	.	.
cord-254580-nhpjvgt4	47	1	13	13	CD
cord-254580-nhpjvgt4	48	1	The	the	DT
cord-254580-nhpjvgt4	48	2	systemic	systemic	JJ
cord-254580-nhpjvgt4	48	3	retinoid	retinoid	NN
cord-254580-nhpjvgt4	48	4	,	,	,
cord-254580-nhpjvgt4	48	5	acitretin	acitretin	NNP
cord-254580-nhpjvgt4	48	6	,	,	,
cord-254580-nhpjvgt4	48	7	is	be	VBZ
cord-254580-nhpjvgt4	48	8	anti	anti	JJ
cord-254580-nhpjvgt4	48	9	-	-	JJ
cord-254580-nhpjvgt4	48	10	inflammatory	inflammatory	JJ
cord-254580-nhpjvgt4	48	11	and	and	CC
cord-254580-nhpjvgt4	48	12	inhibits	inhibit	VBZ
cord-254580-nhpjvgt4	48	13	cell	cell	NN
cord-254580-nhpjvgt4	48	14	differentiation	differentiation	NN
cord-254580-nhpjvgt4	48	15	;	;	:
cord-254580-nhpjvgt4	48	16	it	-PRON-	PRP
cord-254580-nhpjvgt4	48	17	is	be	VBZ
cord-254580-nhpjvgt4	48	18	Food	Food	NNP
cord-254580-nhpjvgt4	48	19	and	and	CC
cord-254580-nhpjvgt4	48	20	Drug	Drug	NNP
cord-254580-nhpjvgt4	48	21	Administration	Administration	NNP
cord-254580-nhpjvgt4	48	22	(	(	-LRB-
cord-254580-nhpjvgt4	48	23	FDA)-approved	fda)-approve	VBN
cord-254580-nhpjvgt4	48	24	for	for	IN
cord-254580-nhpjvgt4	48	25	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	48	26	.	.	.
cord-254580-nhpjvgt4	49	1	14	14	CD
cord-254580-nhpjvgt4	50	1	It	-PRON-	PRP
cord-254580-nhpjvgt4	50	2	does	do	VBZ
cord-254580-nhpjvgt4	50	3	not	not	RB
cord-254580-nhpjvgt4	50	4	suppress	suppress	VB
cord-254580-nhpjvgt4	50	5	the	the	DT
cord-254580-nhpjvgt4	50	6	immune	immune	JJ
cord-254580-nhpjvgt4	50	7	system	system	NN
cord-254580-nhpjvgt4	50	8	to	to	IN
cord-254580-nhpjvgt4	50	9	the	the	DT
cord-254580-nhpjvgt4	50	10	extent	extent	NN
cord-254580-nhpjvgt4	50	11	of	of	IN
cord-254580-nhpjvgt4	50	12	the	the	DT
cord-254580-nhpjvgt4	50	13	other	other	JJ
cord-254580-nhpjvgt4	50	14	conventional	conventional	JJ
cord-254580-nhpjvgt4	50	15	treatments	treatment	NNS
cord-254580-nhpjvgt4	50	16	for	for	IN
cord-254580-nhpjvgt4	50	17	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	50	18	.	.	.
cord-254580-nhpjvgt4	51	1	In	in	IN
cord-254580-nhpjvgt4	51	2	an	an	DT
cord-254580-nhpjvgt4	51	3	observational	observational	JJ
cord-254580-nhpjvgt4	51	4	cohort	cohort	NN
cord-254580-nhpjvgt4	51	5	study	study	NN
cord-254580-nhpjvgt4	51	6	,	,	,
cord-254580-nhpjvgt4	51	7	there	there	EX
cord-254580-nhpjvgt4	51	8	was	be	VBD
cord-254580-nhpjvgt4	51	9	no	no	DT
cord-254580-nhpjvgt4	51	10	increased	increase	VBN
cord-254580-nhpjvgt4	51	11	rate	rate	NN
cord-254580-nhpjvgt4	51	12	of	of	IN
cord-254580-nhpjvgt4	51	13	overall	overall	JJ
cord-254580-nhpjvgt4	51	14	serious	serious	JJ
cord-254580-nhpjvgt4	51	15	infections	infection	NNS
cord-254580-nhpjvgt4	51	16	among	among	IN
cord-254580-nhpjvgt4	51	17	acitretin	acitretin	NN
cord-254580-nhpjvgt4	51	18	-	-	HYPH
cord-254580-nhpjvgt4	51	19	treated	treat	VBN
cord-254580-nhpjvgt4	51	20	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	51	21	patients	patient	NNS
cord-254580-nhpjvgt4	51	22	vs.	vs.	IN
cord-254580-nhpjvgt4	51	23	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	51	24	;	;	:
cord-254580-nhpjvgt4	51	25	acitretin	acitretin	NNP
cord-254580-nhpjvgt4	51	26	increased	increase	VBD
cord-254580-nhpjvgt4	51	27	risk	risk	NN
cord-254580-nhpjvgt4	51	28	of	of	IN
cord-254580-nhpjvgt4	51	29	cellulitis	cellulitis	NN
cord-254580-nhpjvgt4	51	30	compared	compare	VBN
cord-254580-nhpjvgt4	51	31	to	to	IN
cord-254580-nhpjvgt4	51	32	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	51	33	(	(	-LRB-
cord-254580-nhpjvgt4	51	34	propensity	propensity	NN
cord-254580-nhpjvgt4	51	35	score	score	RB
cord-254580-nhpjvgt4	51	36	-	-	HYPH
cord-254580-nhpjvgt4	51	37	adjusted	adjust	VBN
cord-254580-nhpjvgt4	51	38	hazard	hazard	NN
cord-254580-nhpjvgt4	51	39	ratio	ratio	NN
cord-254580-nhpjvgt4	51	40	[	[	-LRB-
cord-254580-nhpjvgt4	51	41	HR	HR	NNP
cord-254580-nhpjvgt4	51	42	]	]	-RRB-
cord-254580-nhpjvgt4	51	43	,	,	,
cord-254580-nhpjvgt4	51	44	1.76	1.76	CD
cord-254580-nhpjvgt4	51	45	;	;	.
cord-254580-nhpjvgt4	52	1	95	95	CD
cord-254580-nhpjvgt4	52	2	%	%	NN
cord-254580-nhpjvgt4	52	3	CI	CI	NNP
cord-254580-nhpjvgt4	52	4	,	,	,
cord-254580-nhpjvgt4	52	5	1.11	1.11	CD
cord-254580-nhpjvgt4	52	6	-	-	SYM
cord-254580-nhpjvgt4	52	7	2.80	2.80	CD
cord-254580-nhpjvgt4	52	8	)	)	-RRB-
cord-254580-nhpjvgt4	52	9	,	,	,
cord-254580-nhpjvgt4	52	10	possibly	possibly	RB
cord-254580-nhpjvgt4	52	11	due	due	JJ
cord-254580-nhpjvgt4	52	12	to	to	IN
cord-254580-nhpjvgt4	52	13	skin	skin	NN
cord-254580-nhpjvgt4	52	14	fragility	fragility	NN
cord-254580-nhpjvgt4	52	15	and	and	CC
cord-254580-nhpjvgt4	52	16	staphylococcus	staphylococcus	NN
cord-254580-nhpjvgt4	52	17	aureus	aureus	NNP
cord-254580-nhpjvgt4	52	18	colonization	colonization	NN
cord-254580-nhpjvgt4	52	19	.	.	.
cord-254580-nhpjvgt4	53	1	15	15	CD
cord-254580-nhpjvgt4	54	1	Therefore	therefore	RB
cord-254580-nhpjvgt4	54	2	,	,	,
cord-254580-nhpjvgt4	54	3	acitretin	acitretin	NNP
cord-254580-nhpjvgt4	54	4	has	have	VBZ
cord-254580-nhpjvgt4	54	5	not	not	RB
cord-254580-nhpjvgt4	54	6	shown	show	VBN
cord-254580-nhpjvgt4	54	7	increased	increase	VBN
cord-254580-nhpjvgt4	54	8	viral	viral	JJ
cord-254580-nhpjvgt4	54	9	/	/	SYM
cord-254580-nhpjvgt4	54	10	respiratory	respiratory	JJ
cord-254580-nhpjvgt4	54	11	infection	infection	NN
cord-254580-nhpjvgt4	54	12	risk	risk	NN
cord-254580-nhpjvgt4	54	13	and	and	CC
cord-254580-nhpjvgt4	54	14	can	can	MD
cord-254580-nhpjvgt4	54	15	be	be	VB
cord-254580-nhpjvgt4	54	16	safely	safely	RB
cord-254580-nhpjvgt4	54	17	used	use	VBN
cord-254580-nhpjvgt4	54	18	during	during	IN
cord-254580-nhpjvgt4	54	19	the	the	DT
cord-254580-nhpjvgt4	54	20	pandemic	pandemic	NN
cord-254580-nhpjvgt4	54	21	.	.	.
cord-254580-nhpjvgt4	55	1	Retinoids	retinoid	NNS
cord-254580-nhpjvgt4	55	2	have	have	VBP
cord-254580-nhpjvgt4	55	3	been	be	VBN
cord-254580-nhpjvgt4	55	4	shown	show	VBN
cord-254580-nhpjvgt4	55	5	to	to	TO
cord-254580-nhpjvgt4	55	6	inhibit	inhibit	VB
cord-254580-nhpjvgt4	55	7	human	human	JJ
cord-254580-nhpjvgt4	55	8	herpesvirus	herpesvirus	NN
cord-254580-nhpjvgt4	55	9	eight	eight	CD
cord-254580-nhpjvgt4	55	10	replication	replication	NN
cord-254580-nhpjvgt4	55	11	,	,	,
cord-254580-nhpjvgt4	56	1	their	-PRON-	PRP$
cord-254580-nhpjvgt4	56	2	effect	effect	NN
cord-254580-nhpjvgt4	56	3	on	on	IN
cord-254580-nhpjvgt4	56	4	SARS	SARS	NNP
cord-254580-nhpjvgt4	56	5	-	-	HYPH
cord-254580-nhpjvgt4	56	6	CoV-2	CoV-2	NNP
cord-254580-nhpjvgt4	56	7	remains	remain	VBZ
cord-254580-nhpjvgt4	56	8	to	to	TO
cord-254580-nhpjvgt4	56	9	be	be	VB
cord-254580-nhpjvgt4	56	10	established	establish	VBN
cord-254580-nhpjvgt4	56	11	.	.	.
cord-254580-nhpjvgt4	57	1	16	16	CD
cord-254580-nhpjvgt4	57	2	 	 	_SP
cord-254580-nhpjvgt4	58	1	This	this	DT
cord-254580-nhpjvgt4	58	2	article	article	NN
cord-254580-nhpjvgt4	58	3	is	be	VBZ
cord-254580-nhpjvgt4	58	4	protected	protect	VBN
cord-254580-nhpjvgt4	58	5	by	by	IN
cord-254580-nhpjvgt4	58	6	copyright	copyright	NN
cord-254580-nhpjvgt4	58	7	.	.	.
cord-254580-nhpjvgt4	59	1	All	all	DT
cord-254580-nhpjvgt4	59	2	rights	right	NNS
cord-254580-nhpjvgt4	59	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	59	4	.	.	.
cord-254580-nhpjvgt4	60	1	Azathioprine	Azathioprine	NNP
cord-254580-nhpjvgt4	60	2	is	be	VBZ
cord-254580-nhpjvgt4	60	3	used	use	VBN
cord-254580-nhpjvgt4	60	4	off	off	IN
cord-254580-nhpjvgt4	60	5	-	-	HYPH
cord-254580-nhpjvgt4	60	6	label	label	NN
cord-254580-nhpjvgt4	60	7	in	in	IN
cord-254580-nhpjvgt4	60	8	the	the	DT
cord-254580-nhpjvgt4	60	9	US	US	NNP
cord-254580-nhpjvgt4	60	10	for	for	IN
cord-254580-nhpjvgt4	60	11	AD	ad	NN
cord-254580-nhpjvgt4	60	12	treatment	treatment	NN
cord-254580-nhpjvgt4	60	13	in	in	IN
cord-254580-nhpjvgt4	60	14	patients	patient	NNS
cord-254580-nhpjvgt4	60	15	recalcitrant	recalcitrant	JJ
cord-254580-nhpjvgt4	60	16	or	or	CC
cord-254580-nhpjvgt4	60	17	who	who	WP
cord-254580-nhpjvgt4	60	18	have	have	VBP
cord-254580-nhpjvgt4	60	19	contraindications	contraindication	NNS
cord-254580-nhpjvgt4	60	20	to	to	IN
cord-254580-nhpjvgt4	60	21	cyclosporine	cyclosporine	NN
cord-254580-nhpjvgt4	60	22	and	and	CC
cord-254580-nhpjvgt4	60	23	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	60	24	.	.	.
cord-254580-nhpjvgt4	61	1	In	in	IN
cord-254580-nhpjvgt4	61	2	12	12	CD
cord-254580-nhpjvgt4	61	3	AD	ad	NN
cord-254580-nhpjvgt4	61	4	children	child	NNS
cord-254580-nhpjvgt4	61	5	treated	treat	VBN
cord-254580-nhpjvgt4	61	6	with	with	IN
cord-254580-nhpjvgt4	61	7	azathioprine	azathioprine	NN
cord-254580-nhpjvgt4	61	8	,	,	,
cord-254580-nhpjvgt4	61	9	there	there	EX
cord-254580-nhpjvgt4	61	10	were	be	VBD
cord-254580-nhpjvgt4	61	11	no	no	DT
cord-254580-nhpjvgt4	61	12	associated	associate	VBN
cord-254580-nhpjvgt4	61	13	infections	infection	NNS
cord-254580-nhpjvgt4	61	14	.	.	.
cord-254580-nhpjvgt4	62	1	17	17	CD
cord-254580-nhpjvgt4	63	1	In	in	IN
cord-254580-nhpjvgt4	63	2	a	a	DT
cord-254580-nhpjvgt4	63	3	double	double	JJ
cord-254580-nhpjvgt4	63	4	-	-	HYPH
cord-254580-nhpjvgt4	63	5	blind	blind	JJ
cord-254580-nhpjvgt4	63	6	,	,	,
cord-254580-nhpjvgt4	63	7	placebo	placebo	NN
cord-254580-nhpjvgt4	63	8	-	-	HYPH
cord-254580-nhpjvgt4	63	9	controlled	control	VBN
cord-254580-nhpjvgt4	63	10	,	,	,
cord-254580-nhpjvgt4	63	11	crossover	crossover	NN
cord-254580-nhpjvgt4	63	12	study	study	NN
cord-254580-nhpjvgt4	63	13	of	of	IN
cord-254580-nhpjvgt4	63	14	37	37	CD
cord-254580-nhpjvgt4	63	15	AD	ad	NN
cord-254580-nhpjvgt4	63	16	adults	adult	NNS
cord-254580-nhpjvgt4	63	17	treated	treat	VBN
cord-254580-nhpjvgt4	63	18	with	with	IN
cord-254580-nhpjvgt4	63	19	azathioprine	azathioprine	NN
cord-254580-nhpjvgt4	63	20	,	,	,
cord-254580-nhpjvgt4	63	21	there	there	EX
cord-254580-nhpjvgt4	63	22	were	be	VBD
cord-254580-nhpjvgt4	63	23	five	five	CD
cord-254580-nhpjvgt4	63	24	cases	case	NNS
cord-254580-nhpjvgt4	63	25	of	of	IN
cord-254580-nhpjvgt4	63	26	upper	upper	JJ
cord-254580-nhpjvgt4	63	27	respiratory	respiratory	JJ
cord-254580-nhpjvgt4	63	28	infections	infection	NNS
cord-254580-nhpjvgt4	63	29	(	(	-LRB-
cord-254580-nhpjvgt4	63	30	URIs	URIs	NNP
cord-254580-nhpjvgt4	63	31	)	)	-RRB-
cord-254580-nhpjvgt4	63	32	(	(	-LRB-
cord-254580-nhpjvgt4	63	33	14	14	CD
cord-254580-nhpjvgt4	63	34	%	%	NN
cord-254580-nhpjvgt4	63	35	)	)	-RRB-
cord-254580-nhpjvgt4	63	36	,	,	,
cord-254580-nhpjvgt4	63	37	two	two	CD
cord-254580-nhpjvgt4	63	38	cases	case	NNS
cord-254580-nhpjvgt4	63	39	folliculitis	folliculitis	VBP
cord-254580-nhpjvgt4	63	40	(	(	-LRB-
cord-254580-nhpjvgt4	63	41	5	5	CD
cord-254580-nhpjvgt4	63	42	%	%	NN
cord-254580-nhpjvgt4	63	43	)	)	-RRB-
cord-254580-nhpjvgt4	63	44	,	,	,
cord-254580-nhpjvgt4	63	45	and	and	CC
cord-254580-nhpjvgt4	63	46	one	one	CD
cord-254580-nhpjvgt4	63	47	report	report	NN
cord-254580-nhpjvgt4	63	48	each	each	DT
cord-254580-nhpjvgt4	63	49	impetigo	impetigo	NNS
cord-254580-nhpjvgt4	63	50	(	(	-LRB-
cord-254580-nhpjvgt4	63	51	3	3	CD
cord-254580-nhpjvgt4	63	52	%	%	NN
cord-254580-nhpjvgt4	63	53	)	)	-RRB-
cord-254580-nhpjvgt4	63	54	and	and	CC
cord-254580-nhpjvgt4	63	55	sore	sore	JJ
cord-254580-nhpjvgt4	63	56	throat	throat	NN
cord-254580-nhpjvgt4	63	57	(	(	-LRB-
cord-254580-nhpjvgt4	63	58	3	3	CD
cord-254580-nhpjvgt4	63	59	%	%	NN
cord-254580-nhpjvgt4	63	60	)	)	-RRB-
cord-254580-nhpjvgt4	63	61	.	.	.
cord-254580-nhpjvgt4	64	1	18	18	CD
cord-254580-nhpjvgt4	65	1	In	in	IN
cord-254580-nhpjvgt4	65	2	a	a	DT
cord-254580-nhpjvgt4	65	3	retrospective	retrospective	JJ
cord-254580-nhpjvgt4	65	4	analysis	analysis	NN
cord-254580-nhpjvgt4	65	5	of	of	IN
cord-254580-nhpjvgt4	65	6	232,611	232,611	CD
cord-254580-nhpjvgt4	65	7	systemically	systemically	RB
cord-254580-nhpjvgt4	65	8	-	-	HYPH
cord-254580-nhpjvgt4	65	9	treated	treat	VBN
cord-254580-nhpjvgt4	65	10	adults	adult	NNS
cord-254580-nhpjvgt4	65	11	with	with	IN
cord-254580-nhpjvgt4	65	12	AD	ad	NN
cord-254580-nhpjvgt4	65	13	(	(	-LRB-
cord-254580-nhpjvgt4	65	14	six	six	CD
cord-254580-nhpjvgt4	65	15	months	month	NNS
cord-254580-nhpjvgt4	65	16	)	)	-RRB-
cord-254580-nhpjvgt4	65	17	,	,	,
cord-254580-nhpjvgt4	65	18	there	there	EX
cord-254580-nhpjvgt4	65	19	were	be	VBD
cord-254580-nhpjvgt4	65	20	increased	increase	VBN
cord-254580-nhpjvgt4	65	21	risks	risk	NNS
cord-254580-nhpjvgt4	65	22	of	of	IN
cord-254580-nhpjvgt4	65	23	serious	serious	JJ
cord-254580-nhpjvgt4	65	24	and	and	CC
cord-254580-nhpjvgt4	65	25	opportunistic	opportunistic	JJ
cord-254580-nhpjvgt4	65	26	infections	infection	NNS
cord-254580-nhpjvgt4	65	27	with	with	IN
cord-254580-nhpjvgt4	65	28	azathioprine	azathioprine	NN
cord-254580-nhpjvgt4	65	29	(	(	-LRB-
cord-254580-nhpjvgt4	65	30	RR=1.89	RR=1.89	NNS
cord-254580-nhpjvgt4	65	31	)	)	-RRB-
cord-254580-nhpjvgt4	65	32	and	and	CC
cord-254580-nhpjvgt4	65	33	prednisone	prednisone	NNP
cord-254580-nhpjvgt4	65	34	(	(	-LRB-
cord-254580-nhpjvgt4	65	35	RR=1.78	RR=1.78	NFP
cord-254580-nhpjvgt4	65	36	)	)	-RRB-
cord-254580-nhpjvgt4	65	37	compared	compare	VBN
cord-254580-nhpjvgt4	65	38	with	with	IN
cord-254580-nhpjvgt4	65	39	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	65	40	,	,	,
cord-254580-nhpjvgt4	65	41	with	with	IN
cord-254580-nhpjvgt4	65	42	a	a	DT
cord-254580-nhpjvgt4	65	43	reduced	reduce	VBN
cord-254580-nhpjvgt4	65	44	risk	risk	NN
cord-254580-nhpjvgt4	65	45	with	with	IN
cord-254580-nhpjvgt4	65	46	cyclosporine	cyclosporine	NN
cord-254580-nhpjvgt4	65	47	(	(	-LRB-
cord-254580-nhpjvgt4	65	48	RR=0.87	RR=0.87	NNP
cord-254580-nhpjvgt4	65	49	)	)	-RRB-
cord-254580-nhpjvgt4	65	50	.	.	.
cord-254580-nhpjvgt4	66	1	12	12	CD
cord-254580-nhpjvgt4	67	1	Therefore	therefore	RB
cord-254580-nhpjvgt4	67	2	,	,	,
cord-254580-nhpjvgt4	67	3	azathioprine	azathioprine	NN
cord-254580-nhpjvgt4	67	4	may	may	MD
cord-254580-nhpjvgt4	67	5	increase	increase	VB
cord-254580-nhpjvgt4	67	6	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	67	7	to	to	IN
cord-254580-nhpjvgt4	67	8	infections	infection	NNS
cord-254580-nhpjvgt4	67	9	,	,	,
cord-254580-nhpjvgt4	67	10	and	and	CC
cord-254580-nhpjvgt4	67	11	if	if	IN
cord-254580-nhpjvgt4	67	12	essential	essential	JJ
cord-254580-nhpjvgt4	67	13	,	,	,
cord-254580-nhpjvgt4	67	14	exposure	exposure	NN
cord-254580-nhpjvgt4	67	15	to	to	IN
cord-254580-nhpjvgt4	67	16	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	67	17	should	should	MD
cord-254580-nhpjvgt4	67	18	be	be	VB
cord-254580-nhpjvgt4	67	19	minimized	minimize	VBN
cord-254580-nhpjvgt4	67	20	.	.	.
cord-254580-nhpjvgt4	68	1	Apremilast	Apremilast	NNP
cord-254580-nhpjvgt4	68	2	,	,	,
cord-254580-nhpjvgt4	68	3	an	an	DT
cord-254580-nhpjvgt4	68	4	orally	orally	RB
cord-254580-nhpjvgt4	68	5	administered	administer	VBN
cord-254580-nhpjvgt4	68	6	phosphodiesterase	phosphodiesterase	NN
cord-254580-nhpjvgt4	69	1	four	four	CD
cord-254580-nhpjvgt4	69	2	inhibitor	inhibitor	NN
cord-254580-nhpjvgt4	69	3	is	be	VBZ
cord-254580-nhpjvgt4	69	4	FDA	FDA	NNP
cord-254580-nhpjvgt4	69	5	-	-	HYPH
cord-254580-nhpjvgt4	69	6	approved	approve	VBN
cord-254580-nhpjvgt4	69	7	for	for	IN
cord-254580-nhpjvgt4	69	8	moderate	moderate	JJ
cord-254580-nhpjvgt4	69	9	to	to	IN
cord-254580-nhpjvgt4	69	10	severe	severe	JJ
cord-254580-nhpjvgt4	69	11	plaque	plaque	NN
cord-254580-nhpjvgt4	69	12	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	69	13	and	and	CC
cord-254580-nhpjvgt4	69	14	has	have	VBZ
cord-254580-nhpjvgt4	69	15	been	be	VBN
cord-254580-nhpjvgt4	69	16	used	use	VBN
cord-254580-nhpjvgt4	69	17	off	off	IN
cord-254580-nhpjvgt4	69	18	-	-	HYPH
cord-254580-nhpjvgt4	69	19	label	label	NN
cord-254580-nhpjvgt4	69	20	for	for	IN
cord-254580-nhpjvgt4	69	21	AD	ad	NN
cord-254580-nhpjvgt4	69	22	.	.	.
cord-254580-nhpjvgt4	70	1	[	[	-LRB-
cord-254580-nhpjvgt4	70	2	19	19	CD
cord-254580-nhpjvgt4	70	3	]	]	-RRB-
cord-254580-nhpjvgt4	70	4	[	[	-LRB-
cord-254580-nhpjvgt4	70	5	20	20	CD
cord-254580-nhpjvgt4	70	6	]	]	-RRB-
cord-254580-nhpjvgt4	70	7	[	[	-LRB-
cord-254580-nhpjvgt4	70	8	21	21	CD
cord-254580-nhpjvgt4	70	9	]	]	-RRB-
cord-254580-nhpjvgt4	71	1	Although	although	IN
cord-254580-nhpjvgt4	71	2	it	-PRON-	PRP
cord-254580-nhpjvgt4	71	3	does	do	VBZ
cord-254580-nhpjvgt4	71	4	modulate	modulate	VB
cord-254580-nhpjvgt4	71	5	immunologic	immunologic	JJ
cord-254580-nhpjvgt4	71	6	cascades	cascade	NNS
cord-254580-nhpjvgt4	71	7	,	,	,
cord-254580-nhpjvgt4	71	8	this	this	DT
cord-254580-nhpjvgt4	71	9	pathway	pathway	NN
cord-254580-nhpjvgt4	71	10	does	do	VBZ
cord-254580-nhpjvgt4	71	11	not	not	RB
cord-254580-nhpjvgt4	71	12	seem	seem	VB
cord-254580-nhpjvgt4	71	13	to	to	TO
cord-254580-nhpjvgt4	71	14	particularly	particularly	RB
cord-254580-nhpjvgt4	71	15	increase	increase	VB
cord-254580-nhpjvgt4	71	16	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	71	17	to	to	IN
cord-254580-nhpjvgt4	71	18	infection	infection	NN
cord-254580-nhpjvgt4	71	19	.	.	.
cord-254580-nhpjvgt4	72	1	In	in	IN
cord-254580-nhpjvgt4	72	2	a	a	DT
cord-254580-nhpjvgt4	72	3	pooled	pool	VBN
cord-254580-nhpjvgt4	72	4	safety	safety	NN
cord-254580-nhpjvgt4	72	5	analysis	analysis	NN
cord-254580-nhpjvgt4	72	6	of	of	IN
cord-254580-nhpjvgt4	72	7	two	two	CD
cord-254580-nhpjvgt4	72	8	randomized	randomized	JJ
cord-254580-nhpjvgt4	72	9	,	,	,
cord-254580-nhpjvgt4	72	10	controlled	control	VBN
cord-254580-nhpjvgt4	72	11	trials	trial	NNS
cord-254580-nhpjvgt4	72	12	(	(	-LRB-
cord-254580-nhpjvgt4	72	13	RCTs	RCTs	NNP
cord-254580-nhpjvgt4	72	14	)	)	-RRB-
cord-254580-nhpjvgt4	72	15	involving	involve	VBG
cord-254580-nhpjvgt4	72	16	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	72	17	patients	patient	NNS
cord-254580-nhpjvgt4	72	18	treated	treat	VBN
cord-254580-nhpjvgt4	72	19	with	with	IN
cord-254580-nhpjvgt4	72	20	apremilast	apremilast	NNP
cord-254580-nhpjvgt4	72	21	(	(	-LRB-
cord-254580-nhpjvgt4	72	22	n=1184	n=1184	CD
cord-254580-nhpjvgt4	72	23	)	)	-RRB-
cord-254580-nhpjvgt4	72	24	,	,	,
cord-254580-nhpjvgt4	72	25	URIs	uri	NNS
cord-254580-nhpjvgt4	72	26	and	and	CC
cord-254580-nhpjvgt4	72	27	nasopharyngitis	nasopharyngitis	NNP
cord-254580-nhpjvgt4	72	28	occurred	occur	VBD
cord-254580-nhpjvgt4	72	29	in	in	IN
cord-254580-nhpjvgt4	72	30	19.2	19.2	CD
cord-254580-nhpjvgt4	72	31	%	%	NN
cord-254580-nhpjvgt4	72	32	and	and	CC
cord-254580-nhpjvgt4	72	33	16.6	16.6	CD
cord-254580-nhpjvgt4	72	34	%	%	NN
cord-254580-nhpjvgt4	72	35	of	of	IN
cord-254580-nhpjvgt4	72	36	patients	patient	NNS
cord-254580-nhpjvgt4	72	37	,	,	,
cord-254580-nhpjvgt4	72	38	respectively	respectively	RB
cord-254580-nhpjvgt4	72	39	;	;	:
cord-254580-nhpjvgt4	72	40	serious	serious	JJ
cord-254580-nhpjvgt4	72	41	infections	infection	NNS
cord-254580-nhpjvgt4	72	42	(	(	-LRB-
cord-254580-nhpjvgt4	72	43	urinary	urinary	JJ
cord-254580-nhpjvgt4	72	44	tract	tract	NN
cord-254580-nhpjvgt4	72	45	infection	infection	NN
cord-254580-nhpjvgt4	72	46	n=2	n=2	NNS
cord-254580-nhpjvgt4	72	47	;	;	:
cord-254580-nhpjvgt4	72	48	appendicitis	appendicitis	JJ
cord-254580-nhpjvgt4	72	49	n=3	n=3	NN
cord-254580-nhpjvgt4	72	50	;	;	:
cord-254580-nhpjvgt4	72	51	pneumonia=2	pneumonia=2	NNS
cord-254580-nhpjvgt4	72	52	)	)	-RRB-
cord-254580-nhpjvgt4	72	53	occurred	occur	VBD
cord-254580-nhpjvgt4	72	54	in	in	IN
cord-254580-nhpjvgt4	72	55	1.4	1.4	CD
cord-254580-nhpjvgt4	72	56	%	%	NN
cord-254580-nhpjvgt4	72	57	.	.	.
cord-254580-nhpjvgt4	73	1	22	22	CD
cord-254580-nhpjvgt4	74	1	Furthermore	furthermore	RB
cord-254580-nhpjvgt4	74	2	,	,	,
cord-254580-nhpjvgt4	74	3	in	in	IN
cord-254580-nhpjvgt4	74	4	an	an	DT
cord-254580-nhpjvgt4	74	5	observational	observational	JJ
cord-254580-nhpjvgt4	74	6	cohort	cohort	NN
cord-254580-nhpjvgt4	74	7	study	study	NN
cord-254580-nhpjvgt4	74	8	including	include	VBG
cord-254580-nhpjvgt4	74	9	systemically	systemically	RB
cord-254580-nhpjvgt4	74	10	treated	treat	VBN
cord-254580-nhpjvgt4	74	11	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	74	12	patients	patient	NNS
cord-254580-nhpjvgt4	74	13	,	,	,
cord-254580-nhpjvgt4	74	14	overall	overall	JJ
cord-254580-nhpjvgt4	74	15	serious	serious	JJ
cord-254580-nhpjvgt4	74	16	infections	infection	NNS
cord-254580-nhpjvgt4	74	17	were	be	VBD
cord-254580-nhpjvgt4	74	18	decreased	decrease	VBN
cord-254580-nhpjvgt4	74	19	with	with	IN
cord-254580-nhpjvgt4	74	20	apremilast	apremilast	NNP
cord-254580-nhpjvgt4	74	21	vs.	vs.	FW
cord-254580-nhpjvgt4	74	22	methotrexate	methotrexate	NNP
cord-254580-nhpjvgt4	74	23	(	(	-LRB-
cord-254580-nhpjvgt4	74	24	HR	HR	NNP
cord-254580-nhpjvgt4	74	25	,	,	,
cord-254580-nhpjvgt4	74	26	0.50	0.50	CD
cord-254580-nhpjvgt4	74	27	;	;	:
cord-254580-nhpjvgt4	74	28	95	95	CD
cord-254580-nhpjvgt4	74	29	%	%	NN
cord-254580-nhpjvgt4	74	30	CI	ci	NN
cord-254580-nhpjvgt4	74	31	,	,	,
cord-254580-nhpjvgt4	74	32	0.26	0.26	CD
cord-254580-nhpjvgt4	74	33	-	-	SYM
cord-254580-nhpjvgt4	74	34	0.94	0.94	CD
cord-254580-nhpjvgt4	74	35	)	)	-RRB-
cord-254580-nhpjvgt4	74	36	.	.	.
cord-254580-nhpjvgt4	75	1	Thus	thus	RB
cord-254580-nhpjvgt4	75	2	,	,	,
cord-254580-nhpjvgt4	75	3	apremilast	apremilast	NNP
cord-254580-nhpjvgt4	75	4	seems	seem	VBZ
cord-254580-nhpjvgt4	75	5	to	to	TO
cord-254580-nhpjvgt4	75	6	be	be	VB
cord-254580-nhpjvgt4	75	7	a	a	DT
cord-254580-nhpjvgt4	75	8	safe	safe	JJ
cord-254580-nhpjvgt4	75	9	alternative	alternative	NN
cord-254580-nhpjvgt4	75	10	for	for	IN
cord-254580-nhpjvgt4	75	11	uninfected	uninfected	JJ
cord-254580-nhpjvgt4	75	12	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	75	13	patients	patient	NNS
cord-254580-nhpjvgt4	75	14	during	during	IN
cord-254580-nhpjvgt4	75	15	the	the	DT
cord-254580-nhpjvgt4	75	16	pandemic	pandemic	NN
cord-254580-nhpjvgt4	75	17	,	,	,
cord-254580-nhpjvgt4	75	18	but	but	CC
cord-254580-nhpjvgt4	75	19	specific	specific	JJ
cord-254580-nhpjvgt4	75	20	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	75	21	data	datum	NNS
cord-254580-nhpjvgt4	75	22	is	be	VBZ
cord-254580-nhpjvgt4	75	23	needed	need	VBN
cord-254580-nhpjvgt4	75	24	.	.	.
cord-254580-nhpjvgt4	76	1	Data	datum	NNS
cord-254580-nhpjvgt4	76	2	regarding	regard	VBG
cord-254580-nhpjvgt4	76	3	infection	infection	NN
cord-254580-nhpjvgt4	76	4	risks	risk	NNS
cord-254580-nhpjvgt4	76	5	of	of	IN
cord-254580-nhpjvgt4	76	6	nonbiological	nonbiological	JJ
cord-254580-nhpjvgt4	76	7	therapies	therapy	NNS
cord-254580-nhpjvgt4	76	8	for	for	IN
cord-254580-nhpjvgt4	76	9	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	76	10	and	and	CC
cord-254580-nhpjvgt4	76	11	AD	ad	NN
cord-254580-nhpjvgt4	76	12	is	be	VBZ
cord-254580-nhpjvgt4	76	13	summarized	summarize	VBN
cord-254580-nhpjvgt4	76	14	in	in	IN
cord-254580-nhpjvgt4	76	15	table	table	NN
cord-254580-nhpjvgt4	76	16	1	1	CD
cord-254580-nhpjvgt4	76	17	.	.	.
cord-254580-nhpjvgt4	77	1	Biologic	biologic	JJ
cord-254580-nhpjvgt4	77	2	medications	medication	NNS
cord-254580-nhpjvgt4	77	3	are	be	VBP
cord-254580-nhpjvgt4	77	4	widely	widely	RB
cord-254580-nhpjvgt4	77	5	used	use	VBN
cord-254580-nhpjvgt4	77	6	for	for	IN
cord-254580-nhpjvgt4	77	7	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	77	8	and	and	CC
cord-254580-nhpjvgt4	77	9	AD	ad	NN
cord-254580-nhpjvgt4	77	10	patients	patient	NNS
cord-254580-nhpjvgt4	77	11	,	,	,
cord-254580-nhpjvgt4	77	12	with	with	IN
cord-254580-nhpjvgt4	77	13	limited	limited	JJ
cord-254580-nhpjvgt4	77	14	data	datum	NNS
cord-254580-nhpjvgt4	77	15	regarding	regard	VBG
cord-254580-nhpjvgt4	77	16	infection	infection	NN
cord-254580-nhpjvgt4	77	17	risk	risk	NN
cord-254580-nhpjvgt4	77	18	.	.	.
cord-254580-nhpjvgt4	78	1	Since	since	IN
cord-254580-nhpjvgt4	78	2	biologics	biologic	NNS
cord-254580-nhpjvgt4	78	3	inhibit	inhibit	VBP
cord-254580-nhpjvgt4	78	4	immune	immune	JJ
cord-254580-nhpjvgt4	78	5	-	-	HYPH
cord-254580-nhpjvgt4	78	6	mediated	mediate	VBN
cord-254580-nhpjvgt4	78	7	pathways	pathway	NNS
cord-254580-nhpjvgt4	78	8	involving	involve	VBG
cord-254580-nhpjvgt4	78	9	specific	specific	JJ
cord-254580-nhpjvgt4	78	10	cytokines	cytokine	NNS
cord-254580-nhpjvgt4	78	11	,	,	,
cord-254580-nhpjvgt4	78	12	there	there	EX
cord-254580-nhpjvgt4	78	13	is	be	VBZ
cord-254580-nhpjvgt4	78	14	at	at	IN
cord-254580-nhpjvgt4	78	15	least	least	JJS
cord-254580-nhpjvgt4	78	16	theoretical	theoretical	JJ
cord-254580-nhpjvgt4	78	17	risk	risk	NN
cord-254580-nhpjvgt4	78	18	of	of	IN
cord-254580-nhpjvgt4	78	19	increased	increase	VBN
cord-254580-nhpjvgt4	78	20	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	78	21	to	to	IN
cord-254580-nhpjvgt4	78	22	and	and	CC
cord-254580-nhpjvgt4	78	23	severity	severity	NN
cord-254580-nhpjvgt4	78	24	of	of	IN
cord-254580-nhpjvgt4	78	25	infection	infection	NN
cord-254580-nhpjvgt4	78	26	.	.	.
cord-254580-nhpjvgt4	79	1	A	a	DT
cord-254580-nhpjvgt4	79	2	common	common	JJ
cord-254580-nhpjvgt4	79	3	reason	reason	NN
cord-254580-nhpjvgt4	79	4	for	for	IN
cord-254580-nhpjvgt4	79	5	discontinuation	discontinuation	NN
cord-254580-nhpjvgt4	79	6	of	of	IN
cord-254580-nhpjvgt4	79	7	biologics	biologic	NNS
cord-254580-nhpjvgt4	79	8	is	be	VBZ
cord-254580-nhpjvgt4	79	9	infection	infection	NN
cord-254580-nhpjvgt4	79	10	.	.	.
cord-254580-nhpjvgt4	80	1	23	23	CD
cord-254580-nhpjvgt4	81	1	Among	among	IN
cord-254580-nhpjvgt4	81	2	the	the	DT
cord-254580-nhpjvgt4	81	3	targeted	target	VBN
cord-254580-nhpjvgt4	81	4	cytokines	cytokine	NNS
cord-254580-nhpjvgt4	81	5	for	for	IN
cord-254580-nhpjvgt4	81	6	these	these	DT
cord-254580-nhpjvgt4	81	7	biologics	biologic	NNS
cord-254580-nhpjvgt4	81	8	,	,	,
cord-254580-nhpjvgt4	81	9	tumor	tumor	NN
cord-254580-nhpjvgt4	81	10	necrosis	necrosis	NN
cord-254580-nhpjvgt4	81	11	factor	factor	NN
cord-254580-nhpjvgt4	81	12	-	-	HYPH
cord-254580-nhpjvgt4	81	13	alpha	alpha	NN
cord-254580-nhpjvgt4	81	14	(	(	-LRB-
cord-254580-nhpjvgt4	81	15	TNF	TNF	NNP
cord-254580-nhpjvgt4	81	16	-	-	HYPH
cord-254580-nhpjvgt4	81	17	α	α	NNP
cord-254580-nhpjvgt4	81	18	)	)	-RRB-
cord-254580-nhpjvgt4	81	19	plays	play	VBZ
cord-254580-nhpjvgt4	81	20	a	a	DT
cord-254580-nhpjvgt4	81	21	crucial	crucial	JJ
cord-254580-nhpjvgt4	81	22	role	role	NN
cord-254580-nhpjvgt4	81	23	in	in	IN
cord-254580-nhpjvgt4	81	24	the	the	DT
cord-254580-nhpjvgt4	81	25	immune	immune	JJ
cord-254580-nhpjvgt4	81	26	response	response	NN
cord-254580-nhpjvgt4	81	27	against	against	IN
cord-254580-nhpjvgt4	81	28	intracellular	intracellular	JJ
cord-254580-nhpjvgt4	81	29	pathogens	pathogen	NNS
cord-254580-nhpjvgt4	81	30	and	and	CC
cord-254580-nhpjvgt4	81	31	formation	formation	NN
cord-254580-nhpjvgt4	81	32	of	of	IN
cord-254580-nhpjvgt4	81	33	granulomas	granuloma	NNS
cord-254580-nhpjvgt4	81	34	,	,	,
cord-254580-nhpjvgt4	81	35	24	24	CD
cord-254580-nhpjvgt4	81	36	and	and	CC
cord-254580-nhpjvgt4	81	37	Interleukin	Interleukin	NNP
cord-254580-nhpjvgt4	81	38	(	(	-LRB-
cord-254580-nhpjvgt4	81	39	IL	IL	NNP
cord-254580-nhpjvgt4	81	40	)	)	-RRB-
cord-254580-nhpjvgt4	82	1	-12	-12	.
cord-254580-nhpjvgt4	83	1	and	and	CC
cord-254580-nhpjvgt4	83	2	IL-23	IL-23	NNP
cord-254580-nhpjvgt4	83	3	are	be	VBP
cord-254580-nhpjvgt4	83	4	involved	involve	VBN
cord-254580-nhpjvgt4	83	5	in	in	IN
cord-254580-nhpjvgt4	83	6	cell	cell	NN
cord-254580-nhpjvgt4	83	7	-	-	HYPH
cord-254580-nhpjvgt4	83	8	mediated	mediate	VBN
cord-254580-nhpjvgt4	83	9	immunity	immunity	NN
cord-254580-nhpjvgt4	83	10	by	by	IN
cord-254580-nhpjvgt4	83	11	inducing	induce	VBG
cord-254580-nhpjvgt4	83	12	interferon	interferon	NN
cord-254580-nhpjvgt4	83	13	-	-	HYPH
cord-254580-nhpjvgt4	83	14	γ	γ	NN
cord-254580-nhpjvgt4	83	15	.	.	.
cord-254580-nhpjvgt4	84	1	25	25	CD
cord-254580-nhpjvgt4	84	2	IL-23	IL-23	NNP
cord-254580-nhpjvgt4	84	3	also	also	RB
cord-254580-nhpjvgt4	84	4	induces	induce	VBZ
cord-254580-nhpjvgt4	84	5	T	t	NN
cord-254580-nhpjvgt4	84	6	-	-	HYPH
cord-254580-nhpjvgt4	84	7	helper	helper	NN
cord-254580-nhpjvgt4	84	8	17	17	CD
cord-254580-nhpjvgt4	84	9	cell	cell	NN
cord-254580-nhpjvgt4	84	10	differentiation	differentiation	NN
cord-254580-nhpjvgt4	84	11	and	and	CC
cord-254580-nhpjvgt4	84	12	IL-17secretion	IL-17secretion	NNP
cord-254580-nhpjvgt4	84	13	,	,	,
cord-254580-nhpjvgt4	84	14	fundamental	fundamental	JJ
cord-254580-nhpjvgt4	84	15	in	in	IN
cord-254580-nhpjvgt4	84	16	providing	provide	VBG
cord-254580-nhpjvgt4	84	17	immunity	immunity	NN
cord-254580-nhpjvgt4	84	18	against	against	IN
cord-254580-nhpjvgt4	84	19	bacteria	bacteria	NNS
cord-254580-nhpjvgt4	84	20	,	,	,
cord-254580-nhpjvgt4	84	21	viruses	virus	NNS
cord-254580-nhpjvgt4	84	22	,	,	,
cord-254580-nhpjvgt4	84	23	fungi	fungus	NNS
cord-254580-nhpjvgt4	84	24	and	and	CC
cord-254580-nhpjvgt4	84	25	parasites	parasite	NNS
cord-254580-nhpjvgt4	84	26	.	.	.
cord-254580-nhpjvgt4	85	1	26	26	CD
cord-254580-nhpjvgt4	85	2	,	,	,
cord-254580-nhpjvgt4	85	3	27	27	CD
cord-254580-nhpjvgt4	85	4	IL-4	IL-4	NNP
cord-254580-nhpjvgt4	85	5	and	and	CC
cord-254580-nhpjvgt4	85	6	IL-13	IL-13	NNP
cord-254580-nhpjvgt4	85	7	play	play	VBP
cord-254580-nhpjvgt4	85	8	key	key	JJ
cord-254580-nhpjvgt4	85	9	roles	role	NNS
cord-254580-nhpjvgt4	85	10	in	in	IN
cord-254580-nhpjvgt4	85	11	the	the	DT
cord-254580-nhpjvgt4	85	12	immune	immune	JJ
cord-254580-nhpjvgt4	85	13	response	response	NN
cord-254580-nhpjvgt4	85	14	against	against	IN
cord-254580-nhpjvgt4	85	15	helminth	helminth	JJ
cord-254580-nhpjvgt4	85	16	infections	infection	NNS
cord-254580-nhpjvgt4	85	17	.	.	.
cord-254580-nhpjvgt4	86	1	28	28	CD
cord-254580-nhpjvgt4	86	2	Five	five	CD
cord-254580-nhpjvgt4	86	3	classes	class	NNS
cord-254580-nhpjvgt4	86	4	of	of	IN
cord-254580-nhpjvgt4	86	5	biologic	biologic	JJ
cord-254580-nhpjvgt4	86	6	therapies	therapy	NNS
cord-254580-nhpjvgt4	86	7	are	be	VBP
cord-254580-nhpjvgt4	86	8	used	use	VBN
cord-254580-nhpjvgt4	86	9	for	for	IN
cord-254580-nhpjvgt4	86	10	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	86	11	or	or	CC
cord-254580-nhpjvgt4	86	12	AD	ad	NN
cord-254580-nhpjvgt4	86	13	:	:	:
cord-254580-nhpjvgt4	87	1	TNF	TNF	NNP
cord-254580-nhpjvgt4	87	2	-	-	HYPH
cord-254580-nhpjvgt4	87	3	α	α	NNP
cord-254580-nhpjvgt4	87	4	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	87	5	(	(	-LRB-
cord-254580-nhpjvgt4	87	6	table	table	NN
cord-254580-nhpjvgt4	87	7	2	2	CD
cord-254580-nhpjvgt4	87	8	)	)	-RRB-
cord-254580-nhpjvgt4	87	9	,	,	,
cord-254580-nhpjvgt4	87	10	IL-17	IL-17	NNP
cord-254580-nhpjvgt4	87	11	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	87	12	,	,	,
cord-254580-nhpjvgt4	87	13	an	an	DT
cord-254580-nhpjvgt4	87	14	IL-12/23	il-12/23	NN
cord-254580-nhpjvgt4	87	15	inhibitor	inhibitor	NN
cord-254580-nhpjvgt4	87	16	,	,	,
cord-254580-nhpjvgt4	87	17	IL-23	IL-23	NNP
cord-254580-nhpjvgt4	87	18	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	87	19	,	,	,
cord-254580-nhpjvgt4	87	20	an	an	DT
cord-254580-nhpjvgt4	87	21	IL-4/13	il-4/13	NN
cord-254580-nhpjvgt4	87	22	inhibitor	inhibitor	NN
cord-254580-nhpjvgt4	87	23	,	,	,
cord-254580-nhpjvgt4	87	24	and	and	CC
cord-254580-nhpjvgt4	87	25	a	a	DT
cord-254580-nhpjvgt4	87	26	Janus	Janus	NNP
cord-254580-nhpjvgt4	87	27	kinase	kinase	NN
cord-254580-nhpjvgt4	87	28	(	(	-LRB-
cord-254580-nhpjvgt4	87	29	JAK	JAK	NNP
cord-254580-nhpjvgt4	87	30	)	)	-RRB-
cord-254580-nhpjvgt4	87	31	inhibitor	inhibitor	NN
cord-254580-nhpjvgt4	87	32	(	(	-LRB-
cord-254580-nhpjvgt4	87	33	table	table	NN
cord-254580-nhpjvgt4	87	34	3	3	CD
cord-254580-nhpjvgt4	87	35	)	)	-RRB-
cord-254580-nhpjvgt4	87	36	.	.	.
cord-254580-nhpjvgt4	88	1	This	this	DT
cord-254580-nhpjvgt4	88	2	article	article	NN
cord-254580-nhpjvgt4	88	3	is	be	VBZ
cord-254580-nhpjvgt4	88	4	protected	protect	VBN
cord-254580-nhpjvgt4	88	5	by	by	IN
cord-254580-nhpjvgt4	88	6	copyright	copyright	NN
cord-254580-nhpjvgt4	88	7	.	.	.
cord-254580-nhpjvgt4	89	1	All	all	DT
cord-254580-nhpjvgt4	89	2	rights	right	NNS
cord-254580-nhpjvgt4	89	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	89	4	.	.	.
cord-254580-nhpjvgt4	90	1	Anti	Anti	NNP
cord-254580-nhpjvgt4	90	2	-	-	NNP
cord-254580-nhpjvgt4	90	3	TNF	TNF	NNP
cord-254580-nhpjvgt4	90	4	-	-	HYPH
cord-254580-nhpjvgt4	90	5	α	α	NNP
cord-254580-nhpjvgt4	90	6	therapies	therapy	NNS
cord-254580-nhpjvgt4	90	7	inhibit	inhibit	VBP
cord-254580-nhpjvgt4	90	8	a	a	DT
cord-254580-nhpjvgt4	90	9	crucial	crucial	JJ
cord-254580-nhpjvgt4	90	10	immunological	immunological	JJ
cord-254580-nhpjvgt4	90	11	pathway	pathway	NN
cord-254580-nhpjvgt4	90	12	,	,	,
cord-254580-nhpjvgt4	90	13	therefore	therefore	RB
cord-254580-nhpjvgt4	90	14	an	an	DT
cord-254580-nhpjvgt4	90	15	immunosuppressive	immunosuppressive	JJ
cord-254580-nhpjvgt4	90	16	effect	effect	NN
cord-254580-nhpjvgt4	90	17	and	and	CC
cord-254580-nhpjvgt4	90	18	increased	increase	VBN
cord-254580-nhpjvgt4	90	19	infection	infection	NN
cord-254580-nhpjvgt4	90	20	risk	risk	NN
cord-254580-nhpjvgt4	90	21	are	be	VBP
cord-254580-nhpjvgt4	90	22	expected	expect	VBN
cord-254580-nhpjvgt4	90	23	.	.	.
cord-254580-nhpjvgt4	91	1	There	there	EX
cord-254580-nhpjvgt4	91	2	is	be	VBZ
cord-254580-nhpjvgt4	91	3	an	an	DT
cord-254580-nhpjvgt4	91	4	FDArequired	fdarequired	JJ
cord-254580-nhpjvgt4	91	5	black	black	JJ
cord-254580-nhpjvgt4	91	6	box	box	NN
cord-254580-nhpjvgt4	91	7	warning	warning	NN
cord-254580-nhpjvgt4	91	8	of	of	IN
cord-254580-nhpjvgt4	91	9	infection	infection	NN
cord-254580-nhpjvgt4	91	10	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	91	11	.	.	.
cord-254580-nhpjvgt4	92	1	29	29	CD
cord-254580-nhpjvgt4	93	1	However	however	RB
cord-254580-nhpjvgt4	93	2	,	,	,
cord-254580-nhpjvgt4	93	3	assessing	assess	VBG
cord-254580-nhpjvgt4	93	4	infection	infection	NN
cord-254580-nhpjvgt4	93	5	risk	risk	NN
cord-254580-nhpjvgt4	93	6	is	be	VBZ
cord-254580-nhpjvgt4	93	7	challenging	challenging	JJ
cord-254580-nhpjvgt4	93	8	because	because	IN
cord-254580-nhpjvgt4	93	9	RCTs	rct	NNS
cord-254580-nhpjvgt4	93	10	are	be	VBP
cord-254580-nhpjvgt4	93	11	often	often	RB
cord-254580-nhpjvgt4	93	12	not	not	RB
cord-254580-nhpjvgt4	93	13	adequately	adequately	RB
cord-254580-nhpjvgt4	93	14	powered	powered	JJ
cord-254580-nhpjvgt4	93	15	to	to	TO
cord-254580-nhpjvgt4	93	16	detect	detect	VB
cord-254580-nhpjvgt4	93	17	rare	rare	JJ
cord-254580-nhpjvgt4	93	18	events	event	NNS
cord-254580-nhpjvgt4	93	19	and	and	CC
cord-254580-nhpjvgt4	93	20	ineligibility	ineligibility	NN
cord-254580-nhpjvgt4	93	21	criteria	criterion	NNS
cord-254580-nhpjvgt4	93	22	may	may	MD
cord-254580-nhpjvgt4	93	23	exclude	exclude	VB
cord-254580-nhpjvgt4	93	24	up	up	IN
cord-254580-nhpjvgt4	93	25	to	to	TO
cord-254580-nhpjvgt4	93	26	30	30	CD
cord-254580-nhpjvgt4	93	27	%	%	NN
cord-254580-nhpjvgt4	93	28	of	of	IN
cord-254580-nhpjvgt4	93	29	real	real	JJ
cord-254580-nhpjvgt4	93	30	-	-	HYPH
cord-254580-nhpjvgt4	93	31	world	world	NN
cord-254580-nhpjvgt4	93	32	patients	patient	NNS
cord-254580-nhpjvgt4	93	33	.	.	.
cord-254580-nhpjvgt4	94	1	30	30	CD
cord-254580-nhpjvgt4	94	2	Certolizumab	Certolizumab	NNP
cord-254580-nhpjvgt4	94	3	increased	increase	VBD
cord-254580-nhpjvgt4	94	4	risks	risk	NNS
cord-254580-nhpjvgt4	94	5	of	of	IN
cord-254580-nhpjvgt4	94	6	all	all	DT
cord-254580-nhpjvgt4	94	7	infections	infection	NNS
cord-254580-nhpjvgt4	94	8	,	,	,
cord-254580-nhpjvgt4	94	9	URIs	uri	NNS
cord-254580-nhpjvgt4	94	10	and	and	CC
cord-254580-nhpjvgt4	94	11	nasopharyngitis	nasopharyngitis	NN
cord-254580-nhpjvgt4	94	12	by	by	IN
cord-254580-nhpjvgt4	94	13	5	5	CD
cord-254580-nhpjvgt4	94	14	%	%	NN
cord-254580-nhpjvgt4	94	15	,	,	,
cord-254580-nhpjvgt4	94	16	2	2	CD
cord-254580-nhpjvgt4	94	17	%	%	NN
cord-254580-nhpjvgt4	94	18	and	and	CC
cord-254580-nhpjvgt4	94	19	2	2	CD
cord-254580-nhpjvgt4	94	20	%	%	NN
cord-254580-nhpjvgt4	94	21	,	,	,
cord-254580-nhpjvgt4	94	22	respectively	respectively	RB
cord-254580-nhpjvgt4	94	23	.	.	.
cord-254580-nhpjvgt4	95	1	29	29	CD
cord-254580-nhpjvgt4	96	1	Additionally	additionally	RB
cord-254580-nhpjvgt4	96	2	,	,	,
cord-254580-nhpjvgt4	96	3	anti	anti	JJ
cord-254580-nhpjvgt4	96	4	-	-	JJ
cord-254580-nhpjvgt4	96	5	TNF	TNF	NNP
cord-254580-nhpjvgt4	96	6	-	-	HYPH
cord-254580-nhpjvgt4	96	7	α	α	NN
cord-254580-nhpjvgt4	96	8	therapy	therapy	NN
cord-254580-nhpjvgt4	96	9	is	be	VBZ
cord-254580-nhpjvgt4	96	10	associated	associate	VBN
cord-254580-nhpjvgt4	96	11	with	with	IN
cord-254580-nhpjvgt4	96	12	latent	latent	JJ
cord-254580-nhpjvgt4	96	13	tuberculosis	tuberculosis	NN
cord-254580-nhpjvgt4	96	14	reactivation	reactivation	NN
cord-254580-nhpjvgt4	96	15	,	,	,
cord-254580-nhpjvgt4	96	16	even	even	RB
cord-254580-nhpjvgt4	96	17	with	with	IN
cord-254580-nhpjvgt4	96	18	chemoprophylaxis	chemoprophylaxis	NNP
cord-254580-nhpjvgt4	96	19	;	;	:
cord-254580-nhpjvgt4	96	20	infliximab	infliximab	NNP
cord-254580-nhpjvgt4	96	21	is	be	VBZ
cord-254580-nhpjvgt4	96	22	associated	associate	VBN
cord-254580-nhpjvgt4	96	23	with	with	IN
cord-254580-nhpjvgt4	96	24	increased	increase	VBN
cord-254580-nhpjvgt4	96	25	risk	risk	NN
cord-254580-nhpjvgt4	96	26	of	of	IN
cord-254580-nhpjvgt4	96	27	herpes	herpes	NNP
cord-254580-nhpjvgt4	96	28	zoster	zoster	NNP
cord-254580-nhpjvgt4	96	29	.	.	.
cord-254580-nhpjvgt4	97	1	34	34	CD
cord-254580-nhpjvgt4	97	2	,	,	,
cord-254580-nhpjvgt4	97	3	35	35	CD
cord-254580-nhpjvgt4	97	4	Therefore	therefore	RB
cord-254580-nhpjvgt4	97	5	,	,	,
cord-254580-nhpjvgt4	97	6	based	base	VBN
cord-254580-nhpjvgt4	97	7	on	on	IN
cord-254580-nhpjvgt4	97	8	available	available	JJ
cord-254580-nhpjvgt4	97	9	data	datum	NNS
cord-254580-nhpjvgt4	97	10	,	,	,
cord-254580-nhpjvgt4	97	11	anti	anti	JJ
cord-254580-nhpjvgt4	97	12	-	-	JJ
cord-254580-nhpjvgt4	97	13	TNF	TNF	NNP
cord-254580-nhpjvgt4	97	14	-	-	HYPH
cord-254580-nhpjvgt4	97	15	α	α	NNP
cord-254580-nhpjvgt4	97	16	biologics	biologic	NNS
cord-254580-nhpjvgt4	97	17	should	should	MD
cord-254580-nhpjvgt4	97	18	be	be	VB
cord-254580-nhpjvgt4	97	19	held	hold	VBN
cord-254580-nhpjvgt4	97	20	Similarly	similarly	RB
cord-254580-nhpjvgt4	97	21	,	,	,
cord-254580-nhpjvgt4	97	22	an	an	DT
cord-254580-nhpjvgt4	97	23	11	11	CD
cord-254580-nhpjvgt4	97	24	%	%	NN
cord-254580-nhpjvgt4	97	25	increased	increase	VBN
cord-254580-nhpjvgt4	97	26	risk	risk	NN
cord-254580-nhpjvgt4	97	27	in	in	IN
cord-254580-nhpjvgt4	97	28	overall	overall	JJ
cord-254580-nhpjvgt4	97	29	infections	infection	NNS
cord-254580-nhpjvgt4	97	30	with	with	IN
cord-254580-nhpjvgt4	97	31	secukinumab	secukinumab	NNS
cord-254580-nhpjvgt4	97	32	was	be	VBD
cord-254580-nhpjvgt4	97	33	reported	report	VBN
cord-254580-nhpjvgt4	97	34	based	base	VBN
cord-254580-nhpjvgt4	97	35	on	on	IN
cord-254580-nhpjvgt4	97	36	pivotal	pivotal	JJ
cord-254580-nhpjvgt4	97	37	trials	trial	NNS
cord-254580-nhpjvgt4	97	38	,	,	,
cord-254580-nhpjvgt4	97	39	with	with	IN
cord-254580-nhpjvgt4	97	40	most	most	RBS
cord-254580-nhpjvgt4	97	41	attributable	attributable	JJ
cord-254580-nhpjvgt4	97	42	to	to	IN
cord-254580-nhpjvgt4	97	43	yeast	yeast	NN
cord-254580-nhpjvgt4	97	44	infections	infection	NNS
cord-254580-nhpjvgt4	97	45	;	;	:
cord-254580-nhpjvgt4	97	46	URIs	uri	NNS
cord-254580-nhpjvgt4	97	47	were	be	VBD
cord-254580-nhpjvgt4	97	48	increased	increase	VBN
cord-254580-nhpjvgt4	97	49	slightly	slightly	RB
cord-254580-nhpjvgt4	97	50	for	for	IN
cord-254580-nhpjvgt4	97	51	secukinumab	secukinumab	NNS
cord-254580-nhpjvgt4	97	52	,	,	,
cord-254580-nhpjvgt4	97	53	but	but	CC
cord-254580-nhpjvgt4	97	54	not	not	RB
cord-254580-nhpjvgt4	97	55	for	for	IN
cord-254580-nhpjvgt4	97	56	ixekizumab	ixekizumab	NNP
cord-254580-nhpjvgt4	97	57	or	or	CC
cord-254580-nhpjvgt4	97	58	brodalumab	brodalumab	NNP
cord-254580-nhpjvgt4	97	59	.	.	.
cord-254580-nhpjvgt4	98	1	29	29	CD
cord-254580-nhpjvgt4	99	1	Since	since	IN
cord-254580-nhpjvgt4	99	2	IL-17	IL-17	NNP
cord-254580-nhpjvgt4	99	3	plays	play	VBZ
cord-254580-nhpjvgt4	99	4	an	an	DT
cord-254580-nhpjvgt4	99	5	important	important	JJ
cord-254580-nhpjvgt4	99	6	role	role	NN
cord-254580-nhpjvgt4	99	7	in	in	IN
cord-254580-nhpjvgt4	99	8	immunological	immunological	JJ
cord-254580-nhpjvgt4	99	9	response	response	NN
cord-254580-nhpjvgt4	99	10	against	against	IN
cord-254580-nhpjvgt4	99	11	candida	candida	NN
cord-254580-nhpjvgt4	99	12	infections	infection	NNS
cord-254580-nhpjvgt4	99	13	,	,	,
cord-254580-nhpjvgt4	99	14	there	there	EX
cord-254580-nhpjvgt4	99	15	is	be	VBZ
cord-254580-nhpjvgt4	99	16	a	a	DT
cord-254580-nhpjvgt4	99	17	theoretical	theoretical	JJ
cord-254580-nhpjvgt4	99	18	increased	increase	VBN
cord-254580-nhpjvgt4	99	19	risk	risk	NN
cord-254580-nhpjvgt4	99	20	of	of	IN
cord-254580-nhpjvgt4	99	21	yeast	yeast	NN
cord-254580-nhpjvgt4	99	22	infections	infection	NNS
cord-254580-nhpjvgt4	99	23	with	with	IN
cord-254580-nhpjvgt4	99	24	anti	anti	JJ
cord-254580-nhpjvgt4	99	25	-	-	JJ
cord-254580-nhpjvgt4	99	26	IL17	il17	JJ
cord-254580-nhpjvgt4	99	27	therapies	therapy	NNS
cord-254580-nhpjvgt4	99	28	.	.	.
cord-254580-nhpjvgt4	100	1	40	40	CD
cord-254580-nhpjvgt4	101	1	In	in	IN
cord-254580-nhpjvgt4	101	2	a	a	DT
cord-254580-nhpjvgt4	101	3	pooled	pool	VBN
cord-254580-nhpjvgt4	101	4	analysis	analysis	NN
cord-254580-nhpjvgt4	101	5	from	from	IN
cord-254580-nhpjvgt4	101	6	10	10	CD
cord-254580-nhpjvgt4	101	7	phase	phase	NN
cord-254580-nhpjvgt4	101	8	two	two	CD
cord-254580-nhpjvgt4	101	9	and	and	CC
cord-254580-nhpjvgt4	101	10	three	three	CD
cord-254580-nhpjvgt4	101	11	clinical	clinical	JJ
cord-254580-nhpjvgt4	101	12	studies	study	NNS
cord-254580-nhpjvgt4	101	13	on	on	IN
cord-254580-nhpjvgt4	101	14	3,430	3,430	CD
cord-254580-nhpjvgt4	101	15	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	101	16	patients	patient	NNS
cord-254580-nhpjvgt4	101	17	treated	treat	VBN
cord-254580-nhpjvgt4	101	18	with	with	IN
cord-254580-nhpjvgt4	101	19	secukinumab	secukinumab	NNP
cord-254580-nhpjvgt4	101	20	300	300	CD
cord-254580-nhpjvgt4	101	21	mg	mg	NNP
cord-254580-nhpjvgt4	101	22	(	(	-LRB-
cord-254580-nhpjvgt4	101	23	n=1,1410	n=1,1410	NNP
cord-254580-nhpjvgt4	101	24	)	)	-RRB-
cord-254580-nhpjvgt4	101	25	,	,	,
cord-254580-nhpjvgt4	101	26	150	150	CD
cord-254580-nhpjvgt4	101	27	mg	mg	NN
cord-254580-nhpjvgt4	101	28	(	(	-LRB-
cord-254580-nhpjvgt4	101	29	n=1,395	n=1,395	NNP
cord-254580-nhpjvgt4	101	30	)	)	-RRB-
cord-254580-nhpjvgt4	101	31	and	and	CC
cord-254580-nhpjvgt4	101	32	etanercept	etanercept	NNP
cord-254580-nhpjvgt4	101	33	(	(	-LRB-
cord-254580-nhpjvgt4	101	34	n=323	n=323	NNP
cord-254580-nhpjvgt4	101	35	)	)	-RRB-
cord-254580-nhpjvgt4	102	1	,	,	,
cord-254580-nhpjvgt4	102	2	candida	candida	NN
cord-254580-nhpjvgt4	102	3	infections	infection	NNS
cord-254580-nhpjvgt4	102	4	were	be	VBD
cord-254580-nhpjvgt4	102	5	reported	report	VBN
cord-254580-nhpjvgt4	102	6	in	in	IN
cord-254580-nhpjvgt4	102	7	2.9	2.9	CD
cord-254580-nhpjvgt4	102	8	%	%	NN
cord-254580-nhpjvgt4	102	9	,	,	,
cord-254580-nhpjvgt4	102	10	1.5	1.5	CD
cord-254580-nhpjvgt4	102	11	%	%	NN
cord-254580-nhpjvgt4	102	12	and	and	CC
cord-254580-nhpjvgt4	102	13	1.2	1.2	CD
cord-254580-nhpjvgt4	102	14	%	%	NN
cord-254580-nhpjvgt4	102	15	of	of	IN
cord-254580-nhpjvgt4	102	16	subjects	subject	NNS
cord-254580-nhpjvgt4	102	17	,	,	,
cord-254580-nhpjvgt4	102	18	respectively	respectively	RB
cord-254580-nhpjvgt4	102	19	.	.	.
cord-254580-nhpjvgt4	103	1	41	41	CD
cord-254580-nhpjvgt4	104	1	All	all	DT
cord-254580-nhpjvgt4	104	2	infections	infection	NNS
cord-254580-nhpjvgt4	104	3	were	be	VBD
cord-254580-nhpjvgt4	104	4	mild	mild	JJ
cord-254580-nhpjvgt4	104	5	,	,	,
cord-254580-nhpjvgt4	104	6	resolved	resolve	VBN
cord-254580-nhpjvgt4	104	7	spontaneously	spontaneously	RB
cord-254580-nhpjvgt4	104	8	or	or	CC
cord-254580-nhpjvgt4	104	9	responded	respond	VBD
cord-254580-nhpjvgt4	104	10	to	to	IN
cord-254580-nhpjvgt4	104	11	standard	standard	JJ
cord-254580-nhpjvgt4	104	12	treatment	treatment	NN
cord-254580-nhpjvgt4	104	13	,	,	,
cord-254580-nhpjvgt4	104	14	without	without	IN
cord-254580-nhpjvgt4	104	15	causing	cause	VBG
cord-254580-nhpjvgt4	104	16	treatment	treatment	NN
cord-254580-nhpjvgt4	104	17	discontinuation	discontinuation	NN
cord-254580-nhpjvgt4	104	18	.	.	.
cord-254580-nhpjvgt4	105	1	41	41	CD
cord-254580-nhpjvgt4	105	2	Overall	Overall	NNP
cord-254580-nhpjvgt4	105	3	,	,	,
cord-254580-nhpjvgt4	105	4	increased	increase	VBN
cord-254580-nhpjvgt4	105	5	infection	infection	NN
cord-254580-nhpjvgt4	105	6	risk	risk	NN
cord-254580-nhpjvgt4	105	7	has	have	VBZ
cord-254580-nhpjvgt4	105	8	been	be	VBN
cord-254580-nhpjvgt4	105	9	shown	show	VBN
cord-254580-nhpjvgt4	105	10	with	with	IN
cord-254580-nhpjvgt4	105	11	IL-17	IL-17	NNP
cord-254580-nhpjvgt4	105	12	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	105	13	,	,	,
cord-254580-nhpjvgt4	105	14	but	but	CC
cord-254580-nhpjvgt4	105	15	yeast	yeast	NN
cord-254580-nhpjvgt4	105	16	infections	infection	NNS
cord-254580-nhpjvgt4	105	17	may	may	MD
cord-254580-nhpjvgt4	105	18	constitute	constitute	VB
cord-254580-nhpjvgt4	105	19	a	a	DT
cord-254580-nhpjvgt4	105	20	large	large	JJ
cord-254580-nhpjvgt4	105	21	proportion	proportion	NN
cord-254580-nhpjvgt4	105	22	of	of	IN
cord-254580-nhpjvgt4	105	23	that	that	DT
cord-254580-nhpjvgt4	105	24	increase	increase	NN
cord-254580-nhpjvgt4	105	25	;	;	:
cord-254580-nhpjvgt4	105	26	URIs	uri	NNS
cord-254580-nhpjvgt4	105	27	are	be	VBP
cord-254580-nhpjvgt4	105	28	particularly	particularly	RB
cord-254580-nhpjvgt4	105	29	uncommon	uncommon	JJ
cord-254580-nhpjvgt4	105	30	.	.	.
cord-254580-nhpjvgt4	106	1	Therefore	therefore	RB
cord-254580-nhpjvgt4	106	2	,	,	,
cord-254580-nhpjvgt4	106	3	IL-17	IL-17	NNP
cord-254580-nhpjvgt4	106	4	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	106	5	may	may	MD
cord-254580-nhpjvgt4	106	6	be	be	VB
cord-254580-nhpjvgt4	106	7	safely	safely	RB
cord-254580-nhpjvgt4	106	8	prescribed	prescribe	VBN
cord-254580-nhpjvgt4	106	9	and	and	CC
cord-254580-nhpjvgt4	106	10	continued	continue	VBD
cord-254580-nhpjvgt4	106	11	,	,	,
cord-254580-nhpjvgt4	106	12	unless	unless	IN
cord-254580-nhpjvgt4	106	13	the	the	DT
cord-254580-nhpjvgt4	106	14	patient	patient	NN
cord-254580-nhpjvgt4	106	15	is	be	VBZ
cord-254580-nhpjvgt4	106	16	symptomatic	symptomatic	JJ
cord-254580-nhpjvgt4	106	17	or	or	CC
cord-254580-nhpjvgt4	106	18	positive	positive	JJ
cord-254580-nhpjvgt4	106	19	for	for	IN
cord-254580-nhpjvgt4	106	20	SARS	SARS	NNP
cord-254580-nhpjvgt4	106	21	-	-	HYPH
cord-254580-nhpjvgt4	106	22	CoV-2	CoV-2	NNP
cord-254580-nhpjvgt4	106	23	.	.	.
cord-254580-nhpjvgt4	107	1	Ustekinumab	Ustekinumab	NNP
cord-254580-nhpjvgt4	107	2	inhibits	inhibit	VBZ
cord-254580-nhpjvgt4	107	3	IL-12	IL-12	NNP
cord-254580-nhpjvgt4	107	4	and	and	CC
cord-254580-nhpjvgt4	107	5	IL-23	IL-23	NNP
cord-254580-nhpjvgt4	107	6	,	,	,
cord-254580-nhpjvgt4	107	7	with	with	IN
cord-254580-nhpjvgt4	107	8	IL-12	IL-12	NNP
cord-254580-nhpjvgt4	107	9	playing	play	VBG
cord-254580-nhpjvgt4	107	10	an	an	DT
cord-254580-nhpjvgt4	107	11	important	important	JJ
cord-254580-nhpjvgt4	107	12	role	role	NN
cord-254580-nhpjvgt4	107	13	in	in	IN
cord-254580-nhpjvgt4	107	14	protection	protection	NN
cord-254580-nhpjvgt4	107	15	against	against	IN
cord-254580-nhpjvgt4	107	16	viral	viral	JJ
cord-254580-nhpjvgt4	107	17	infections	infection	NNS
cord-254580-nhpjvgt4	107	18	.	.	.
cord-254580-nhpjvgt4	108	1	29	29	CD
cord-254580-nhpjvgt4	108	2	,	,	,
cord-254580-nhpjvgt4	108	3	42	42	CD
cord-254580-nhpjvgt4	108	4	,	,	,
cord-254580-nhpjvgt4	108	5	43	43	CD
cord-254580-nhpjvgt4	109	1	However	however	RB
cord-254580-nhpjvgt4	109	2	,	,	,
cord-254580-nhpjvgt4	109	3	no	no	DT
cord-254580-nhpjvgt4	109	4	increased	increase	VBN
cord-254580-nhpjvgt4	109	5	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	109	6	to	to	IN
cord-254580-nhpjvgt4	109	7	infection	infection	NN
cord-254580-nhpjvgt4	109	8	with	with	IN
cord-254580-nhpjvgt4	109	9	ustekinumab	ustekinumab	NN
cord-254580-nhpjvgt4	109	10	has	have	VBZ
cord-254580-nhpjvgt4	109	11	been	be	VBN
cord-254580-nhpjvgt4	109	12	reported	report	VBN
cord-254580-nhpjvgt4	109	13	.	.	.
cord-254580-nhpjvgt4	110	1	In	in	IN
cord-254580-nhpjvgt4	110	2	a	a	DT
cord-254580-nhpjvgt4	110	3	pooled	pool	VBN
cord-254580-nhpjvgt4	110	4	analysis	analysis	NN
cord-254580-nhpjvgt4	110	5	of	of	IN
cord-254580-nhpjvgt4	110	6	four	four	CD
cord-254580-nhpjvgt4	110	7	phase	phase	NN
cord-254580-nhpjvgt4	110	8	two	two	CD
cord-254580-nhpjvgt4	110	9	/	/	SYM
cord-254580-nhpjvgt4	110	10	three	three	CD
cord-254580-nhpjvgt4	110	11	studies	study	NNS
cord-254580-nhpjvgt4	110	12	of	of	IN
cord-254580-nhpjvgt4	110	13	3	3	CD
cord-254580-nhpjvgt4	110	14	,	,	,
cord-254580-nhpjvgt4	110	15	117	117	CD
cord-254580-nhpjvgt4	110	16	This	this	DT
cord-254580-nhpjvgt4	110	17	article	article	NN
cord-254580-nhpjvgt4	110	18	is	be	VBZ
cord-254580-nhpjvgt4	110	19	protected	protect	VBN
cord-254580-nhpjvgt4	110	20	by	by	IN
cord-254580-nhpjvgt4	110	21	copyright	copyright	NN
cord-254580-nhpjvgt4	110	22	.	.	.
cord-254580-nhpjvgt4	111	1	All	all	DT
cord-254580-nhpjvgt4	111	2	rights	right	NNS
cord-254580-nhpjvgt4	111	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	111	4	.	.	.
cord-254580-nhpjvgt4	111	5	 	 	_SP
cord-254580-nhpjvgt4	112	1	Contrary	contrary	JJ
cord-254580-nhpjvgt4	112	2	to	to	IN
cord-254580-nhpjvgt4	112	3	IL-12/23	il-12/23	NN
cord-254580-nhpjvgt4	112	4	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	112	5	,	,	,
cord-254580-nhpjvgt4	113	1	anti	anti	JJ
cord-254580-nhpjvgt4	113	2	-	-	JJ
cord-254580-nhpjvgt4	113	3	IL-23	IL-23	NNP
cord-254580-nhpjvgt4	113	4	therapies	therapy	NNS
cord-254580-nhpjvgt4	113	5	do	do	VBP
cord-254580-nhpjvgt4	113	6	not	not	RB
cord-254580-nhpjvgt4	113	7	target	target	VB
cord-254580-nhpjvgt4	113	8	IL-12	IL-12	NNP
cord-254580-nhpjvgt4	113	9	,	,	,
cord-254580-nhpjvgt4	113	10	and	and	CC
cord-254580-nhpjvgt4	113	11	IL-12	IL-12	NNP
cord-254580-nhpjvgt4	113	12	plays	play	VBZ
cord-254580-nhpjvgt4	113	13	a	a	DT
cord-254580-nhpjvgt4	113	14	key	key	JJ
cord-254580-nhpjvgt4	113	15	role	role	NN
cord-254580-nhpjvgt4	113	16	fighting	fight	VBG
cord-254580-nhpjvgt4	113	17	viral	viral	JJ
cord-254580-nhpjvgt4	113	18	infections	infection	NNS
cord-254580-nhpjvgt4	113	19	.	.	.
cord-254580-nhpjvgt4	114	1	29	29	CD
cord-254580-nhpjvgt4	114	2	,	,	,
cord-254580-nhpjvgt4	114	3	45	45	CD
cord-254580-nhpjvgt4	114	4	Reduced	reduce	VBN
cord-254580-nhpjvgt4	114	5	risks	risk	NNS
cord-254580-nhpjvgt4	114	6	of	of	IN
cord-254580-nhpjvgt4	114	7	salmonella	salmonella	NN
cord-254580-nhpjvgt4	114	8	,	,	,
cord-254580-nhpjvgt4	114	9	candida	candida	NN
cord-254580-nhpjvgt4	114	10	and	and	CC
cord-254580-nhpjvgt4	114	11	mycobacterium	mycobacterium	NN
cord-254580-nhpjvgt4	114	12	infections	infection	NNS
cord-254580-nhpjvgt4	114	13	were	be	VBD
cord-254580-nhpjvgt4	114	14	seen	see	VBN
cord-254580-nhpjvgt4	114	15	in	in	IN
cord-254580-nhpjvgt4	114	16	IL-23p19-targeted	IL-23p19-targeted	NNP
cord-254580-nhpjvgt4	114	17	vs.	vs.	FW
cord-254580-nhpjvgt4	114	18	IL-12/23p40-targeted	IL-12/23p40-targeted	NNP
cord-254580-nhpjvgt4	114	19	animal	animal	NN
cord-254580-nhpjvgt4	114	20	models	model	NNS
cord-254580-nhpjvgt4	114	21	.	.	.
cord-254580-nhpjvgt4	115	1	46	46	CD
cord-254580-nhpjvgt4	115	2	-	-	SYM
cord-254580-nhpjvgt4	115	3	49	49	CD
cord-254580-nhpjvgt4	116	1	Nonetheless	nonetheless	RB
cord-254580-nhpjvgt4	116	2	,	,	,
cord-254580-nhpjvgt4	116	3	RCTs	RCTs	NNPS
cord-254580-nhpjvgt4	116	4	on	on	IN
cord-254580-nhpjvgt4	116	5	IL-23	IL-23	NNP
cord-254580-nhpjvgt4	116	6	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	116	7	have	have	VBP
cord-254580-nhpjvgt4	116	8	shown	show	VBN
cord-254580-nhpjvgt4	116	9	conflicting	conflict	VBG
cord-254580-nhpjvgt4	116	10	results	result	NNS
cord-254580-nhpjvgt4	116	11	regarding	regard	VBG
cord-254580-nhpjvgt4	116	12	infection	infection	NN
cord-254580-nhpjvgt4	116	13	risks	risk	NNS
cord-254580-nhpjvgt4	116	14	.	.	.
cord-254580-nhpjvgt4	117	1	In	in	IN
cord-254580-nhpjvgt4	117	2	a	a	DT
cord-254580-nhpjvgt4	117	3	phase	phase	NN
cord-254580-nhpjvgt4	117	4	III	iii	CD
cord-254580-nhpjvgt4	117	5	,	,	,
cord-254580-nhpjvgt4	117	6	double	double	RB
cord-254580-nhpjvgt4	117	7	-	-	HYPH
cord-254580-nhpjvgt4	117	8	blinded	blinded	JJ
cord-254580-nhpjvgt4	117	9	,	,	,
cord-254580-nhpjvgt4	117	10	placebo	placebo	NN
cord-254580-nhpjvgt4	117	11	-	-	HYPH
cord-254580-nhpjvgt4	117	12	controlled	control	VBN
cord-254580-nhpjvgt4	117	13	study	study	NN
cord-254580-nhpjvgt4	117	14	on	on	IN
cord-254580-nhpjvgt4	117	15	837	837	CD
cord-254580-nhpjvgt4	117	16	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	117	17	patients	patient	NNS
cord-254580-nhpjvgt4	117	18	randomized	randomize	VBN
cord-254580-nhpjvgt4	117	19	to	to	IN
cord-254580-nhpjvgt4	117	20	treatment	treatment	NN
cord-254580-nhpjvgt4	117	21	with	with	IN
cord-254580-nhpjvgt4	117	22	guselkumab	guselkumab	NNS
cord-254580-nhpjvgt4	117	23	,	,	,
cord-254580-nhpjvgt4	117	24	adalimumab	adalimumab	NNS
cord-254580-nhpjvgt4	117	25	or	or	CC
cord-254580-nhpjvgt4	117	26	placebo	placebo	NN
cord-254580-nhpjvgt4	117	27	,	,	,
cord-254580-nhpjvgt4	117	28	overall	overall	RB
cord-254580-nhpjvgt4	117	29	,	,	,
cord-254580-nhpjvgt4	117	30	candida	candida	NN
cord-254580-nhpjvgt4	117	31	,	,	,
cord-254580-nhpjvgt4	117	32	and	and	CC
cord-254580-nhpjvgt4	117	33	serious	serious	JJ
cord-254580-nhpjvgt4	117	34	infections	infection	NNS
cord-254580-nhpjvgt4	117	35	,	,	,
cord-254580-nhpjvgt4	117	36	occurred	occur	VBD
cord-254580-nhpjvgt4	117	37	at	at	IN
cord-254580-nhpjvgt4	117	38	comparable	comparable	JJ
cord-254580-nhpjvgt4	117	39	rates	rate	NNS
cord-254580-nhpjvgt4	117	40	across	across	IN
cord-254580-nhpjvgt4	117	41	treatment	treatment	NN
cord-254580-nhpjvgt4	117	42	groups	group	NNS
cord-254580-nhpjvgt4	117	43	.	.	.
cord-254580-nhpjvgt4	118	1	50	50	CD
cord-254580-nhpjvgt4	119	1	In	in	IN
cord-254580-nhpjvgt4	119	2	798	798	CD
cord-254580-nhpjvgt4	119	3	risankizumab	risankizumab	NNS
cord-254580-nhpjvgt4	119	4	-	-	HYPH
cord-254580-nhpjvgt4	119	5	treated	treat	VBN
cord-254580-nhpjvgt4	119	6	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	119	7	patients	patient	NNS
cord-254580-nhpjvgt4	119	8	,	,	,
cord-254580-nhpjvgt4	119	9	there	there	EX
cord-254580-nhpjvgt4	119	10	was	be	VBD
cord-254580-nhpjvgt4	119	11	increased	increase	VBN
cord-254580-nhpjvgt4	120	1	overall	overall	JJ
cord-254580-nhpjvgt4	120	2	infection	infection	NN
cord-254580-nhpjvgt4	120	3	risk	risk	NN
cord-254580-nhpjvgt4	120	4	in	in	IN
cord-254580-nhpjvgt4	120	5	two	two	CD
cord-254580-nhpjvgt4	120	6	This	this	DT
cord-254580-nhpjvgt4	120	7	article	article	NN
cord-254580-nhpjvgt4	120	8	is	be	VBZ
cord-254580-nhpjvgt4	120	9	protected	protect	VBN
cord-254580-nhpjvgt4	120	10	by	by	IN
cord-254580-nhpjvgt4	120	11	copyright	copyright	NN
cord-254580-nhpjvgt4	120	12	.	.	.
cord-254580-nhpjvgt4	121	1	All	all	DT
cord-254580-nhpjvgt4	121	2	rights	right	NNS
cord-254580-nhpjvgt4	121	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	121	4	.	.	.
cord-254580-nhpjvgt4	122	1	phase	phase	NN
cord-254580-nhpjvgt4	122	2	three	three	CD
cord-254580-nhpjvgt4	122	3	studies	study	NNS
cord-254580-nhpjvgt4	122	4	.	.	.
cord-254580-nhpjvgt4	123	1	51	51	CD
cord-254580-nhpjvgt4	124	1	The	the	DT
cord-254580-nhpjvgt4	124	2	most	most	RBS
cord-254580-nhpjvgt4	124	3	common	common	JJ
cord-254580-nhpjvgt4	124	4	infections	infection	NNS
cord-254580-nhpjvgt4	124	5	were	be	VBD
cord-254580-nhpjvgt4	124	6	URIs	uri	NNS
cord-254580-nhpjvgt4	124	7	,	,	,
cord-254580-nhpjvgt4	124	8	urinary	urinary	JJ
cord-254580-nhpjvgt4	124	9	tract	tract	JJ
cord-254580-nhpjvgt4	124	10	infections	infection	NNS
cord-254580-nhpjvgt4	124	11	and	and	CC
cord-254580-nhpjvgt4	124	12	influenza	influenza	NN
cord-254580-nhpjvgt4	124	13	.	.	.
cord-254580-nhpjvgt4	125	1	51	51	CD
cord-254580-nhpjvgt4	126	1	Two	two	CD
cord-254580-nhpjvgt4	126	2	cases	case	NNS
cord-254580-nhpjvgt4	126	3	of	of	IN
cord-254580-nhpjvgt4	126	4	latent	latent	JJ
cord-254580-nhpjvgt4	126	5	tuberculosis	tuberculosis	NN
cord-254580-nhpjvgt4	126	6	were	be	VBD
cord-254580-nhpjvgt4	126	7	reported	report	VBN
cord-254580-nhpjvgt4	126	8	in	in	IN
cord-254580-nhpjvgt4	126	9	the	the	DT
cord-254580-nhpjvgt4	126	10	risankizumab	risankizumab	NNP
cord-254580-nhpjvgt4	126	11	group	group	NN
cord-254580-nhpjvgt4	126	12	;	;	:
cord-254580-nhpjvgt4	126	13	both	both	DT
cord-254580-nhpjvgt4	126	14	patients	patient	NNS
cord-254580-nhpjvgt4	126	15	tested	test	VBD
cord-254580-nhpjvgt4	126	16	negative	negative	JJ
cord-254580-nhpjvgt4	126	17	at	at	IN
cord-254580-nhpjvgt4	126	18	baseline	baseline	NN
cord-254580-nhpjvgt4	126	19	.	.	.
cord-254580-nhpjvgt4	127	1	51	51	CD
cord-254580-nhpjvgt4	128	1	Data	datum	NNS
cord-254580-nhpjvgt4	128	2	assessing	assess	VBG
cord-254580-nhpjvgt4	128	3	infection	infection	NN
cord-254580-nhpjvgt4	128	4	risk	risk	NN
cord-254580-nhpjvgt4	128	5	with	with	IN
cord-254580-nhpjvgt4	128	6	tildrakizumab	tildrakizumab	NNP
cord-254580-nhpjvgt4	128	7	is	be	VBZ
cord-254580-nhpjvgt4	128	8	sparse	sparse	JJ
cord-254580-nhpjvgt4	128	9	.	.	.
cord-254580-nhpjvgt4	129	1	Lebwohl	Lebwohl	NNP
cord-254580-nhpjvgt4	129	2	et	et	FW
cord-254580-nhpjvgt4	129	3	al	al	NNP
cord-254580-nhpjvgt4	129	4	reported	report	VBD
cord-254580-nhpjvgt4	129	5	an	an	DT
cord-254580-nhpjvgt4	129	6	increase	increase	NN
cord-254580-nhpjvgt4	129	7	in	in	IN
cord-254580-nhpjvgt4	129	8	nasopharyngitis	nasopharyngitis	NNP
cord-254580-nhpjvgt4	129	9	(	(	-LRB-
cord-254580-nhpjvgt4	129	10	4	4	CD
cord-254580-nhpjvgt4	129	11	%	%	NN
cord-254580-nhpjvgt4	129	12	)	)	-RRB-
cord-254580-nhpjvgt4	129	13	with	with	IN
cord-254580-nhpjvgt4	129	14	tildrakizumab	tildrakizumab	NNS
cord-254580-nhpjvgt4	129	15	compared	compare	VBN
cord-254580-nhpjvgt4	129	16	with	with	IN
cord-254580-nhpjvgt4	129	17	placebo	placebo	NN
cord-254580-nhpjvgt4	129	18	.	.	.
cord-254580-nhpjvgt4	130	1	29	29	CD
cord-254580-nhpjvgt4	130	2	Risk	risk	NN
cord-254580-nhpjvgt4	130	3	,	,	,
cord-254580-nhpjvgt4	130	4	however	however	RB
cord-254580-nhpjvgt4	130	5	,	,	,
cord-254580-nhpjvgt4	130	6	is	be	VBZ
cord-254580-nhpjvgt4	130	7	low	low	JJ
cord-254580-nhpjvgt4	130	8	and	and	CC
cord-254580-nhpjvgt4	130	9	comparable	comparable	JJ
cord-254580-nhpjvgt4	130	10	to	to	IN
cord-254580-nhpjvgt4	130	11	placebo	placebo	NN
cord-254580-nhpjvgt4	130	12	.	.	.
cord-254580-nhpjvgt4	131	1	Therefore	therefore	RB
cord-254580-nhpjvgt4	131	2	,	,	,
cord-254580-nhpjvgt4	131	3	based	base	VBN
cord-254580-nhpjvgt4	131	4	on	on	IN
cord-254580-nhpjvgt4	131	5	available	available	JJ
cord-254580-nhpjvgt4	131	6	data	datum	NNS
cord-254580-nhpjvgt4	131	7	,	,	,
cord-254580-nhpjvgt4	131	8	IL-23	IL-23	NNP
cord-254580-nhpjvgt4	131	9	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	131	10	may	may	MD
cord-254580-nhpjvgt4	131	11	be	be	VB
cord-254580-nhpjvgt4	131	12	continued	continue	VBN
cord-254580-nhpjvgt4	131	13	/	/	SYM
cord-254580-nhpjvgt4	131	14	initiated	initiate	VBN
cord-254580-nhpjvgt4	131	15	,	,	,
cord-254580-nhpjvgt4	131	16	unless	unless	IN
cord-254580-nhpjvgt4	131	17	the	the	DT
cord-254580-nhpjvgt4	131	18	patient	patient	NN
cord-254580-nhpjvgt4	131	19	is	be	VBZ
cord-254580-nhpjvgt4	131	20	symptomatic	symptomatic	JJ
cord-254580-nhpjvgt4	131	21	or	or	CC
cord-254580-nhpjvgt4	131	22	positive	positive	JJ
cord-254580-nhpjvgt4	131	23	for	for	IN
cord-254580-nhpjvgt4	131	24	SARS	SARS	NNP
cord-254580-nhpjvgt4	131	25	-	-	HYPH
cord-254580-nhpjvgt4	131	26	CoV-2	CoV-2	NNP
cord-254580-nhpjvgt4	131	27	.	.	.
cord-254580-nhpjvgt4	132	1	Tofacitinib	Tofacitinib	NNP
cord-254580-nhpjvgt4	132	2	is	be	VBZ
cord-254580-nhpjvgt4	132	3	a	a	DT
cord-254580-nhpjvgt4	132	4	small	small	JJ
cord-254580-nhpjvgt4	132	5	molecule	molecule	NN
cord-254580-nhpjvgt4	132	6	inhibitor	inhibitor	NN
cord-254580-nhpjvgt4	132	7	of	of	IN
cord-254580-nhpjvgt4	132	8	tyrosine	tyrosine	NN
cord-254580-nhpjvgt4	132	9	kinases	kinase	NNS
cord-254580-nhpjvgt4	132	10	of	of	IN
cord-254580-nhpjvgt4	132	11	the	the	DT
cord-254580-nhpjvgt4	132	12	Janus	Janus	NNP
cord-254580-nhpjvgt4	132	13	family	family	NN
cord-254580-nhpjvgt4	132	14	,	,	,
cord-254580-nhpjvgt4	132	15	preferentially	preferentially	RB
cord-254580-nhpjvgt4	132	16	JAK1	JAK1	NNP
cord-254580-nhpjvgt4	132	17	and	and	CC
cord-254580-nhpjvgt4	132	18	JAK3	JAK3	NNP
cord-254580-nhpjvgt4	132	19	,	,	,
cord-254580-nhpjvgt4	132	20	downregulating	downregulate	VBG
cord-254580-nhpjvgt4	132	21	cytokines	cytokine	NNS
cord-254580-nhpjvgt4	132	22	crucial	crucial	JJ
cord-254580-nhpjvgt4	132	23	for	for	IN
cord-254580-nhpjvgt4	132	24	lymphocyte	lymphocyte	NN
cord-254580-nhpjvgt4	132	25	development	development	NN
cord-254580-nhpjvgt4	132	26	;	;	:
cord-254580-nhpjvgt4	132	27	therefore	therefore	RB
cord-254580-nhpjvgt4	132	28	,	,	,
cord-254580-nhpjvgt4	132	29	there	there	EX
cord-254580-nhpjvgt4	132	30	is	be	VBZ
cord-254580-nhpjvgt4	132	31	potential	potential	JJ
cord-254580-nhpjvgt4	132	32	for	for	IN
cord-254580-nhpjvgt4	132	33	increased	increase	VBN
cord-254580-nhpjvgt4	132	34	risks	risk	NNS
cord-254580-nhpjvgt4	132	35	of	of	IN
cord-254580-nhpjvgt4	132	36	intracellular	intracellular	JJ
cord-254580-nhpjvgt4	132	37	bacterial	bacterial	JJ
cord-254580-nhpjvgt4	132	38	and	and	CC
cord-254580-nhpjvgt4	132	39	viral	viral	JJ
cord-254580-nhpjvgt4	132	40	infections	infection	NNS
cord-254580-nhpjvgt4	132	41	.	.	.
cord-254580-nhpjvgt4	133	1	52	52	CD
cord-254580-nhpjvgt4	134	1	It	-PRON-	PRP
cord-254580-nhpjvgt4	134	2	has	have	VBZ
cord-254580-nhpjvgt4	134	3	been	be	VBN
cord-254580-nhpjvgt4	134	4	hypothesized	hypothesize	VBN
cord-254580-nhpjvgt4	134	5	,	,	,
cord-254580-nhpjvgt4	134	6	nonetheless	nonetheless	RB
cord-254580-nhpjvgt4	134	7	,	,	,
cord-254580-nhpjvgt4	134	8	that	that	IN
cord-254580-nhpjvgt4	134	9	fluctuations	fluctuation	NNS
cord-254580-nhpjvgt4	134	10	in	in	IN
cord-254580-nhpjvgt4	134	11	plasma	plasma	NN
cord-254580-nhpjvgt4	134	12	levels	level	NNS
cord-254580-nhpjvgt4	134	13	of	of	IN
cord-254580-nhpjvgt4	134	14	JAK	JAK	NNP
cord-254580-nhpjvgt4	134	15	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	134	16	throughout	throughout	IN
cord-254580-nhpjvgt4	134	17	the	the	DT
cord-254580-nhpjvgt4	134	18	day	day	NN
cord-254580-nhpjvgt4	134	19	may	may	MD
cord-254580-nhpjvgt4	134	20	preserve	preserve	VB
cord-254580-nhpjvgt4	134	21	immunogenicity	immunogenicity	NN
cord-254580-nhpjvgt4	134	22	against	against	IN
cord-254580-nhpjvgt4	134	23	infectious	infectious	JJ
cord-254580-nhpjvgt4	134	24	pathogens	pathogen	NNS
cord-254580-nhpjvgt4	134	25	.	.	.
cord-254580-nhpjvgt4	135	1	53	53	CD
cord-254580-nhpjvgt4	136	1	Tofacitinib	Tofacitinib	NNP
cord-254580-nhpjvgt4	136	2	carries	carry	VBZ
cord-254580-nhpjvgt4	136	3	an	an	DT
cord-254580-nhpjvgt4	136	4	FDA	FDA	NNP
cord-254580-nhpjvgt4	136	5	-	-	HYPH
cord-254580-nhpjvgt4	136	6	required	require	VBN
cord-254580-nhpjvgt4	136	7	black	black	JJ
cord-254580-nhpjvgt4	136	8	box	box	NN
cord-254580-nhpjvgt4	136	9	warning	warn	VBG
cord-254580-nhpjvgt4	136	10	for	for	IN
cord-254580-nhpjvgt4	136	11	serious	serious	JJ
cord-254580-nhpjvgt4	136	12	infections	infection	NNS
cord-254580-nhpjvgt4	136	13	.	.	.
cord-254580-nhpjvgt4	137	1	In	in	IN
cord-254580-nhpjvgt4	137	2	one	one	CD
cord-254580-nhpjvgt4	137	3	placebo	placebo	NN
cord-254580-nhpjvgt4	137	4	-	-	HYPH
cord-254580-nhpjvgt4	137	5	controlled	control	VBN
cord-254580-nhpjvgt4	137	6	phase	phase	NN
cord-254580-nhpjvgt4	137	7	three	three	CD
cord-254580-nhpjvgt4	137	8	trial	trial	NN
cord-254580-nhpjvgt4	137	9	of	of	IN
cord-254580-nhpjvgt4	137	10	422	422	CD
cord-254580-nhpjvgt4	137	11	patients	patient	NNS
cord-254580-nhpjvgt4	137	12	with	with	IN
cord-254580-nhpjvgt4	137	13	psoriatic	psoriatic	JJ
cord-254580-nhpjvgt4	137	14	arthritis	arthritis	NN
cord-254580-nhpjvgt4	137	15	,	,	,
cord-254580-nhpjvgt4	137	16	randomized	randomize	VBN
cord-254580-nhpjvgt4	137	17	to	to	IN
cord-254580-nhpjvgt4	137	18	treatment	treatment	NN
cord-254580-nhpjvgt4	137	19	with	with	IN
cord-254580-nhpjvgt4	137	20	5-mg	5-mg	CD
cord-254580-nhpjvgt4	137	21	or	or	CC
cord-254580-nhpjvgt4	137	22	10-mg	10-mg	CD
cord-254580-nhpjvgt4	137	23	tofacitinib	tofacitinib	NNP
cord-254580-nhpjvgt4	137	24	,	,	,
cord-254580-nhpjvgt4	137	25	adalimumab	adalimumab	NNS
cord-254580-nhpjvgt4	137	26	,	,	,
cord-254580-nhpjvgt4	137	27	or	or	CC
cord-254580-nhpjvgt4	137	28	placebo	placebo	NN
cord-254580-nhpjvgt4	137	29	,	,	,
cord-254580-nhpjvgt4	137	30	nasopharyngitis	nasopharyngitis	NNP
cord-254580-nhpjvgt4	137	31	(	(	-LRB-
cord-254580-nhpjvgt4	137	32	in	in	IN
cord-254580-nhpjvgt4	137	33	7	7	CD
cord-254580-nhpjvgt4	137	34	%	%	NN
cord-254580-nhpjvgt4	137	35	,	,	,
cord-254580-nhpjvgt4	137	36	12	12	CD
cord-254580-nhpjvgt4	137	37	%	%	NN
cord-254580-nhpjvgt4	137	38	and	and	CC
cord-254580-nhpjvgt4	137	39	10	10	CD
cord-254580-nhpjvgt4	137	40	%	%	NN
cord-254580-nhpjvgt4	137	41	,	,	,
cord-254580-nhpjvgt4	137	42	respectively	respectively	RB
cord-254580-nhpjvgt4	137	43	)	)	-RRB-
cord-254580-nhpjvgt4	137	44	and	and	CC
cord-254580-nhpjvgt4	137	45	URIs	URIs	NNP
cord-254580-nhpjvgt4	137	46	(	(	-LRB-
cord-254580-nhpjvgt4	137	47	in	in	IN
cord-254580-nhpjvgt4	137	48	9	9	CD
cord-254580-nhpjvgt4	137	49	%	%	NN
cord-254580-nhpjvgt4	137	50	,	,	,
cord-254580-nhpjvgt4	137	51	11	11	CD
cord-254580-nhpjvgt4	137	52	%	%	NN
cord-254580-nhpjvgt4	137	53	,	,	,
cord-254580-nhpjvgt4	137	54	and	and	CC
cord-254580-nhpjvgt4	137	55	8	8	CD
cord-254580-nhpjvgt4	137	56	%	%	NN
cord-254580-nhpjvgt4	137	57	,	,	,
cord-254580-nhpjvgt4	137	58	respectively	respectively	RB
cord-254580-nhpjvgt4	137	59	)	)	-RRB-
cord-254580-nhpjvgt4	137	60	were	be	VBD
cord-254580-nhpjvgt4	137	61	the	the	DT
cord-254580-nhpjvgt4	137	62	most	most	RBS
cord-254580-nhpjvgt4	137	63	common	common	JJ
cord-254580-nhpjvgt4	137	64	adverse	adverse	JJ
cord-254580-nhpjvgt4	137	65	events	event	NNS
cord-254580-nhpjvgt4	137	66	.	.	.
cord-254580-nhpjvgt4	138	1	54	54	CD
cord-254580-nhpjvgt4	139	1	There	there	EX
cord-254580-nhpjvgt4	139	2	were	be	VBD
cord-254580-nhpjvgt4	139	3	three	three	CD
cord-254580-nhpjvgt4	139	4	cases	case	NNS
cord-254580-nhpjvgt4	139	5	of	of	IN
cord-254580-nhpjvgt4	139	6	serious	serious	JJ
cord-254580-nhpjvgt4	139	7	infections	infection	NNS
cord-254580-nhpjvgt4	139	8	(	(	-LRB-
cord-254580-nhpjvgt4	139	9	influenza	influenza	NN
cord-254580-nhpjvgt4	139	10	,	,	,
cord-254580-nhpjvgt4	139	11	appendicitis	appendicitis	NN
cord-254580-nhpjvgt4	139	12	and	and	CC
cord-254580-nhpjvgt4	139	13	pneumonia	pneumonia	NN
cord-254580-nhpjvgt4	139	14	)	)	-RRB-
cord-254580-nhpjvgt4	139	15	and	and	CC
cord-254580-nhpjvgt4	139	16	four	four	CD
cord-254580-nhpjvgt4	139	17	cases	case	NNS
cord-254580-nhpjvgt4	139	18	of	of	IN
cord-254580-nhpjvgt4	139	19	herpes	herpe	NNS
cord-254580-nhpjvgt4	139	20	zoster	zoster	NN
cord-254580-nhpjvgt4	139	21	in	in	IN
cord-254580-nhpjvgt4	139	22	the	the	DT
cord-254580-nhpjvgt4	139	23	tofacitinib	tofacitinib	RB
cord-254580-nhpjvgt4	139	24	-	-	HYPH
cord-254580-nhpjvgt4	139	25	treated	treat	VBN
cord-254580-nhpjvgt4	139	26	group	group	NN
cord-254580-nhpjvgt4	139	27	.	.	.
cord-254580-nhpjvgt4	140	1	54	54	CD
cord-254580-nhpjvgt4	141	1	Similarly	similarly	RB
cord-254580-nhpjvgt4	141	2	,	,	,
cord-254580-nhpjvgt4	141	3	in	in	IN
cord-254580-nhpjvgt4	141	4	two	two	CD
cord-254580-nhpjvgt4	141	5	randomized	randomized	JJ
cord-254580-nhpjvgt4	141	6	,	,	,
cord-254580-nhpjvgt4	141	7	placebo	placebo	NN
cord-254580-nhpjvgt4	141	8	-	-	HYPH
cord-254580-nhpjvgt4	141	9	controlled	control	VBN
cord-254580-nhpjvgt4	141	10	studies	study	NNS
cord-254580-nhpjvgt4	141	11	of	of	IN
cord-254580-nhpjvgt4	141	12	745	745	CD
cord-254580-nhpjvgt4	141	13	and	and	CC
cord-254580-nhpjvgt4	141	14	741	741	CD
cord-254580-nhpjvgt4	141	15	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	141	16	patients	patient	NNS
cord-254580-nhpjvgt4	141	17	treated	treat	VBN
cord-254580-nhpjvgt4	141	18	with	with	IN
cord-254580-nhpjvgt4	141	19	tofacitinib	tofacitinib	NNP
cord-254580-nhpjvgt4	141	20	5-mg	5-mg	CD
cord-254580-nhpjvgt4	141	21	and	and	CC
cord-254580-nhpjvgt4	141	22	10-mg	10-mg	CD
cord-254580-nhpjvgt4	141	23	,	,	,
cord-254580-nhpjvgt4	141	24	respectively	respectively	RB
cord-254580-nhpjvgt4	141	25	,	,	,
cord-254580-nhpjvgt4	141	26	nasopharyngitis	nasopharyngitis	NNP
cord-254580-nhpjvgt4	141	27	and	and	CC
cord-254580-nhpjvgt4	141	28	URIs	uri	NNS
cord-254580-nhpjvgt4	141	29	were	be	VBD
cord-254580-nhpjvgt4	141	30	the	the	DT
cord-254580-nhpjvgt4	141	31	most	most	RBS
cord-254580-nhpjvgt4	141	32	common	common	JJ
cord-254580-nhpjvgt4	141	33	infections	infection	NNS
cord-254580-nhpjvgt4	141	34	,	,	,
cord-254580-nhpjvgt4	141	35	and	and	CC
cord-254580-nhpjvgt4	141	36	5	5	CD
cord-254580-nhpjvgt4	141	37	serious	serious	JJ
cord-254580-nhpjvgt4	141	38	infections	infection	NNS
cord-254580-nhpjvgt4	141	39	(	(	-LRB-
cord-254580-nhpjvgt4	141	40	pneumonia	pneumonia	NN
cord-254580-nhpjvgt4	141	41	,	,	,
cord-254580-nhpjvgt4	141	42	herpes	herpes	NNP
cord-254580-nhpjvgt4	141	43	zoster	zoster	NN
cord-254580-nhpjvgt4	141	44	and	and	CC
cord-254580-nhpjvgt4	141	45	erysipelas	erysipela	NNS
cord-254580-nhpjvgt4	141	46	in	in	IN
cord-254580-nhpjvgt4	141	47	the	the	DT
cord-254580-nhpjvgt4	141	48	5-mg	5-mg	CD
cord-254580-nhpjvgt4	141	49	group	group	NN
cord-254580-nhpjvgt4	141	50	;	;	:
cord-254580-nhpjvgt4	141	51	and	and	CC
cord-254580-nhpjvgt4	141	52	appendicitis	appendicitis	NN
cord-254580-nhpjvgt4	141	53	,	,	,
cord-254580-nhpjvgt4	141	54	pneumonia	pneumonia	NN
cord-254580-nhpjvgt4	141	55	and	and	CC
cord-254580-nhpjvgt4	141	56	pyelonephritis	pyelonephritis	NN
cord-254580-nhpjvgt4	141	57	in	in	IN
cord-254580-nhpjvgt4	141	58	the	the	DT
cord-254580-nhpjvgt4	141	59	10-mg	10-mg	CD
cord-254580-nhpjvgt4	141	60	group	group	NN
cord-254580-nhpjvgt4	141	61	)	)	-RRB-
cord-254580-nhpjvgt4	141	62	were	be	VBD
cord-254580-nhpjvgt4	141	63	reported	report	VBN
cord-254580-nhpjvgt4	141	64	in	in	IN
cord-254580-nhpjvgt4	141	65	tofacitinib	tofacitinib	RB
cord-254580-nhpjvgt4	141	66	-	-	HYPH
cord-254580-nhpjvgt4	141	67	treated	treat	VBN
cord-254580-nhpjvgt4	141	68	patients	patient	NNS
cord-254580-nhpjvgt4	141	69	.	.	.
cord-254580-nhpjvgt4	142	1	55	55	CD
cord-254580-nhpjvgt4	143	1	Furthermore	furthermore	RB
cord-254580-nhpjvgt4	143	2	,	,	,
cord-254580-nhpjvgt4	143	3	herpes	herpes	NN
cord-254580-nhpjvgt4	143	4	zoster	zoster	NN
cord-254580-nhpjvgt4	143	5	was	be	VBD
cord-254580-nhpjvgt4	143	6	reported	report	VBN
cord-254580-nhpjvgt4	143	7	in	in	IN
cord-254580-nhpjvgt4	143	8	12	12	CD
cord-254580-nhpjvgt4	143	9	tofacitinib	tofacitinib	RB
cord-254580-nhpjvgt4	143	10	-	-	HYPH
cord-254580-nhpjvgt4	143	11	treated	treat	VBN
cord-254580-nhpjvgt4	143	12	patients	patient	NNS
cord-254580-nhpjvgt4	143	13	versus	versus	IN
cord-254580-nhpjvgt4	143	14	none	none	NN
cord-254580-nhpjvgt4	143	15	in	in	IN
cord-254580-nhpjvgt4	143	16	the	the	DT
cord-254580-nhpjvgt4	143	17	placebo	placebo	NN
cord-254580-nhpjvgt4	143	18	groups	group	NNS
cord-254580-nhpjvgt4	143	19	.	.	.
cord-254580-nhpjvgt4	144	1	55	55	CD
cord-254580-nhpjvgt4	145	1	Thus	thus	RB
cord-254580-nhpjvgt4	145	2	,	,	,
cord-254580-nhpjvgt4	145	3	tofacitinib	tofacitinib	NNP
cord-254580-nhpjvgt4	145	4	has	have	VBZ
cord-254580-nhpjvgt4	145	5	an	an	DT
cord-254580-nhpjvgt4	145	6	association	association	NN
cord-254580-nhpjvgt4	145	7	with	with	IN
cord-254580-nhpjvgt4	145	8	increased	increase	VBN
cord-254580-nhpjvgt4	145	9	infection	infection	NN
cord-254580-nhpjvgt4	145	10	risk	risk	NN
cord-254580-nhpjvgt4	145	11	in	in	IN
cord-254580-nhpjvgt4	145	12	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	145	13	/	/	SYM
cord-254580-nhpjvgt4	145	14	psoriatic	psoriatic	JJ
cord-254580-nhpjvgt4	145	15	arthritis	arthritis	NN
cord-254580-nhpjvgt4	145	16	patients	patient	NNS
cord-254580-nhpjvgt4	145	17	.	.	.
cord-254580-nhpjvgt4	146	1	Tofacitinibtreated	tofacitinibtreated	JJ
cord-254580-nhpjvgt4	146	2	patients	patient	NNS
cord-254580-nhpjvgt4	146	3	may	may	MD
cord-254580-nhpjvgt4	146	4	be	be	VB
cord-254580-nhpjvgt4	146	5	more	more	RBR
cord-254580-nhpjvgt4	146	6	susceptible	susceptible	JJ
cord-254580-nhpjvgt4	146	7	to	to	IN
cord-254580-nhpjvgt4	146	8	COVID-19	covid-19	JJ
cord-254580-nhpjvgt4	146	9	,	,	,
cord-254580-nhpjvgt4	146	10	strict	strict	JJ
cord-254580-nhpjvgt4	146	11	protective	protective	JJ
cord-254580-nhpjvgt4	146	12	measures	measure	NNS
cord-254580-nhpjvgt4	146	13	are	be	VBP
cord-254580-nhpjvgt4	146	14	recommended	recommend	VBN
cord-254580-nhpjvgt4	146	15	to	to	TO
cord-254580-nhpjvgt4	146	16	minimize	minimize	VB
cord-254580-nhpjvgt4	146	17	viral	viral	JJ
cord-254580-nhpjvgt4	146	18	exposure	exposure	NN
cord-254580-nhpjvgt4	146	19	.	.	.
cord-254580-nhpjvgt4	147	1	Dupilumab	Dupilumab	NNP
cord-254580-nhpjvgt4	147	2	targets	target	NNS
cord-254580-nhpjvgt4	147	3	IL-4	IL-4	NNP
cord-254580-nhpjvgt4	147	4	and	and	CC
cord-254580-nhpjvgt4	147	5	IL-13	IL-13	NNP
cord-254580-nhpjvgt4	147	6	,	,	,
cord-254580-nhpjvgt4	147	7	elements	element	NNS
cord-254580-nhpjvgt4	147	8	of	of	IN
cord-254580-nhpjvgt4	147	9	the	the	DT
cord-254580-nhpjvgt4	147	10	type	type	NN
cord-254580-nhpjvgt4	147	11	two	two	CD
cord-254580-nhpjvgt4	147	12	immune	immune	JJ
cord-254580-nhpjvgt4	147	13	response	response	NN
cord-254580-nhpjvgt4	147	14	.	.	.
cord-254580-nhpjvgt4	148	1	56	56	CD
cord-254580-nhpjvgt4	149	1	As	as	IN
cord-254580-nhpjvgt4	149	2	type	type	NN
cord-254580-nhpjvgt4	149	3	one	one	CD
cord-254580-nhpjvgt4	149	4	and	and	CC
cord-254580-nhpjvgt4	149	5	type	type	VB
cord-254580-nhpjvgt4	149	6	two	two	CD
cord-254580-nhpjvgt4	149	7	immune	immune	JJ
cord-254580-nhpjvgt4	149	8	responses	response	NNS
cord-254580-nhpjvgt4	149	9	cross	cross	VBP
cord-254580-nhpjvgt4	149	10	-	-	JJ
cord-254580-nhpjvgt4	149	11	regulate	regulate	VBP
cord-254580-nhpjvgt4	149	12	each	each	DT
cord-254580-nhpjvgt4	149	13	other	other	JJ
cord-254580-nhpjvgt4	149	14	,	,	,
cord-254580-nhpjvgt4	149	15	suppression	suppression	NN
cord-254580-nhpjvgt4	149	16	of	of	IN
cord-254580-nhpjvgt4	149	17	type	type	NN
cord-254580-nhpjvgt4	149	18	one	one	CD
cord-254580-nhpjvgt4	149	19	immunity	immunity	NN
cord-254580-nhpjvgt4	149	20	can	can	MD
cord-254580-nhpjvgt4	149	21	potentially	potentially	RB
cord-254580-nhpjvgt4	149	22	facilitate	facilitate	VB
cord-254580-nhpjvgt4	149	23	uncontrolled	uncontrolled	JJ
cord-254580-nhpjvgt4	149	24	or	or	CC
cord-254580-nhpjvgt4	149	25	persistent	persistent	JJ
cord-254580-nhpjvgt4	149	26	viral	viral	JJ
cord-254580-nhpjvgt4	149	27	and	and	CC
cord-254580-nhpjvgt4	149	28	bacterial	bacterial	JJ
cord-254580-nhpjvgt4	149	29	infections	infection	NNS
cord-254580-nhpjvgt4	149	30	.	.	.
cord-254580-nhpjvgt4	150	1	57	57	CD
cord-254580-nhpjvgt4	151	1	Nonetheless	nonetheless	RB
cord-254580-nhpjvgt4	151	2	,	,	,
cord-254580-nhpjvgt4	151	3	Dupilumab	Dupilumab	NNP
cord-254580-nhpjvgt4	151	4	has	have	VBZ
cord-254580-nhpjvgt4	151	5	been	be	VBN
cord-254580-nhpjvgt4	151	6	associated	associate	VBN
cord-254580-nhpjvgt4	151	7	with	with	IN
cord-254580-nhpjvgt4	151	8	a	a	DT
cord-254580-nhpjvgt4	151	9	reduced	reduce	VBN
cord-254580-nhpjvgt4	151	10	infection	infection	NN
cord-254580-nhpjvgt4	151	11	rate	rate	NN
cord-254580-nhpjvgt4	151	12	in	in	IN
cord-254580-nhpjvgt4	151	13	AD	ad	NN
cord-254580-nhpjvgt4	151	14	patients	patient	NNS
cord-254580-nhpjvgt4	151	15	.	.	.
cord-254580-nhpjvgt4	152	1	A	a	DT
cord-254580-nhpjvgt4	152	2	pooled	pool	VBN
cord-254580-nhpjvgt4	152	3	analysis	analysis	NN
cord-254580-nhpjvgt4	152	4	of	of	IN
cord-254580-nhpjvgt4	152	5	seven	seven	CD
cord-254580-nhpjvgt4	152	6	RCTs	rct	NNS
cord-254580-nhpjvgt4	152	7	on	on	IN
cord-254580-nhpjvgt4	152	8	dupilumab	dupilumab	NNP
cord-254580-nhpjvgt4	152	9	-	-	HYPH
cord-254580-nhpjvgt4	152	10	treated	treat	VBN
cord-254580-nhpjvgt4	152	11	AD	ad	NN
cord-254580-nhpjvgt4	152	12	adults	adult	NNS
cord-254580-nhpjvgt4	152	13	showed	show	VBD
cord-254580-nhpjvgt4	152	14	a	a	DT
cord-254580-nhpjvgt4	152	15	decreased	decreased	JJ
cord-254580-nhpjvgt4	152	16	risk	risk	NN
cord-254580-nhpjvgt4	152	17	of	of	IN
cord-254580-nhpjvgt4	152	18	serious	serious	JJ
cord-254580-nhpjvgt4	152	19	infections	infection	NNS
cord-254580-nhpjvgt4	152	20	,	,	,
cord-254580-nhpjvgt4	152	21	skin	skin	NN
cord-254580-nhpjvgt4	152	22	infections	infection	NNS
cord-254580-nhpjvgt4	152	23	and	and	CC
cord-254580-nhpjvgt4	152	24	herpes	herpes	NN
cord-254580-nhpjvgt4	152	25	infections	infection	NNS
cord-254580-nhpjvgt4	152	26	(	(	-LRB-
cord-254580-nhpjvgt4	152	27	eczema	eczema	NN
cord-254580-nhpjvgt4	152	28	herpeticum	herpeticum	NNP
cord-254580-nhpjvgt4	152	29	or	or	CC
cord-254580-nhpjvgt4	152	30	herpes	herpes	NNP
cord-254580-nhpjvgt4	152	31	zoster	zoster	NNP
cord-254580-nhpjvgt4	152	32	)	)	-RRB-
cord-254580-nhpjvgt4	152	33	in	in	IN
cord-254580-nhpjvgt4	152	34	the	the	DT
cord-254580-nhpjvgt4	152	35	dupilumab	dupilumab	NN
cord-254580-nhpjvgt4	152	36	groups	group	NNS
cord-254580-nhpjvgt4	152	37	compared	compare	VBN
cord-254580-nhpjvgt4	152	38	with	with	IN
cord-254580-nhpjvgt4	152	39	placebo	placebo	NN
cord-254580-nhpjvgt4	152	40	.	.	.
cord-254580-nhpjvgt4	153	1	Furthermore	furthermore	RB
cord-254580-nhpjvgt4	153	2	,	,	,
cord-254580-nhpjvgt4	153	3	by	by	IN
cord-254580-nhpjvgt4	153	4	also	also	RB
cord-254580-nhpjvgt4	153	5	treating	treat	VBG
cord-254580-nhpjvgt4	153	6	asthma	asthma	NN
cord-254580-nhpjvgt4	153	7	,	,	,
cord-254580-nhpjvgt4	153	8	dupilumab	dupilumab	NNP
cord-254580-nhpjvgt4	153	9	may	may	MD
cord-254580-nhpjvgt4	153	10	theoretically	theoretically	RB
cord-254580-nhpjvgt4	153	11	decrease	decrease	VB
cord-254580-nhpjvgt4	153	12	risk	risk	NN
cord-254580-nhpjvgt4	153	13	for	for	IN
cord-254580-nhpjvgt4	153	14	COVID-19	covid-19	JJ
cord-254580-nhpjvgt4	153	15	infected	infected	JJ
cord-254580-nhpjvgt4	153	16	patients	patient	NNS
cord-254580-nhpjvgt4	153	17	for	for	IN
cord-254580-nhpjvgt4	153	18	severe	severe	JJ
cord-254580-nhpjvgt4	153	19	respiratory	respiratory	JJ
cord-254580-nhpjvgt4	153	20	disease	disease	NN
cord-254580-nhpjvgt4	153	21	.	.	.
cord-254580-nhpjvgt4	154	1	56	56	CD
cord-254580-nhpjvgt4	155	1	Therefore	therefore	RB
cord-254580-nhpjvgt4	155	2	,	,	,
cord-254580-nhpjvgt4	155	3	current	current	JJ
cord-254580-nhpjvgt4	155	4	evidence	evidence	NN
cord-254580-nhpjvgt4	155	5	suggests	suggest	VBZ
cord-254580-nhpjvgt4	155	6	continuing	continue	VBG
cord-254580-nhpjvgt4	155	7	and	and	CC
cord-254580-nhpjvgt4	155	8	initiating	initiate	VBG
cord-254580-nhpjvgt4	155	9	dupilumab	dupilumab	JJ
cord-254580-nhpjvgt4	155	10	treatment	treatment	NN
cord-254580-nhpjvgt4	155	11	in	in	IN
cord-254580-nhpjvgt4	155	12	AD	ad	NN
cord-254580-nhpjvgt4	155	13	patients	patient	NNS
cord-254580-nhpjvgt4	155	14	during	during	IN
cord-254580-nhpjvgt4	155	15	the	the	DT
cord-254580-nhpjvgt4	155	16	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	155	17	pandemic	pandemic	NN
cord-254580-nhpjvgt4	155	18	.	.	.
cord-254580-nhpjvgt4	156	1	It	-PRON-	PRP
cord-254580-nhpjvgt4	156	2	is	be	VBZ
cord-254580-nhpjvgt4	156	3	difficult	difficult	JJ
cord-254580-nhpjvgt4	156	4	to	to	TO
cord-254580-nhpjvgt4	156	5	make	make	VB
cord-254580-nhpjvgt4	156	6	definitive	definitive	JJ
cord-254580-nhpjvgt4	156	7	conclusions	conclusion	NNS
cord-254580-nhpjvgt4	156	8	about	about	IN
cord-254580-nhpjvgt4	156	9	susceptibility	susceptibility	NN
cord-254580-nhpjvgt4	156	10	to	to	IN
cord-254580-nhpjvgt4	156	11	SARS	SARS	NNP
cord-254580-nhpjvgt4	156	12	-	-	HYPH
cord-254580-nhpjvgt4	156	13	CoV-2	CoV-2	NNP
cord-254580-nhpjvgt4	156	14	infection	infection	NN
cord-254580-nhpjvgt4	156	15	in	in	IN
cord-254580-nhpjvgt4	156	16	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	156	17	or	or	CC
cord-254580-nhpjvgt4	156	18	AD	ad	NN
cord-254580-nhpjvgt4	156	19	patients	patient	NNS
cord-254580-nhpjvgt4	156	20	on	on	IN
cord-254580-nhpjvgt4	156	21	systemic	systemic	JJ
cord-254580-nhpjvgt4	156	22	treatments	treatment	NNS
cord-254580-nhpjvgt4	156	23	,	,	,
cord-254580-nhpjvgt4	156	24	solely	solely	RB
cord-254580-nhpjvgt4	156	25	based	base	VBN
cord-254580-nhpjvgt4	156	26	on	on	IN
cord-254580-nhpjvgt4	156	27	general	general	JJ
cord-254580-nhpjvgt4	156	28	infection	infection	NN
cord-254580-nhpjvgt4	156	29	risk	risk	NN
cord-254580-nhpjvgt4	156	30	data	datum	NNS
cord-254580-nhpjvgt4	156	31	.	.	.
cord-254580-nhpjvgt4	157	1	Furthermore	furthermore	RB
cord-254580-nhpjvgt4	157	2	,	,	,
cord-254580-nhpjvgt4	157	3	the	the	DT
cord-254580-nhpjvgt4	157	4	majority	majority	NN
cord-254580-nhpjvgt4	157	5	of	of	IN
cord-254580-nhpjvgt4	157	6	studies	study	NNS
cord-254580-nhpjvgt4	157	7	included	include	VBD
cord-254580-nhpjvgt4	157	8	patients	patient	NNS
cord-254580-nhpjvgt4	157	9	with	with	IN
cord-254580-nhpjvgt4	157	10	mean	mean	JJ
cord-254580-nhpjvgt4	157	11	age	age	NN
cord-254580-nhpjvgt4	157	12	of	of	IN
cord-254580-nhpjvgt4	157	13	approximately	approximately	RB
cord-254580-nhpjvgt4	157	14	40	40	CD
cord-254580-nhpjvgt4	157	15	years	year	NNS
cord-254580-nhpjvgt4	157	16	;	;	:
cord-254580-nhpjvgt4	157	17	therefore	therefore	RB
cord-254580-nhpjvgt4	157	18	,	,	,
cord-254580-nhpjvgt4	157	19	these	these	DT
cord-254580-nhpjvgt4	157	20	recommendations	recommendation	NNS
cord-254580-nhpjvgt4	157	21	may	may	MD
cord-254580-nhpjvgt4	157	22	not	not	RB
cord-254580-nhpjvgt4	157	23	be	be	VB
cord-254580-nhpjvgt4	157	24	applicable	applicable	JJ
cord-254580-nhpjvgt4	157	25	to	to	IN
cord-254580-nhpjvgt4	157	26	older	old	JJR
cord-254580-nhpjvgt4	157	27	individuals	individual	NNS
cord-254580-nhpjvgt4	157	28	,	,	,
cord-254580-nhpjvgt4	157	29	who	who	WP
cord-254580-nhpjvgt4	157	30	on	on	IN
cord-254580-nhpjvgt4	157	31	average	average	JJ
cord-254580-nhpjvgt4	157	32	have	have	VBP
cord-254580-nhpjvgt4	157	33	higher	high	JJR
cord-254580-nhpjvgt4	157	34	COVID-19	covid-19	NN
cord-254580-nhpjvgt4	157	35	associated	associated	JJ
cord-254580-nhpjvgt4	157	36	mortality	mortality	NN
cord-254580-nhpjvgt4	157	37	.	.	.
cord-254580-nhpjvgt4	158	1	There	there	EX
cord-254580-nhpjvgt4	158	2	is	be	VBZ
cord-254580-nhpjvgt4	158	3	also	also	RB
cord-254580-nhpjvgt4	158	4	a	a	DT
cord-254580-nhpjvgt4	158	5	potential	potential	JJ
cord-254580-nhpjvgt4	158	6	role	role	NN
cord-254580-nhpjvgt4	158	7	for	for	IN
cord-254580-nhpjvgt4	158	8	some	some	DT
cord-254580-nhpjvgt4	158	9	of	of	IN
cord-254580-nhpjvgt4	158	10	these	these	DT
cord-254580-nhpjvgt4	158	11	medications	medication	NNS
cord-254580-nhpjvgt4	158	12	as	as	IN
cord-254580-nhpjvgt4	158	13	treatments	treatment	NNS
cord-254580-nhpjvgt4	158	14	of	of	IN
cord-254580-nhpjvgt4	158	15	COVID-19	covid-19	NN
cord-254580-nhpjvgt4	158	16	but	but	CC
cord-254580-nhpjvgt4	158	17	this	this	DT
cord-254580-nhpjvgt4	158	18	remains	remain	VBZ
cord-254580-nhpjvgt4	158	19	largely	largely	RB
cord-254580-nhpjvgt4	158	20	unknown	unknown	JJ
cord-254580-nhpjvgt4	158	21	.	.	.
cord-254580-nhpjvgt4	159	1	In	in	IN
cord-254580-nhpjvgt4	159	2	We	-PRON-	PRP
cord-254580-nhpjvgt4	159	3	suggest	suggest	VBP
cord-254580-nhpjvgt4	159	4	the	the	DT
cord-254580-nhpjvgt4	159	5	following	follow	VBG
cord-254580-nhpjvgt4	159	6	algorithms	algorithm	NNS
cord-254580-nhpjvgt4	159	7	for	for	IN
cord-254580-nhpjvgt4	159	8	treatment	treatment	NN
cord-254580-nhpjvgt4	159	9	of	of	IN
cord-254580-nhpjvgt4	159	10	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	159	11	and	and	CC
cord-254580-nhpjvgt4	159	12	AD	ad	NN
cord-254580-nhpjvgt4	159	13	during	during	IN
cord-254580-nhpjvgt4	159	14	the	the	DT
cord-254580-nhpjvgt4	159	15	COVID-19	covid-19	JJ
cord-254580-nhpjvgt4	159	16	pandemic	pandemic	NN
cord-254580-nhpjvgt4	159	17	(	(	-LRB-
cord-254580-nhpjvgt4	159	18	Figures	figure	NNS
cord-254580-nhpjvgt4	159	19	1	1	CD
cord-254580-nhpjvgt4	159	20	,	,	,
cord-254580-nhpjvgt4	159	21	2	2	CD
cord-254580-nhpjvgt4	159	22	)	)	-RRB-
cord-254580-nhpjvgt4	159	23	.	.	.
cord-254580-nhpjvgt4	160	1	This	this	DT
cord-254580-nhpjvgt4	160	2	article	article	NN
cord-254580-nhpjvgt4	160	3	is	be	VBZ
cord-254580-nhpjvgt4	160	4	protected	protect	VBN
cord-254580-nhpjvgt4	160	5	by	by	IN
cord-254580-nhpjvgt4	160	6	copyright	copyright	NN
cord-254580-nhpjvgt4	160	7	.	.	.
cord-254580-nhpjvgt4	161	1	All	all	DT
cord-254580-nhpjvgt4	161	2	rights	right	NNS
cord-254580-nhpjvgt4	161	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	161	4	.	.	.
cord-254580-nhpjvgt4	162	1	This	this	DT
cord-254580-nhpjvgt4	162	2	article	article	NN
cord-254580-nhpjvgt4	162	3	is	be	VBZ
cord-254580-nhpjvgt4	162	4	protected	protect	VBN
cord-254580-nhpjvgt4	162	5	by	by	IN
cord-254580-nhpjvgt4	162	6	copyright	copyright	NN
cord-254580-nhpjvgt4	162	7	.	.	.
cord-254580-nhpjvgt4	163	1	All	all	DT
cord-254580-nhpjvgt4	163	2	rights	right	NNS
cord-254580-nhpjvgt4	163	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	163	4	.	.	.
cord-254580-nhpjvgt4	164	1	This	this	DT
cord-254580-nhpjvgt4	164	2	article	article	NN
cord-254580-nhpjvgt4	164	3	is	be	VBZ
cord-254580-nhpjvgt4	164	4	protected	protect	VBN
cord-254580-nhpjvgt4	164	5	by	by	IN
cord-254580-nhpjvgt4	164	6	copyright	copyright	NN
cord-254580-nhpjvgt4	164	7	.	.	.
cord-254580-nhpjvgt4	165	1	All	all	DT
cord-254580-nhpjvgt4	165	2	rights	right	NNS
cord-254580-nhpjvgt4	165	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	165	4	.	.	.
cord-254580-nhpjvgt4	166	1	This	this	DT
cord-254580-nhpjvgt4	166	2	article	article	NN
cord-254580-nhpjvgt4	166	3	is	be	VBZ
cord-254580-nhpjvgt4	166	4	protected	protect	VBN
cord-254580-nhpjvgt4	166	5	by	by	IN
cord-254580-nhpjvgt4	166	6	copyright	copyright	NN
cord-254580-nhpjvgt4	166	7	.	.	.
cord-254580-nhpjvgt4	167	1	All	all	DT
cord-254580-nhpjvgt4	167	2	rights	right	NNS
cord-254580-nhpjvgt4	167	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	167	4	.	.	.
cord-254580-nhpjvgt4	168	1	This	this	DT
cord-254580-nhpjvgt4	168	2	article	article	NN
cord-254580-nhpjvgt4	168	3	is	be	VBZ
cord-254580-nhpjvgt4	168	4	protected	protect	VBN
cord-254580-nhpjvgt4	168	5	by	by	IN
cord-254580-nhpjvgt4	168	6	copyright	copyright	NN
cord-254580-nhpjvgt4	168	7	.	.	.
cord-254580-nhpjvgt4	169	1	All	all	DT
cord-254580-nhpjvgt4	169	2	rights	right	NNS
cord-254580-nhpjvgt4	169	3	reserved	reserve	VBN
cord-254580-nhpjvgt4	169	4	.	.	.
cord-254580-nhpjvgt4	169	5	 	 	_SP
cord-254580-nhpjvgt4	170	1	Coronavirus	Coronavirus	NNP
cord-254580-nhpjvgt4	170	2	COVID-19	COVID-19	NNP
cord-254580-nhpjvgt4	170	3	Global	Global	NNP
cord-254580-nhpjvgt4	170	4	Cases	Cases	NNPS
cord-254580-nhpjvgt4	170	5	by	by	IN
cord-254580-nhpjvgt4	170	6	the	the	DT
cord-254580-nhpjvgt4	170	7	Cross	Cross	NNP
cord-254580-nhpjvgt4	170	8	-	-	HYPH
cord-254580-nhpjvgt4	170	9	Country	Country	NNP
cord-254580-nhpjvgt4	170	10	Comparison	Comparison	NNP
cord-254580-nhpjvgt4	170	11	of	of	IN
cord-254580-nhpjvgt4	170	12	Case	Case	NNP
cord-254580-nhpjvgt4	170	13	Fatality	Fatality	NNP
cord-254580-nhpjvgt4	170	14	Rates	rate	NNS
cord-254580-nhpjvgt4	170	15	of	of	IN
cord-254580-nhpjvgt4	170	16	COVID	COVID	NNP
cord-254580-nhpjvgt4	170	17	Sleep	Sleep	NNP
cord-254580-nhpjvgt4	170	18	disturbances	disturbance	NNS
cord-254580-nhpjvgt4	170	19	in	in	IN
cord-254580-nhpjvgt4	170	20	adults	adult	NNS
cord-254580-nhpjvgt4	170	21	with	with	IN
cord-254580-nhpjvgt4	170	22	eczema	eczema	NN
cord-254580-nhpjvgt4	170	23	are	be	VBP
cord-254580-nhpjvgt4	170	24	associated	associate	VBN
cord-254580-nhpjvgt4	170	25	with	with	IN
cord-254580-nhpjvgt4	170	26	impaired	impaired	JJ
cord-254580-nhpjvgt4	170	27	overall	overall	JJ
cord-254580-nhpjvgt4	170	28	health	health	NN
cord-254580-nhpjvgt4	170	29	:	:	:
cord-254580-nhpjvgt4	170	30	a	a	DT
cord-254580-nhpjvgt4	170	31	US	US	NNP
cord-254580-nhpjvgt4	170	32	population	population	NN
cord-254580-nhpjvgt4	170	33	-	-	HYPH
cord-254580-nhpjvgt4	170	34	based	base	VBN
cord-254580-nhpjvgt4	170	35	study	study	NN
cord-254580-nhpjvgt4	170	36	National	National	NNP
cord-254580-nhpjvgt4	170	37	Health	Health	NNP
cord-254580-nhpjvgt4	170	38	and	and	CC
cord-254580-nhpjvgt4	170	39	Nutrition	Nutrition	NNP
cord-254580-nhpjvgt4	170	40	Examination	Examination	NNP
cord-254580-nhpjvgt4	170	41	Surveys	Surveys	NNPS
cord-254580-nhpjvgt4	170	42	Atopic	Atopic	NNP
cord-254580-nhpjvgt4	170	43	dermatitis	dermatitis	NN
cord-254580-nhpjvgt4	170	44	and	and	CC
cord-254580-nhpjvgt4	170	45	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	170	46	:	:	:
cord-254580-nhpjvgt4	170	47	two	two	CD
cord-254580-nhpjvgt4	170	48	different	different	JJ
cord-254580-nhpjvgt4	170	49	immune	immune	JJ
cord-254580-nhpjvgt4	170	50	diseases	disease	NNS
cord-254580-nhpjvgt4	170	51	or	or	CC
cord-254580-nhpjvgt4	170	52	one	one	CD
cord-254580-nhpjvgt4	170	53	spectrum	spectrum	NN
cord-254580-nhpjvgt4	170	54	?	?	.
cord-254580-nhpjvgt4	171	1	Recategorization	recategorization	NN
cord-254580-nhpjvgt4	171	2	of	of	IN
cord-254580-nhpjvgt4	171	3	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	171	4	severity	severity	NN
cord-254580-nhpjvgt4	171	5	:	:	:
cord-254580-nhpjvgt4	171	6	Delphi	Delphi	NNP
cord-254580-nhpjvgt4	171	7	consensus	consensus	NN
cord-254580-nhpjvgt4	171	8	from	from	IN
cord-254580-nhpjvgt4	171	9	the	the	DT
cord-254580-nhpjvgt4	171	10	International	International	NNP
cord-254580-nhpjvgt4	171	11	Psoriasis	Psoriasis	NNP
cord-254580-nhpjvgt4	171	12	Council	Council	NNP
cord-254580-nhpjvgt4	171	13	Systemic	Systemic	NNP
cord-254580-nhpjvgt4	171	14	Treatment	Treatment	NNP
cord-254580-nhpjvgt4	171	15	of	of	IN
cord-254580-nhpjvgt4	171	16	Adult	Adult	NNP
cord-254580-nhpjvgt4	171	17	Atopic	Atopic	NNP
cord-254580-nhpjvgt4	171	18	Dermatitis	dermatitis	NN
cord-254580-nhpjvgt4	171	19	:	:	:
cord-254580-nhpjvgt4	172	1	A	a	DT
cord-254580-nhpjvgt4	172	2	Review	Review	NNP
cord-254580-nhpjvgt4	172	3	Systematic	Systematic	NNP
cord-254580-nhpjvgt4	172	4	Review	Review	NNP
cord-254580-nhpjvgt4	172	5	of	of	IN
cord-254580-nhpjvgt4	172	6	the	the	DT
cord-254580-nhpjvgt4	172	7	Toxicity	toxicity	NN
cord-254580-nhpjvgt4	172	8	of	of	IN
cord-254580-nhpjvgt4	172	9	Long	long	JJ
cord-254580-nhpjvgt4	172	10	-	-	HYPH
cord-254580-nhpjvgt4	172	11	Course	course	NN
cord-254580-nhpjvgt4	172	12	Oral	oral	JJ
cord-254580-nhpjvgt4	172	13	Corticosteroids	Corticosteroids	NNPS
cord-254580-nhpjvgt4	172	14	in	in	IN
cord-254580-nhpjvgt4	172	15	Children	child	NNS
cord-254580-nhpjvgt4	173	1	The	the	DT
cord-254580-nhpjvgt4	173	2	effect	effect	NN
cord-254580-nhpjvgt4	173	3	of	of	IN
cord-254580-nhpjvgt4	173	4	corticosteroids	corticosteroid	NNS
cord-254580-nhpjvgt4	173	5	on	on	IN
cord-254580-nhpjvgt4	173	6	mortality	mortality	NN
cord-254580-nhpjvgt4	173	7	of	of	IN
cord-254580-nhpjvgt4	173	8	patients	patient	NNS
cord-254580-nhpjvgt4	173	9	with	with	IN
cord-254580-nhpjvgt4	173	10	influenza	influenza	NN
cord-254580-nhpjvgt4	173	11	pneumonia	pneumonia	NN
cord-254580-nhpjvgt4	173	12	:	:	:
cord-254580-nhpjvgt4	173	13	a	a	DT
cord-254580-nhpjvgt4	173	14	systematic	systematic	JJ
cord-254580-nhpjvgt4	173	15	review	review	NN
cord-254580-nhpjvgt4	173	16	and	and	CC
cord-254580-nhpjvgt4	173	17	meta	meta	NNP
cord-254580-nhpjvgt4	173	18	-	-	HYPH
cord-254580-nhpjvgt4	173	19	analysis	analysis	NN
cord-254580-nhpjvgt4	173	20	Infections	infection	NNS
cord-254580-nhpjvgt4	173	21	in	in	IN
cord-254580-nhpjvgt4	173	22	Moderate	moderate	JJ
cord-254580-nhpjvgt4	173	23	to	to	IN
cord-254580-nhpjvgt4	173	24	Severe	severe	JJ
cord-254580-nhpjvgt4	173	25	Psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	173	26	Patients	patient	NNS
cord-254580-nhpjvgt4	173	27	Treated	treat	VBN
cord-254580-nhpjvgt4	173	28	with	with	IN
cord-254580-nhpjvgt4	173	29	Biological	biological	JJ
cord-254580-nhpjvgt4	173	30	Drugs	drug	NNS
cord-254580-nhpjvgt4	174	1	Compared	compare	VBN
cord-254580-nhpjvgt4	174	2	to	to	IN
cord-254580-nhpjvgt4	174	3	Classic	classic	JJ
cord-254580-nhpjvgt4	174	4	Systemic	systemic	JJ
cord-254580-nhpjvgt4	174	5	Drugs	drug	NNS
cord-254580-nhpjvgt4	174	6	:	:	:
cord-254580-nhpjvgt4	174	7	Findings	finding	NNS
cord-254580-nhpjvgt4	174	8	from	from	IN
cord-254580-nhpjvgt4	174	9	the	the	DT
cord-254580-nhpjvgt4	174	10	BIOBADADERM	BIOBADADERM	NNP
cord-254580-nhpjvgt4	174	11	Registry	Registry	NNP
cord-254580-nhpjvgt4	174	12	Methotrexate	Methotrexate	NNP
cord-254580-nhpjvgt4	174	13	Versus	Versus	NNP
cord-254580-nhpjvgt4	174	14	Cyclosporine	Cyclosporine	NNP
cord-254580-nhpjvgt4	174	15	in	in	IN
cord-254580-nhpjvgt4	174	16	Adults	Adults	NNPS
cord-254580-nhpjvgt4	174	17	with	with	IN
cord-254580-nhpjvgt4	174	18	Moderate	moderate	JJ
cord-254580-nhpjvgt4	174	19	-	-	HYPH
cord-254580-nhpjvgt4	174	20	to	to	IN
cord-254580-nhpjvgt4	174	21	-	-	HYPH
cord-254580-nhpjvgt4	174	22	Severe	severe	JJ
cord-254580-nhpjvgt4	174	23	Atopic	Atopic	NNP
cord-254580-nhpjvgt4	174	24	Dermatitis	dermatitis	NN
cord-254580-nhpjvgt4	174	25	:	:	:
cord-254580-nhpjvgt4	174	26	A	a	DT
cord-254580-nhpjvgt4	174	27	Phase	phase	NN
cord-254580-nhpjvgt4	174	28	III	iii	CD
cord-254580-nhpjvgt4	174	29	Randomized	randomized	JJ
cord-254580-nhpjvgt4	174	30	Noninferiority	Noninferiority	NNP
cord-254580-nhpjvgt4	174	31	Trial	Trial	NNP
cord-254580-nhpjvgt4	174	32	Comparative	Comparative	NNP
cord-254580-nhpjvgt4	174	33	Safety	Safety	NNP
cord-254580-nhpjvgt4	174	34	of	of	IN
cord-254580-nhpjvgt4	174	35	Systemic	Systemic	NNP
cord-254580-nhpjvgt4	174	36	Immuno	immuno	JJ
cord-254580-nhpjvgt4	174	37	-	-	HYPH
cord-254580-nhpjvgt4	174	38	modulatory	modulatory	JJ
cord-254580-nhpjvgt4	174	39	Medications	medication	NNS
cord-254580-nhpjvgt4	174	40	in	in	IN
cord-254580-nhpjvgt4	174	41	Adults	Adults	NNPS
cord-254580-nhpjvgt4	174	42	with	with	IN
cord-254580-nhpjvgt4	174	43	Atopic	Atopic	NNP
cord-254580-nhpjvgt4	174	44	Dermatitis	Dermatitis	NNP
cord-254580-nhpjvgt4	174	45	Suppression	Suppression	NNP
cord-254580-nhpjvgt4	174	46	of	of	IN
cord-254580-nhpjvgt4	174	47	coronavirus	coronavirus	NN
cord-254580-nhpjvgt4	174	48	replication	replication	NN
cord-254580-nhpjvgt4	174	49	by	by	IN
cord-254580-nhpjvgt4	174	50	cyclophilin	cyclophilin	NNP
cord-254580-nhpjvgt4	174	51	inhibitors	inhibitor	NNS
cord-254580-nhpjvgt4	175	1	A	a	DT
cord-254580-nhpjvgt4	175	2	review	review	NN
cord-254580-nhpjvgt4	175	3	of	of	IN
cord-254580-nhpjvgt4	175	4	its	-PRON-	PRP$
cord-254580-nhpjvgt4	175	5	pharmacology	pharmacology	NN
cord-254580-nhpjvgt4	175	6	and	and	CC
cord-254580-nhpjvgt4	175	7	therapeutic	therapeutic	JJ
cord-254580-nhpjvgt4	175	8	use	use	NN
cord-254580-nhpjvgt4	175	9	Risk	risk	NN
cord-254580-nhpjvgt4	175	10	of	of	IN
cord-254580-nhpjvgt4	175	11	Serious	serious	JJ
cord-254580-nhpjvgt4	175	12	Infection	infection	NN
cord-254580-nhpjvgt4	175	13	in	in	IN
cord-254580-nhpjvgt4	175	14	Patients	patient	NNS
cord-254580-nhpjvgt4	175	15	Receiving	receive	VBG
cord-254580-nhpjvgt4	175	16	Systemic	systemic	JJ
cord-254580-nhpjvgt4	175	17	Medications	medication	NNS
cord-254580-nhpjvgt4	175	18	for	for	IN
cord-254580-nhpjvgt4	175	19	the	the	DT
cord-254580-nhpjvgt4	175	20	Treatment	Treatment	NNP
cord-254580-nhpjvgt4	175	21	of	of	IN
cord-254580-nhpjvgt4	175	22	Psoriasis	Psoriasis	NNP
cord-254580-nhpjvgt4	176	1	Retinoic	retinoic	JJ
cord-254580-nhpjvgt4	176	2	acid	acid	NN
cord-254580-nhpjvgt4	176	3	analogues	analogue	NNS
cord-254580-nhpjvgt4	176	4	inhibit	inhibit	VBP
cord-254580-nhpjvgt4	176	5	human	human	JJ
cord-254580-nhpjvgt4	176	6	herpesvirus	herpesvirus	NN
cord-254580-nhpjvgt4	176	7	8	8	CD
cord-254580-nhpjvgt4	176	8	replication	replication	NN
cord-254580-nhpjvgt4	176	9	Adalimumab	Adalimumab	NNP
cord-254580-nhpjvgt4	176	10	therapy	therapy	NN
cord-254580-nhpjvgt4	176	11	for	for	IN
cord-254580-nhpjvgt4	176	12	moderate	moderate	JJ
cord-254580-nhpjvgt4	176	13	to	to	IN
cord-254580-nhpjvgt4	176	14	severe	severe	JJ
cord-254580-nhpjvgt4	176	15	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	176	16	:	:	:
cord-254580-nhpjvgt4	177	1	A	a	DT
cord-254580-nhpjvgt4	177	2	randomized	randomized	JJ
cord-254580-nhpjvgt4	177	3	,	,	,
cord-254580-nhpjvgt4	177	4	controlled	control	VBN
cord-254580-nhpjvgt4	177	5	phase	phase	NN
cord-254580-nhpjvgt4	177	6	III	iii	CD
cord-254580-nhpjvgt4	177	7	trial	trial	NN
cord-254580-nhpjvgt4	177	8	Efficacy	Efficacy	NNP
cord-254580-nhpjvgt4	177	9	and	and	CC
cord-254580-nhpjvgt4	177	10	safety	safety	NN
cord-254580-nhpjvgt4	177	11	of	of	IN
cord-254580-nhpjvgt4	177	12	guselkumab	guselkumab	NNS
cord-254580-nhpjvgt4	177	13	,	,	,
cord-254580-nhpjvgt4	177	14	an	an	DT
cord-254580-nhpjvgt4	177	15	anti	anti	JJ
cord-254580-nhpjvgt4	177	16	-	-	JJ
cord-254580-nhpjvgt4	177	17	interleukin-23	interleukin-23	JJ
cord-254580-nhpjvgt4	177	18	monoclonal	monoclonal	JJ
cord-254580-nhpjvgt4	177	19	antibody	antibody	NN
cord-254580-nhpjvgt4	177	20	,	,	,
cord-254580-nhpjvgt4	177	21	compared	compare	VBN
cord-254580-nhpjvgt4	177	22	with	with	IN
cord-254580-nhpjvgt4	177	23	adalimumab	adalimumab	NNS
cord-254580-nhpjvgt4	177	24	for	for	IN
cord-254580-nhpjvgt4	177	25	the	the	DT
cord-254580-nhpjvgt4	177	26	treatment	treatment	NN
cord-254580-nhpjvgt4	177	27	of	of	IN
cord-254580-nhpjvgt4	177	28	patients	patient	NNS
cord-254580-nhpjvgt4	177	29	with	with	IN
cord-254580-nhpjvgt4	177	30	moderate	moderate	JJ
cord-254580-nhpjvgt4	177	31	to	to	IN
cord-254580-nhpjvgt4	177	32	severe	severe	JJ
cord-254580-nhpjvgt4	177	33	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	177	34	with	with	IN
cord-254580-nhpjvgt4	177	35	randomized	randomized	JJ
cord-254580-nhpjvgt4	177	36	withdrawal	withdrawal	NN
cord-254580-nhpjvgt4	177	37	and	and	CC
cord-254580-nhpjvgt4	177	38	retreatment	retreatment	NN
cord-254580-nhpjvgt4	177	39	:	:	:
cord-254580-nhpjvgt4	177	40	Results	result	NNS
cord-254580-nhpjvgt4	177	41	from	from	IN
cord-254580-nhpjvgt4	177	42	the	the	DT
cord-254580-nhpjvgt4	177	43	phase	phase	NN
cord-254580-nhpjvgt4	177	44	III	iii	CD
cord-254580-nhpjvgt4	177	45	,	,	,
cord-254580-nhpjvgt4	177	46	double	double	JJ
cord-254580-nhpjvgt4	177	47	-	-	HYPH
cord-254580-nhpjvgt4	177	48	blind	blind	JJ
cord-254580-nhpjvgt4	177	49	,	,	,
cord-254580-nhpjvgt4	177	50	placebo	placebo	NN
cord-254580-nhpjvgt4	177	51	-	-	HYPH
cord-254580-nhpjvgt4	177	52	and	and	CC
cord-254580-nhpjvgt4	177	53	active	active	JJ
cord-254580-nhpjvgt4	177	54	comparator	comparator	NN
cord-254580-nhpjvgt4	177	55	-	-	HYPH
cord-254580-nhpjvgt4	177	56	controlled	control	VBN
cord-254580-nhpjvgt4	177	57	VOYAGE	voyage	NN
cord-254580-nhpjvgt4	177	58	2	2	CD
cord-254580-nhpjvgt4	177	59	trial	trial	NN
cord-254580-nhpjvgt4	177	60	Etanercept	Etanercept	NNP
cord-254580-nhpjvgt4	177	61	in	in	IN
cord-254580-nhpjvgt4	177	62	the	the	DT
cord-254580-nhpjvgt4	177	63	treatment	treatment	NN
cord-254580-nhpjvgt4	177	64	of	of	IN
cord-254580-nhpjvgt4	177	65	psoriatic	psoriatic	JJ
cord-254580-nhpjvgt4	177	66	arthritis	arthritis	NN
cord-254580-nhpjvgt4	177	67	and	and	CC
cord-254580-nhpjvgt4	177	68	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	177	69	:	:	:
cord-254580-nhpjvgt4	177	70	a	a	DT
cord-254580-nhpjvgt4	177	71	randomised	randomised	JJ
cord-254580-nhpjvgt4	177	72	trial	trial	NN
cord-254580-nhpjvgt4	177	73	Secukinumab	Secukinumab	NNP
cord-254580-nhpjvgt4	177	74	in	in	IN
cord-254580-nhpjvgt4	177	75	plaque	plaque	NN
cord-254580-nhpjvgt4	177	76	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	177	77	--	--	:
cord-254580-nhpjvgt4	177	78	results	result	NNS
cord-254580-nhpjvgt4	177	79	of	of	IN
cord-254580-nhpjvgt4	177	80	two	two	CD
cord-254580-nhpjvgt4	177	81	phase	phase	NN
cord-254580-nhpjvgt4	177	82	3	3	CD
cord-254580-nhpjvgt4	177	83	trials	trial	NNS
cord-254580-nhpjvgt4	178	1	Infliximab	Infliximab	NNP
cord-254580-nhpjvgt4	178	2	monotherapy	monotherapy	RB
cord-254580-nhpjvgt4	178	3	provides	provide	VBZ
cord-254580-nhpjvgt4	178	4	rapid	rapid	JJ
cord-254580-nhpjvgt4	178	5	and	and	CC
cord-254580-nhpjvgt4	178	6	sustained	sustained	JJ
cord-254580-nhpjvgt4	178	7	benefit	benefit	NN
cord-254580-nhpjvgt4	178	8	for	for	IN
cord-254580-nhpjvgt4	178	9	plaque	plaque	NN
cord-254580-nhpjvgt4	178	10	-	-	HYPH
cord-254580-nhpjvgt4	178	11	type	type	NN
cord-254580-nhpjvgt4	178	12	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	179	1	Infliximab	Infliximab	NNP
cord-254580-nhpjvgt4	179	2	induction	induction	NN
cord-254580-nhpjvgt4	179	3	and	and	CC
cord-254580-nhpjvgt4	179	4	maintenance	maintenance	NN
cord-254580-nhpjvgt4	179	5	therapy	therapy	NN
cord-254580-nhpjvgt4	179	6	for	for	IN
cord-254580-nhpjvgt4	179	7	moderate	moderate	JJ
cord-254580-nhpjvgt4	179	8	-	-	HYPH
cord-254580-nhpjvgt4	179	9	to	to	IN
cord-254580-nhpjvgt4	179	10	-	-	HYPH
cord-254580-nhpjvgt4	179	11	severe	severe	JJ
cord-254580-nhpjvgt4	179	12	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	179	13	:	:	:
cord-254580-nhpjvgt4	179	14	a	a	DT
cord-254580-nhpjvgt4	179	15	phase	phase	NN
cord-254580-nhpjvgt4	179	16	III	III	NNP
cord-254580-nhpjvgt4	179	17	,	,	,
cord-254580-nhpjvgt4	179	18	multicentre	multicentre	NNP
cord-254580-nhpjvgt4	179	19	,	,	,
cord-254580-nhpjvgt4	179	20	double	double	JJ
cord-254580-nhpjvgt4	179	21	-	-	HYPH
cord-254580-nhpjvgt4	179	22	blind	blind	JJ
cord-254580-nhpjvgt4	179	23	trial	trial	NN
cord-254580-nhpjvgt4	180	1	A	a	DT
cord-254580-nhpjvgt4	180	2	randomized	randomized	JJ
cord-254580-nhpjvgt4	180	3	comparison	comparison	NN
cord-254580-nhpjvgt4	180	4	of	of	IN
cord-254580-nhpjvgt4	180	5	continuous	continuous	JJ
cord-254580-nhpjvgt4	180	6	vs	vs	IN
cord-254580-nhpjvgt4	180	7	year	year	NN
cord-254580-nhpjvgt4	180	8	in	in	IN
cord-254580-nhpjvgt4	180	9	the	the	DT
cord-254580-nhpjvgt4	180	10	treatment	treatment	NN
cord-254580-nhpjvgt4	180	11	of	of	IN
cord-254580-nhpjvgt4	180	12	moderate	moderate	JJ
cord-254580-nhpjvgt4	180	13	-	-	HYPH
cord-254580-nhpjvgt4	180	14	to	to	IN
cord-254580-nhpjvgt4	180	15	-	-	HYPH
cord-254580-nhpjvgt4	180	16	severe	severe	JJ
cord-254580-nhpjvgt4	180	17	plaque	plaque	NN
cord-254580-nhpjvgt4	180	18	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	180	19	Certolizumab	Certolizumab	NNP
cord-254580-nhpjvgt4	180	20	pegol	pegol	NN
cord-254580-nhpjvgt4	180	21	for	for	IN
cord-254580-nhpjvgt4	180	22	the	the	DT
cord-254580-nhpjvgt4	180	23	treatment	treatment	NN
cord-254580-nhpjvgt4	180	24	of	of	IN
cord-254580-nhpjvgt4	180	25	patients	patient	NNS
cord-254580-nhpjvgt4	180	26	with	with	IN
cord-254580-nhpjvgt4	180	27	moderate	moderate	JJ
cord-254580-nhpjvgt4	180	28	-	-	HYPH
cord-254580-nhpjvgt4	180	29	to	to	IN
cord-254580-nhpjvgt4	180	30	-	-	HYPH
cord-254580-nhpjvgt4	180	31	severe	severe	JJ
cord-254580-nhpjvgt4	180	32	chronic	chronic	JJ
cord-254580-nhpjvgt4	180	33	plaque	plaque	NN
cord-254580-nhpjvgt4	180	34	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	180	35	:	:	:
cord-254580-nhpjvgt4	180	36	pooled	pool	VBN
cord-254580-nhpjvgt4	180	37	analysis	analysis	NN
cord-254580-nhpjvgt4	180	38	of	of	IN
cord-254580-nhpjvgt4	180	39	week	week	NN
cord-254580-nhpjvgt4	180	40	16	16	CD
cord-254580-nhpjvgt4	180	41	data	datum	NNS
cord-254580-nhpjvgt4	180	42	from	from	IN
cord-254580-nhpjvgt4	180	43	three	three	CD
cord-254580-nhpjvgt4	180	44	randomized	randomized	JJ
cord-254580-nhpjvgt4	180	45	controlled	control	VBN
cord-254580-nhpjvgt4	180	46	trials	trial	NNS
cord-254580-nhpjvgt4	180	47	Guselkumab	Guselkumab	NNP
cord-254580-nhpjvgt4	180	48	versus	versus	IN
cord-254580-nhpjvgt4	180	49	secukinumab	secukinumab	NNS
cord-254580-nhpjvgt4	180	50	for	for	IN
cord-254580-nhpjvgt4	180	51	the	the	DT
cord-254580-nhpjvgt4	180	52	treatment	treatment	NN
cord-254580-nhpjvgt4	180	53	of	of	IN
cord-254580-nhpjvgt4	180	54	moderate	moderate	JJ
cord-254580-nhpjvgt4	180	55	-	-	HYPH
cord-254580-nhpjvgt4	180	56	to	to	IN
cord-254580-nhpjvgt4	180	57	-	-	HYPH
cord-254580-nhpjvgt4	180	58	severe	severe	JJ
cord-254580-nhpjvgt4	180	59	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	180	60	(	(	-LRB-
cord-254580-nhpjvgt4	180	61	ECLIPSE	ECLIPSE	NNP
cord-254580-nhpjvgt4	180	62	)	)	-RRB-
cord-254580-nhpjvgt4	180	63	:	:	:
cord-254580-nhpjvgt4	180	64	results	result	NNS
cord-254580-nhpjvgt4	180	65	from	from	IN
cord-254580-nhpjvgt4	180	66	a	a	DT
cord-254580-nhpjvgt4	180	67	phase	phase	NN
cord-254580-nhpjvgt4	180	68	3	3	CD
cord-254580-nhpjvgt4	180	69	,	,	,
cord-254580-nhpjvgt4	180	70	randomised	randomise	VBN
cord-254580-nhpjvgt4	180	71	controlled	control	VBN
cord-254580-nhpjvgt4	180	72	trial	trial	NN
cord-254580-nhpjvgt4	180	73	Longterm	longterm	JJ
cord-254580-nhpjvgt4	180	74	safety	safety	NN
cord-254580-nhpjvgt4	180	75	profile	profile	NN
cord-254580-nhpjvgt4	180	76	of	of	IN
cord-254580-nhpjvgt4	180	77	ixekizumab	ixekizumab	NNP
cord-254580-nhpjvgt4	180	78	in	in	IN
cord-254580-nhpjvgt4	180	79	patients	patient	NNS
cord-254580-nhpjvgt4	180	80	with	with	IN
cord-254580-nhpjvgt4	180	81	moderate	moderate	JJ
cord-254580-nhpjvgt4	180	82	-	-	HYPH
cord-254580-nhpjvgt4	180	83	to	to	IN
cord-254580-nhpjvgt4	180	84	-	-	HYPH
cord-254580-nhpjvgt4	180	85	severe	severe	JJ
cord-254580-nhpjvgt4	180	86	plaque	plaque	NN
cord-254580-nhpjvgt4	180	87	psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	180	88	:	:	:
cord-254580-nhpjvgt4	180	89	an	an	DT
cord-254580-nhpjvgt4	180	90	integrated	integrated	JJ
cord-254580-nhpjvgt4	180	91	analysis	analysis	NN
cord-254580-nhpjvgt4	180	92	from	from	IN
cord-254580-nhpjvgt4	180	93	11	11	CD
cord-254580-nhpjvgt4	180	94	clinical	clinical	JJ
cord-254580-nhpjvgt4	180	95	trials	trial	NNS
cord-254580-nhpjvgt4	180	96	Ixekizumab	Ixekizumab	NNP
cord-254580-nhpjvgt4	180	97	Treatment	Treatment	NNP
cord-254580-nhpjvgt4	180	98	for	for	IN
cord-254580-nhpjvgt4	180	99	up	up	IN
cord-254580-nhpjvgt4	180	100	to	to	TO
cord-254580-nhpjvgt4	180	101	5	5	CD
cord-254580-nhpjvgt4	180	102	Years	year	NNS
cord-254580-nhpjvgt4	180	103	in	in	IN
cord-254580-nhpjvgt4	180	104	Adult	Adult	NNP
cord-254580-nhpjvgt4	180	105	Patients	Patients	NNP
cord-254580-nhpjvgt4	180	106	with	with	IN
cord-254580-nhpjvgt4	180	107	Moderate	moderate	JJ
cord-254580-nhpjvgt4	180	108	-	-	HYPH
cord-254580-nhpjvgt4	180	109	to	to	IN
cord-254580-nhpjvgt4	180	110	-	-	HYPH
cord-254580-nhpjvgt4	180	111	Severe	severe	JJ
cord-254580-nhpjvgt4	180	112	Psoriasis	psoriasis	NN
cord-254580-nhpjvgt4	180	113	:	:	:
cord-254580-nhpjvgt4	180	114	Results	result	NNS
cord-254580-nhpjvgt4	180	115	from	from	IN
cord-254580-nhpjvgt4	180	116	Greater	Greater	NNP
cord-254580-nhpjvgt4	180	117	Than	than	IN
cord-254580-nhpjvgt4	180	118	17,000	17,000	CD
cord-254580-nhpjvgt4	180	119	Patient	Patient	NNP
cord-254580-nhpjvgt4	180	120	-	-	HYPH
cord-254580-nhpjvgt4	180	121	Years	year	NNS
cord-254580-nhpjvgt4	180	122	of	of	IN
cord-254580-nhpjvgt4	180	123	Exposure	Exposure	NNP
cord-254580-nhpjvgt4	180	124	A	a	DT
cord-254580-nhpjvgt4	180	125	prospective	prospective	JJ
cord-254580-nhpjvgt4	180	126	phase	phase	NN
cord-254580-nhpjvgt4	180	127	III	iii	CD
cord-254580-nhpjvgt4	180	128	,	,	,
cord-254580-nhpjvgt4	180	129	randomized	randomized	JJ
cord-254580-nhpjvgt4	180	130	,	,	,
cord-254580-nhpjvgt4	180	131	double	double	JJ
cord-254580-nhpjvgt4	180	132	-	-	HYPH
cord-254580-nhpjvgt4	180	133	blind	blind	JJ
cord-254580-nhpjvgt4	180	134	,	,	,
cord-254580-nhpjvgt4	180	135	placebo	placebo	NN
cord-254580-nhpjvgt4	180	136	-	-	HYPH
cord-254580-nhpjvgt4	180	137	controlled	control	VBN
cord-254580-nhpjvgt4	180	138	study	study	NN
cord-254580-nhpjvgt4	180	139	of	of	IN
cord-254580-nhpjvgt4	180	140	brodalumab	brodalumab	NNP
cord-254580-nhpjvgt4	180	141	in	in	IN
cord-254580-nhpjvgt4	180	142	patients	patient	NNS
cord-254580-nhpjvgt4	180	143	with	with	IN
cord-254580-nhpjvgt4	180	144	moderate	moderate	JJ
cord-254580-nhpjvgt4	180	145	-	-	HYPH
cord-254580-nhpjvgt4	180	146	to	to	IN
cord-254580-nhpjvgt4	180	147	-	-	HYPH
cord-254580-nhpjvgt4	180	148	severe	severe	JJ
cord-254580-nhpjvgt4	180	149	plaque	plaque	NN
cord-254580-nhpjvgt4	180	150	psoriasis	psoriasis	NN